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 The aim of this thesis was to test the hypothesis that structural modifications 
of the stilbene resveratrol, a known chemopreventive agent, would result in 
compounds with greater phase II enzyme induction activity. To this end, two series 
were designed, synthesized and characterized. The first series comprised of 23 
methoxystilbenes. Methoxy groups were introduced in the hope that they would deter 
the rapid metabolic degradation associated with phenolic hydroxyl groups. 
Methoxystilbenes had also been associated with strong antiproliferative activities that 
could contribute to the overall chemopreventive profile of the compound. The second 
series was based on the replacement of the phenolic ring B of resveratrol with a 
bioisosteric indolin-2-one moiety. Sixty one compounds were synthesized and they 
were organized into 4 classes: Classes 1 and 2: 3-substituted indolin-2-ones; Class 3: 
miscellaneous compounds related to 3-substituted indolin-2-ones; Class 4: isoindigos. 
Both libraries were evaluated for induction of NAD(P)H: quinone oxidoreductase 1 
(NQO1) on the mouse hepatoma Hepa1c1c7 cells. Selected members were evaluated 
on a mutant cell line (c1) that lacked a functional CYP1A1 gene. They were also 
evaluated for induction of CYP1A1 activity on Hepa1c1c7 cells using the EROD 
assay. The antiproliferative activities of the compounds were investigated on human 
breast cancer cell (MCF7) and colon cancer (HCT116) cell lines, as well as a normal 
cell line (CCL186). 
 Improved NQO1 induction activity compared to resveratrol was found in some 
methoxystilbenes.  Good activity was associated with the E isomer and the absence of 
hydroxyl groups on ring A. The most promising compound S3E (E-2,4'-
dimethoxystilbene) had a CD (concentration required to increase basal NQO1 activity 
by two fold in Hepa1c1c7 cells) of 0.85 M. S3E had a bifunctional induction profile 
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because it also induced CYP1A1 activity. However, it induced NQO1 activity to a 
greater extent. An active metabolite generated by CYP1A1 might be involved in its 
induction activity.  Antiproliferative activity was found mainly among the Z-
methoxystilbenes, in particular those with methoxy groups on positions 3 and 5 of 
ring A. The different structural requirements for NQO1 induction and antiproliferative 
activities implied that it would be difficult to combine both properties in the same 
molecule.  
 The indolinones and isoindigos of the second series yielded several potent 
NQO1 inducers, with CD values in the nanomolar range. The variation in induction 
activity in this library was more than 104  fold and this permitted useful SAR to be 
proposed: These were (i) retention of the nitrogen-linked Michael acceptor moiety in 
the indolinone template, (ii) the presence of electron withdrawing groups on ring B 
for the monosubstituted Class 1 compounds, (iii) the relative importance of 
substitution on ring B compared to ring A substitution in Class 2 compounds, and (iv) 
the presence of at least  two electron withdrawing groups on the isoindigo ring system. 
Like the methoxystilbenes, the indolinones and isoindigos were found to be 
bifunctional inducers of NQO1, with the possible involvement of an active metabolite 
in the induction process.  An important observation was the correlation between 
potent NQO1 induction and the lack of preferential induction of NQO1 compared to 
CYP1A1. Thus, the isoindigos of Class 4 which were the most potent NQO1 inducers 
in this series induced NQO1 and CYP1A1 activities to almost the same extent. On the 
other hand, compounds that were moderately active NQO1 inducers (CD 0.1-0.25 
M) induced NQO1 to a greater degree than CYP1A1. 
 A QSAR analysis of the NQO1 induction activity was carried out using 
principal component analysis (PCA) and projection to latent structures by partial least 
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squares analysis (PLS). Eighteen descriptors that captured the constitutive, molecular 
orbital related, geometric, lipophilic and electronic properties of the compounds were 
used in the analysis. This analysis provided two important findings, namely that (i) 
the isoindigos differed from the 3-substituted indolin-2-ones and other compounds in 
terms of the following descriptors: the number of H bond donors, VDW surface area 
of these donors and LUMO energies; and (ii) potent induction properties were 
associated with LUMO energy, size, VDW surface area of H bond donors and number 
of rotatable bonds. Since good NQO1 inducers were also non-selective in their 
induction of NQO1 and CYP1A1 proteins, particular attention should be paid to the 
descriptors in (ii) if a molecule is designed to target induction of phase II enzymes. 
Few compounds in the 2nd series were found to be potent antiproliferative 
agents (IC50  10 M) on the HCT116 or MCF7 cell lines. In contrast to their strong 
NQO1 induction activity, the isoindigos had weak growth inhibitory activities. The 
most active compounds were 3-substituted indolin-2-ones which had the following 
features: (i) two methoxy groups on ring A and B, (ii) bulky alkoxy groups on ring B, 
such as phenoxy and 3,4,5-trimethoxy, and (iii) chloro, fluoro and trifluoromethyl 
groups on rings A and B.   These compounds arrested the cell cycle at different stages 
and coincidentally, compounds with features (ii) and (iii) disrupted the cell cycle at 
the G1 phase while compounds with feature (i) caused G2/M arrest. Unlike 
methoxystilbenes, it was possible to identify compounds that had both good /selective 
NQO1 induction and antiproliferative activities. These were compounds 10, 45 and 48. 
In conclusion, both design approaches succeeded in yielding compounds that 
had greater NQO1 induction activity than resveratrol. The indolinones in the 2nd series 
were particularly successful in this respect because several members combined 
moderately strong and selective NQO1 induction with antiproliferative activity. 
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Chapter 1   Introduction 
1.1. Chemoprevention of Cancer 
The National Cancer Act was enacted by President Richard Nixon of the 
United States of America in 1971 with the aim of mobilizing the country's resources 
towards cancer research and to achieve the “conquest of cancer” by the 21st century. 
Sadly, this has not come to pass and the “war on cancer” continues to be fought. In 
fact, drugs for the treatment of cancer have one of the poorest outcomes among 
investigational drugs in clinical development, with success rates that are at least three 
times lower than for cardiovascular diseases. (1) This is in spite of the large amount of 
resources poured into cancer research. Fortunately, a few outstanding drugs like 
imatinib have emerged from the drug development pipeline but the success rates are 
still comparatively low. 
It is estimated that more than 2/3rd of human cancers are preventable through 
life style changes such as cessation of smoking, limiting exposure to radiation and 
toxic chemicals, and inclusion of certain dietary factors. (2) In fact, cancer may be 
viewed as the end result of a chronic disease that starts with carcinogenesis and ends 
in metastases. Carcinogenesis itself is a complex and protracted multistep process that 
involves distinct yet closely linked events of tumor initiation, promotion and 
progression. (3, 4) The transformation of a normal cell into a cancer (initiated) cell is a 
rapid and irreversible process. Once formed, these cells undergo a slow process of 
promotion to pre-neoplastic cells, and progression to neoplastic cells with invasive 
and metastatic potential. The multistage and prolonged process of carcinogenesis 
suggests that timely intervention through the ingestion of dietary or pharmaceutical 
agents may result in the prevention, delay or reversal of the process. This concept is 
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termed “cancer chemoprevention” and was first proposed by Sporn and co-workers in 
1976. (5) 
Many investigators have focused on the natural products present in the diet as 
well as non-nutrient phytochemicals as sources of chemopreventive compounds. (3, 4, 6-
10) Well cited examples include curcumin, capsaicin and 6-gingerol in spices, 
resveratrol in grapes, epigallocatechin-3-gallate in green tea, genistein in soybeans 
and lycopene in tomatoes. (4) Their widespread use notwithstanding, dietary 
chemopreventive agents often lack the optimum potencies, pharmacokinetic 
properties and toxicology profiles that are required of clinically viable drugs. (6) A 
plausible solution to this problem would be to start with the dietary component as a 
lead structure, and introduce appropriate structural changes to address its short-
comings. Some examples follow. Sulforaphane is a potent chemopreventive agent 
isolated from broccoli but its usefulness is limited by toxicity. (11) Medicinal 
chemistry approaches starting from sulforaphane as lead compound has resulted in 
synthetic analogues like sulforamate which is as potent as sulforaphane but less toxic 
(IC50 35 M versus 9.9 M). (12) Several sulforamate analogues with the same 
potencies as sulforamate but with lesser toxicities have been reported. (13) Oxamate is 
another example. It is synthetically more accessible than either sulforaphane or 
sulforamate (Figure 1-1). (14) 
Oleanolic acid, a naturally occurring triterpenoid widely used in traditional 
cures, is another case in point. Several analogues were synthesized in order to 
improve on the weak anti-tumorigenic and anti-inflammatory properties of oleanolic 
acid and two potent members were identified. (15, 16) In a similar way, the poor potency 
of betulinic acid, a pentacyclic triterpene isolated from birch bark and other plants, 
3 
 
was overcome through the synthesis of semi-synthetic analogues that had greater 
potencies than the parent compound for several biological properties. (17) 




























Sulforamate analogues  
1.2. Potential Mechanisms of Chemoprevention 
Chemopreventive agents are commonly classified as blocking or suppressing 
agents. (4, 6, 18) Blocking agents impede the initiation stage by preventing carcinogens 
from reaching the target site, undergoing metabolic activation or interacting with 
crucial cellular macromolecules. Suppressing agents arrest or reverse the promotion 
or progression stages by affecting or perturbing crucial factors that control cell 
proliferation, differentiation, senescence or apoptosis. Some chemopreventive agents 
have both blocking and suppressing properties. For example, it may have a 
cytoprotective effect on normal cells (blocking), and a cytotoxic effect on pre-
neoplastic and neoplastic cells (suppressing). The current understanding suggests that 
that the mechanisms involved in chemoprevention arise from an intricate interplay of 
several intracellular effects, and not just from an isolated biological response. (2) Table 
1-1 gives a list of potential chemopreventive mechanisms proposed by Chen and 
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Kong (6) for dietary chemopreventive agents.  This classification may apply equally 
well to synthetic agents. 
 
Table 1-1:  Mechanisms involved in the blocking and suppressing effects of 
chemopreventive agents  
 
Blocking Agents Suppressing Agents 
- Enhance detoxification of carcinogens 
- Inhibit cytochrome P450 mediated 
activation of carcinogens 
- Scavenge free radicals (antioxidant) 
- Impede interaction with DNA 
- Disrupt cell cycle 
- Induce apoptosis 
- Modulate hormone activity 
- Modulate nuclear receptors 
-  Suppress gene expression 
 
1.3. Induction of NQO1 as a Chemopreventive Strategy 
Metabolizing enzymes are conventionally classified as phase I and phase II 
enzymes. Phase I enzymes are predominantly members of the cytochrome P450 
(CYP450) family and they catalyze functionalization reactions like oxidation, 
reduction and hydrolysis. Phase II enzymes (transferases) catalyze the formation of 
polar conjugates that are sufficiently hydrophilic for excretion from the body. 
The metabolizing enzymes may also be categorized as activating or 
detoxifying enzymes, based on their roles in the production or detoxification of 
carcinogens. Some phase I mediated reactions result in the formation of reactive 
species that will initiate carcinogenesis. These enzymes, most of which are CYP450 
enzymes, are described as “activating.”  Several phase II enzymes deactivate free 
radicals (catalase, superoxide dismutase) and electrophiles (glutathione-S- transferase) 
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and have a detoxifying effect.  How a cell reacts to a potentially harmful xenobiotic 
depends on the balance of activities of enzymes that promote the formation of reactive 
intermediates and those that detoxify these reactive species.  
One notable feature of phase II enzymes is that they are often not functioning 
at their maximum capacity. Thus, their activities may be induced and their induction 
can occur selectively, without concurrently affecting the activity of phase I enzymes. 
The selective induction of phase II enzymes offers a promising strategy for reducing 
the risk of carcinogenesis and is considered to be one of the true hallmarks of 
chemoprevention. (18)   The induction of the phase II enzyme NAD(P)H: quinone 
oxidoreductase 1 (NQO1 or quinone reductase 1) has been the focus of many 
investigations relating to chemoprevention. This is largely due to the seminal work of 
Talalay and co-workers who expounded on the mechanisms underlying induction of 
NQO1 and other phase II enzymes (19-22) and the role of Michael reaction acceptors as 
inducers of NQO1. (23-25) 
NQO1 is a widely distributed multifunctional flavoprotein that detoxifies 
quinones by two-electron reduction to quinols, without generating reactive 
semiquinones (Figure 1-2). It is also involved in the reduction of endogenous 
quinones like ubiquinone and vitamin E quinones. Induction of NQO1 has been 
shown to correlate with the induction of other protective phase II enzymes and hence 
it is widely used as a biomarker for the identification of potential chemopreventive 
agents. (26) The induction of NQO1 has also been shown to stabilize the tumor 
suppressor p53 against proteasomal degradation, highlighting another important role 
for NQO1 in the defense of the cell against carcinogens. (27) Induction of NQO1 gene 
transcription is regulated by two separate signaling pathways, the arylhydrocarbon 
receptor (ARE) /xenobiotic response element  (XRE) and the Kelch-like ECH 
6 
 
associating protein 1 (Keap1) / nuclear factor erythroid 2-related factor 2 (Nrf2) / 
antioxidant response element (ARE), which are briefly discussed in the following 
paragraphs. 
 














1.4. Regulation of NQO1 by the ARE/XRE and Keap1/Nrf2/ARE Pathways 
The arylhydrocarbon receptor (AhR) is a ligand activated cytosolic 
transcription factor. It is often regarded as an orphan receptor because its endogenous 
ligands and biochemical functions remain to be fully elucidated. A great deal more is 
known of the exogenous ligands of AhR, most of which are halogenated and 
polycyclic aromatic hydrocarbons. One of its most potent ligands is 2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCDD), better known for its insidious accumulation in 
wildlife and humans and as the infamous contaminant of Agent Orange, a herbicide 
used in the Vietnam War. The binding of a ligand to the AhR results in its 
transformation to a DNA-binding form via the following processes: a conformational 
change in the receptor protein, its translocation to the nucleus from the cytosol, 
dissociation of its chaperone proteins, formation of a heterodimer with AhR nuclear 
translocator (Arnt), binding of the heterodimer to xenobiotic response elements 
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(XREs) found in the 5'-regulatory domains of AhR responsive genes, and the 
induction of several drug-metabolizing enzymes, such as subfamilies of CYP450 
(CYP1A1,CYP1A2, CYP1B1),  NQO1, glutathione S-transferases (GST), and UDP 
glucuronosyltransferases (UGT). (28, 29) 
Phase II genes (including the NQO1 gene) are also regulated by upstream 
regulatory sequences called antioxidant response elements (AREs). (30) The induction 
process involves the participation of two additional components – the labile 
transcription factor Nrf2 and Keap1, a cytosolic repressor protein that binds to Nrf2 
under normal conditions and promotes its proteasomal degradation. Keap1 has a 
cysteine-rich surface which is susceptible to stress agents like electrophiles and 
oxidants. The Keap1-Nrf2 complex is disrupted under these conditions and the 
liberated Nrf2 migrates to the nucleus where it binds (in heterodimeric forms with 
other transcription factors) to the ARE enhancer regions of NQO1 and other phase II 
genes, and stimulate their transcription. (31) 
 
1.5. Monofunctional and Bifunctional Inducers of Phase II Enzymes 
Inducers of phase II enzymes may be classified as monofunctional or 
bifunctional according to the mechanism by which induction is brought about. An 
agent that selectively induces phase II enzymes by the Keap1-Nrf2-ARE pathway is 
termed monofunctional, whereas an agent that operates via the ARE/XME route and 
induces both phase I and II enzymes is described as bifunctional. (32, 33) 
Notwithstanding the integral role of phase I metabolism in detoxification, the 
elevation of phase I enzyme activity has the unsolicited effect of activating 
procarcinogens to reactive species. (34)  For this reason, an agent that induces phase II 
enzymes selectively would theoretically be a better chemopreventive agent, compared 
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to an agent that induces both phase I and II enzymes. Thus not all bifunctional 
inducers are suited for chemoprevention. But it is still plausible that some bifunctional 
agents elicit stronger induction of phase II enzymes than phase I enzymes, resulting in 
overall protection rather than activation. Current literature suggests that the situation 
may not be so clear cut. There is evidence of coordinate induction of phase I and II 
enzymes, possibly due to cross-talk between the AhR and Nrf2 pathways. (35) 
Proposed links between the AhR and Nrf2 gene batteries include the following: (35) (i) 
Nrf2 is a AhR target gene; (36) (ii) Nrf2 is indirectly activated by CYP1A1-generated 
reactive oxygen species and electrophiles; (37) (iii) AhR/XRE and Nrf2/ARE signaling 
pathways interact directly due to the close proximity of the XRE and ARE in the 
regulatory region of NQO1. (38) Coordinate induction of the two pathways, if 
confirmed in future studies, would serve to attenuate the toxic effects of reactive 
intermediates produced via CYP450 metabolism. 
Most investigators employ the murine hepatoma cells Hepa1c1c7 and its 
mutant cell lines to investigate the monofunctional /bifunctional character of inducers. 
(3, 16, 39, 40) The mutant cell lines may have a defective AhR (for example TAOc1BPrc1 
and BPrc1) or are defective in the expression of CYP1A1 (arylhydrocarbon 
hydroxylase) (for example, c1). Monofunctional inducers will have similar inducing 
abilities in the wild type and mutant Hepa lines whereas bifunctional inducers will 
show a difference, with more induction activity observed in the wild type cells. 
Hepa1c1c7 cells have other advantages that make them desirable for studies on NQO1 
induction: they have high basal and inducible expression level of the NQO1 gene and 






1.6. Stilbenes as Lead Structures for Chemopreventive Activity 
The stilbene moiety is commonly encountered in natural products and many 
members are associated with therapeutically important pharmacological properties. 
(41) Resveratrol (E-3,4',5-trihydroxystilbene) is probably the best known stilbenoid 
(Figure 1-3). Its therapeutic potential is recognized in several areas like the 
chemoprevention of cancer, cardiovascular diseases and neurodegeneration, as 
reviewed by Baur and Sinclair. (42) 
























Resveratrol DMU212 3,4,5,2',4'-pentamethoxystilbene  
Unfortunately, resveratrol has several limitations.  It has poor bioavailability 
owing to the susceptibility of its phenolic hydroxyl (OH) groups to phase II sulfation 
and glucuronidation reactions. Thus resveratrol has a short circulating half-life. The 
activities of the metabolites have not been studied in detail, but one study showed that 
the glucuronide metabolites were inactive as inhibitors of cyclooxygenase enzymes 
(COX-1, COX-2), unlike resveratrol. (43) Another problem is its weak potencies for 
several biological activities. As a growth inhibitor agent, its IC50 (concentration 
required to inhibit cell growth by 50%) ranged from 40-200 M, depending on 
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experimental conditions). (44) It is also a micromolar inhibitor of the COX enzymes. 
(43) In addition, resveratrol acts on many targets, (42) and this leads to problems in 
identifying which target is most important for the treatment of a given disease state. 
For example, the chemopreventive properties of resveratrol could be due to its 
antioxidant properties, induction of phase II enzymes, induction of cell cycle arrest 
and apoptosis. If an attempt is made to optimize the chemopreventive activity of 
resveratrol by modifying its structure, the choice of target would be important because 
structure-activity relationships (SAR) are likely to differ from one target to the next. 
One possible solution would be to develop structurally modified stilbenoids that act 
selectively on one target. This approach would serve to limit the side effects 
associated with a non-selective action on several targets. On the other hand, this 
approach may attenuate potency. 
Many examples in the literature illustrate attempts aimed at addressing the 
limitations of resveratrol. Mikstacka and co-workers proposed the replacement of 4'-
hydroxyl (OH) with a thiomethyl group in order to influence selectivity and inhibitory 
potency towards CYP450 enzymes. (45) Another group of investigators introduced a 
methyl group at the ortho position to the 4'-OH of resveratrol. (46) They found that this 
modification increased antioxidant activity and decreased in vitro genotoxicities.  
Kang and coworkers synthesized a 78-membered library of resveratrol analogues in 
which the substituents on the two aromatic rings and alkene were varied.  Based on 
their results, they established preliminary SAR for inhibition of COX and the 
transcription factor NF-B. (47) Several methoxylated analogues of resveratrol have 
been reported. (48, 49, 50) One of the most promising compounds was 3,4,5,4'-
tetramethoxy-trans-stilbene (DMU 212 or MR4, Figure 1-3) which had a favourable 
pharmacokinetic profile in animals. (44) More importantly, DMU212 affected cell 
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growth by targeting the mitochondrial apoptotic pathway which it affected at a lower 
concentration than resveratrol. (51) 
Various mechanisms have been proposed for the chemopreventive properties 
of reseveratrol. (42) These include inhibition of COX and ornithine decarboxylase, 
inhibition of angiogenesis, induction of phase II enzymes (NQO1, heme oxygenase) 
and induction of cell cycle arrest and apoptosis and antioxidant effects. (42) Of these 
mechanisms, less attention has been paid to preparing resveratrol analogues with the 
aim of increasing its phase II induction potential. Resveratrol is a moderate inducer of 
NQO1, with a CD (concentration required to double the basal activity of NQO1) of 21 
M. (52) It is also a monofunctional inducer and does not induce phase I enzyme 
activity. (52) In fact, resveratrol inhibited the inducible phase 1 enzymes CYP1A1 and 
CYP1B1, (53, 54) an attractive feature that would reduce the exposure of cells to 
carcinogens. However, this same activity could alter the pharmacokinetics of other 
drugs and thus, the extent of CYP450 inhibition would be important. A single report 
by Heo and co-workers showed that a methoxy analogue (E-3,4,5,2',4'-
pentamethoxystilbene, Figure 1-3) improved the NQO1 induction potential of 
resveratrol, as did the replacement of its phenolic ring with thiophene. (55) The paucity 
of work reported in this area suggests that it is timely to revisit the effect of 
structurally modifying the stilbenoid framework with the aim of discovering more 
potent inducers of chemoprotective phase II enzymes. 
 
1.7. Statement of Purpose 
            The preceding section has highlighted the remarkable biological profile of 
resveratrol as well as some of its limitations. These are the pleiotropic nature of 
resveratrol coupled with modest potencies for several activities, and its poor 
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bioavailability due to rapid metabolism. Most medicinal chemistry efforts aim to 
address these problems by providing adequate SAR background for lead optimization, 
which will permit the generation of novel congeners with improved properties. The 
present work is motivated by similar objectives, but with a focus on a specific activity, 
namely the induction of phase II enzyme activity. This focus is prompted by present 
knowledge that resveratrol is a modest inducer with scope for further improvement. In 
addition, it has a desirable monofunctional inducer profile that can be retained even 
on structural modification. 
Two structural modifications of resveratrol are proposed in this thesis. The 
first modification involves the replacement of the phenolic OH of resveratrol on ring 
B with 4'-methoxy and the concurrent introduction of hydroxyl or methoxy groups on 
ring A. The presence of the methoxy group would deter the rapid metabolic 
degradation associated with the phenolic OH groups, and hence improve 
bioavailability. It is possible that the removal of phenolic OH group may lead to a loss 
of antioxidant activity. Since NQO1 serves to maintain the antioxidant function of the 
cell (56) and antioxidants are often associated with NQO1 induction, (24) this may have 
an adverse effect on induction activity. On an optimistic note, methoxylated stilbenes 
may show an unexpected activity profile, as seen with DMU212 and this may have a 
net benefit effect on chemoprevention. This hypothesis will be investigated by 
determining the NQO1 induction profiles of the methoxylated stilbenes, their 
antioxidant properties and their antiproliferative activities. 
 The 2nd modification is to replace the phenolic ring B of resveratrol by a 
surrogate group. An appropriate replacement for a phenolic group is an NH group that 
is rendered acidic through the presence of an electron attracting functionality. 
Wermuth proposed the following bioisoteres for the phenolic OH (Figure 1-4). (57) 
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Replacing OH with methoxy group results in the loss of the hydrogen (H) 
bond donor property, an important characteristic of the phenolic OH group. Most of 
the bioisosteres in Figure 1-4 have the advantage of retaining both H bond donor and 
acceptor properties, and at same time, circumventing the metabolic susceptibility of 
the OH group. Of the various bioisosteres available, the indolin-2-one was chosen for 
the present work because of the synthetic accessibility of this moiety from 
commercial sources which would facilitate synthesis. 
There are two ways of attaching ring A of resveratrol to the indolin-2-one 
fragment which is taken to be equivalent to the phenolic ring B (Figure 1-5). The 1st 
approach places the acidic NH of indolin-2-one at the “same” position as the phenolic 
OH of ring B (para to the unsaturated linker). The 2nd approach is to link indolin-2-




























Both approaches give rise to compounds that only remotely resemble a 
stilbenoid. The 2nd approach is preferred for the following reasons: The resulting 
compound has a lower lipophilicty (ClogP 1.90) compared to resveratrol (ClogP 2.83) 
or the compound from the 1st approach (ClogP 2.07). Since lead modification 
invariably results in bigger and more lipophilic molecules, (58) starting with a less 
lipophilic compound gives greater leeway in modification and fewer concerns about 
exceeding the thresholds set by the Rule of Five. (59) Second, the 2nd approach gives 3-
substituted indolin-2-ones which have a strong record of antitumor activity. (60, 61) 
Sunitinib is a 3-(1H-pyrrol-2-yl)methyleneindolin-2-one derivative approved by the 
Food and Drug Administration for renal cell carcinoma and gastrointestinal stromal 
cancer. (62) However, little is known of the phase II induction properties of substituted 
3-substituted-indolin-2-ones. One interesting observation is that a Michael acceptor 
motif is present in 3-benzylidene-indolin-2-ones, with an added feature of a nitrogen 
atom attached to the electron withdrawing carbonyl group (Figure 1-6). It can be 
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considered as a “nitrogen linked Michael acceptor”, in contrast to the conventional 
Michael acceptors (olefins or acetylenes conjugated to electron withdrawing groups) 
that are widely cited as monofunctional NQO1 inducers. (23, 24, 25) On the other hand, 
indole phytochemicals like indole-3-carbinol and brassinin are bifunctional inducers. 
(63, 64) The 3-benzylideneindolin-2-ones have both structural elements – the indole ring 
and an embedded Michael acceptor moiety, and it would be of interest to see if bi- or 
monofunctional induction would prevail in these compounds.  
To verify these hypotheses, the following investigations will be carried out:  
(i) Synthesis of a representative library of 3-subsituted indolin-2-ones to determine 
NQO1 induction activity; 
 (ii) Investigation on the nature of the induction (mono- or bi-functional); 
 (iii) Investigation on the antiproliferative property of the compounds, the presence of 
which will be an added benefit to chemoprevention;  
(iv) Establishing a SAR profile that will guide further design efforts for this class of 
compounds. 












Chapter 2 Design and Synthesis of Target Compounds 
2.1.  Introduction 
This section describes the rationale for the design of the two classes of target 
compounds that were investigated for chemopreventive activity. These are 
methoxystilbenes related to resveratrol and the 3-substituted indolin-2-ones which are 
bioisosteres of phenol. Each class is discussed separately, starting from the rationale 
underlying the design, chemical considerations of the synthetic routes and general 
experimental methods employed in the syntheses. In the interest of space, 




2.2.1 Rationale of drug design 
Twenty methoxystilbenes were synthesized in this study (Table 2-1). The 
compounds have the following features: 
(i) A methoxy (OCH3) group on ring B, in place of the phenolic 4'-hydroxy (OH) of 
resveratrol.  Most of the compounds have a 4'-OCH3 group, corresponding to 4'-OH 
of resveratrol, except for S15E which has a 2'-OCH3 substituent. 
(ii) About 2/3rd of the compounds also have methoxy groups on ring A, with the 
number of methoxy groups varying from one to three. Many of the compounds are 
regioisomers, such as the mono-methoxy compounds S3-S5 and dimethoxy 
compounds S6-S9.   
(iii) The remaining members have hydroxyl and/or methoxy groups on ring A. 
Compounds S11, S12 and S13 are the hydroxy counterparts of compounds S3, S4 and 
S8 respectively. Their inclusion would allow useful comparisons of activity compared 
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to their respective methoxylated counterparts. Compound S14 has both hydroxyl and 
methoxy groups on ring A. 
(iv) The E and Z isomers were synthesized and purified for all compounds except S9, 
S11 and S15 which were only obtained as E isomers. 
The rationale for inclusion of features (i) – (iv) were threefold. First, replacing 
all or some of the phenolic OH groups on resveratrol with methoxy group serve to 
avert the phase II gluronidation and sulfation reactions that are responsible for the 
poor bioavailability of resveratrol. Second, notwithstanding the many methoxy 
analogues of resveratrol that have been synthesized and evaluated for various 
activities, (49, 50, 65) only limited attempts have been made at evaluating how the 
number and location of methoxy groups affected activity. Features (ii) and (iii) would 
provide a systematic means of addressing this issue. Third, E and Z stilbenoids may 
have different biological profiles, (2) but to date, details as to how this affected phase 














Table 2-1: Structures of methoxylated stilbenes 
 
1 Purchased from commercial sources. 
 
2.2.2. Chemical considerations 
The stilbenes were synthesized by the Wittig reaction which involved the 
reaction of a substituted benzaldehyde with a phosphonium salt. A phosphorus ylid 
was generated in situ when the phosphonium salt was treated with a strong base. The 



























































































































reaction of the ylid with the carbonyl group of the benzaldehyde yielded the stilbene, 
as shown in Scheme 2-1. 
 







































The phosphonium salt was synthesized from 4-methoxybenzyl alcohol. The 
alcoholic OH group was displaced by bromide (from phosphorus tribromide) to give 
the benzyl bromide which was converted to the phosphonium salt by reaction with 
triphenylphosphine. The phenyl ring of the phosphonium salt (S2, Scheme 2-2) would 
eventually be ring B of the final compounds (S3-S14).   
In the presence of butyllithium as base, the phosphonium salt S2 was 
converted to the ylid, which reacted with the substituted benzaldehyde to give the 
stilbene. Both Z and E isomers of the stilbene were obtained in most instances and 
these were separated by column chromatography, with the Z isomer obtained as the 
predominant isomer. The substituted benzaldehydes for stilbenes S3-S11 were 





Scheme 2-2: Synthetic pathway for Stilbenes S3-S11 
 
Reagents and conditions: (a) PBr3, CH2Cl2, 0 ℃ (b) PPh3, toluene, reflux (c) n-BuLi, 
THF, -78 ℃. 
In the case of stilbenes with phenolic hydroxy (OH) groups (S12- S14), the 
phenolic OH group of the benzaldehyde was protected by conversion to the t-
butyldimethylsilyloxy ether by reaction with t-butydimethylsilyl chloride in the 
presence of N,N-diisopropylethylamine in tetrahydrofuran (THF) as solvent (Scheme 
2-3). Once protected in this way, the benzaldehyde was reacted with the phosphonium 
salt S2 to give the silyloxystilbenes S19 and S20. The latter was obtained exclusively 
as Z isomer.  To obtain the corresponding E isomer, the Z isomer was reacted with a 
catalytic amount of iodine in refluxing heptane. Iodine was added to the carbon-
carbon double bond (Z), and then eliminated to reform the double bond, but this time 
in the thermodynamically more stable E configuration. Removal of the protecting 
group from the Z or E isomer gave stilbene S12 or S13, with retention of 
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configuration. It may be of interest to note that stilbene S11E was synthesized without 
the need to protect the 2-OH group on ring A, possibly because of the ortho position 
of this group. The same procedure was adopted for the synthesis of stilbene S14 but 
the silyloxystilbene was obtained as a mixture of E and Z isomers. These were 
separated by column chromatography and each isomer was separately reacted with 
tetrabutylammonium fluoride to give the desired product. 














S16, S19Z, S19 E:R1= OSi(CH3)2C(CH3)3, R2=R3 =H













S12Z, S12E: R1= OH, R2=R3 =H































Reagents and conditions: (a) t-Bu(CH3)2SiCl, DIEA, THF (b) n-BuLi, THF, -78 ℃, 
4-methoxy benzyltriphenylphosphonium bromide S2 (c) I2, heptane, 12 h reflux, (d) 
Bu4NF, THF. Compound S21 was obtained as a mixture of Z and E isomers. These 
were separated by column chromatography and then individually reacted via (d). 
 
Tetrabutyllammonium fluoride was used for the removal of the silyloxy group. 
The mechanism involved attack by the fluoride anion on the tetra-coordinated silicon 
(Si, a reaction made possible by the long Si-C bonds that served to relieve steric 
interaction. In addition, the d orbitals of Si that were targets for the nucleophilic 
fluoride did not have the geometric constraints of the C-O * orbital. A penta-
coordinated intermediate was formed and it broke down to give a silyl fluoride as a 
side product and the deprotected hydroxy group. 





















Unlike other stilbenes, S15 was obtained by the McMurry coupling of 2-
methoxyaldehyde in the presence of a low-valent titanium reagent made of titanium 
trichloride and zinc powder. (66) 2-Methoxybenzaldehyde underwent de-oxygen 







  Scheme 2-5: Synthetic pathways for Stilbene S15E 
 
 
Reagents and conditions: (a) TiCl4, zinc powder, THF, 12 h reflux. (b) I2, heptane, 12 
h reflux. 
 
2.2.3. Assignment of configuration  
The stilbenes were obtained as a mixture of E and Z isomers and assignment 
was made from the coupling constants of the olefinic protons. In the 1H NMR 
spectrum, coupling between protons arises from through-bond and not through-space 
interactions. Larger coupling constants were observed when there was an increase in 
the through bond distance between protons. It was also observed in molecules with a 
larger dihedral angle between the two C-H bonds in question. On the other hand, the 
presence of electronegative substituents results in smaller coupling constants. With 
these considerations in mind, when the hydrogen (H) atoms at either end of a double 
bond are cis (Z), the coupling constant J would be smaller (typically about 10 Hz) 
than when the H atoms are trans (E) (J = 15-18 Hz). This has been attributed to the 
more perfect parallel alignment of the orbitals (“anti” arrangement) in the trans/E 
compound, thus leading to better communication through the bonds. 
 In the case of the methoxystilbenes, the olefinic protons of the Z isomer were 
found at  12 Hz, whereas the same protons of the E isomer were observed at  16 Hz.  
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Coupling constants could not be used to assign the configuration of compound S5 
because of the symmetry in the molecule. Fortunately, S5 had been previously 
reported (67) and it was possible to identify the isomers by comparing their proton 
NMR with reported values for the Z and E isomers. The Z-stilbenes were generally 
found to be oils whereas their E counterparts were solids. The different physical states 
reflect the better packing among the molecules with the E configuration. For those 
compounds that were obtained as a single isomer, comparison with the other isomer 
was not possible. Assignment was thus more difficult and the coupling constant of the 
olefinic protons were compared to expected values of E and Z isomers. Where 
available, melting points were compared to those reported in the literature.  
 
2.2.4. Experimental methods 
Melting points (uncorrected) were determined on a Buchi melting point 
apparatus in open glass capillary tubes. 1H spectra (300 MHz) were recorded on 
Brucker ACF (DPX-300) magnetic resonance spectrometer with DMSO-d6 or CDCl3 
as solvent. Chemical shifts were reported in ppm using residual CHCl3 (δ 7.25) and 
DMSO (δ 2.49) as internal standards. Coupling constants (J) were reported in hertz 
(Hz). Proton (1H) NMR information is tabulated in the following format: multiplicity, 
coupling constant, number of protons. Multiplicities are reported as follows: s=singlet, 
d=doublet, t=triplet, q=quartet, dd=doublet of doublets, td=triplet of doublets, 
ddd=doublet of doublet of doublets, m=multiplet.   Proton decoupled 13C NMR 
spectra (75 MHz) were determined on the same instrument and reported in ppm (δ) 
relative to residual CHCl3 (δ 77.0) and DMSO (39.5). Two-dimensional NOESY 
spectra were recorded on Bruker (DRX-500) 500MHz spectrophotometer with 
DMSO-d6 as solvent and internal standard (δ 2.49 ppm). Reactions were routinely 
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monitored by thin layer chromatography (TLC) on pre-coated plates (silica gel 60 
F254, Merck), with ultraviolet light as visualizing agent.  Column chromatography 
was carried out with silica gel 60 (0.04-0.063 mm) with hexane/ethyl acetate as 
eluting solvents. Nominal mass spectra were collected on LcQ Finnigan MAT mass 
spectrometer with chemical ionization (APCI) as probe. The purities of final 
compounds were verified by reverse phase HPLC on two different solvent systems 
(isocratic mode). Details are given in the Appendix 1. The melting points, nominal 
mass and NMR data of intermediates and final compounds are also given in the 
Appendix 2. 
 
4-Methoxybenzyl bromide (S1) 
Phosphorus tribromide (3.1 ml) was slowly added to a solution of 4-
methoxybenzyl alcohol (12.79 ml) in dichloromethane (150 ml) at 0 ℃, and stirring 
was continued for 12 h. The reaction mixture was poured into aqueous sodium 
bicarbonate and extracted with dichloromethane. Removal of the solvent in vacuo 
from the organic phase gave the product as a clear oil (19.1 g, 95%); 1H NMR (300 
MHz CDCl3)  ppm 7.32 (d, J=8.7 Hz, 2H), 6.86 (d, J=8.6 Hz, 2H), 4.50 (s, 2H), 3.80 
(s, 3H, OCH3). 
4-Methoxybenzyltriphenylphosphonium bromide (S2) 
Triphenylphosphine (25 g) was added to a solution of bromide S1 (19.1 g) in 
toluene (250 ml). The mixture was refluxed for 6 h and then cooled down to room 
temperature. The product was collected, recrystallized from ethanol and obtained as a 
colorless solid (42.3 g, 96%), mp 234-235 ℃; 1H NMR (300 MHz CDCl3)  ppm 7.66 
(m, 15H), 6.96 (d, J=8.7 Hz, 2H), 6.61 (d, J=8.7 Hz, 2H), 5.20 (d, J=13.6 Hz 2H), 
3.68 (s, 3H, OCH3). 
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General procedure for the synthesis of stilbenes (S3-S11) 
n-Butyllithium (1.6 M in hexane, 1 mmol) was added to 4-
methoxybenzyltriphenylphosphonium bromide 2 (1.1 mmol) in anhydrous 
tetrahydrofuran (30 ml) at -78 ℃, and the resulting red solution was stirred under 
nitrogen for 30 min. A solution of aldehyde (1 mmol) in anhydrous tetrahydrofuran 
was added dropwise over 30 min and the mixture was stirred for 16 h. The resulting 
suspension was poured into water and extracted with ethyl acetate. The organic phase 
was washed with brine, and removal of the solvent in vacuo gave a mixture of cis and 
trans isomers. The two isomers were separated by flash column chromatography 
(hexane/ethylacetate 99:1), with the Z isomer eluting first from the column followed 
by the E isomer. The Z isomer was obtained as a clear oil, in contrast to the E isomer 
which was obtained as a colorless solid. The melting points, nominal mass and NMR 
data of S3-S11 are given in the Appendix 2. 
 
General Procedure for the protection of phenolic groups with tert-butyldimethylsilyl 
chloride (S16-S18) 
3-(Tert-Butyldimethylsilyloxy)benzaldehyde (S16) 
Two equivalents (1.29 g) of DIEA and two equivalents (1.79 g) of tert-
butyldimethylsilylchloride were reacted with 3-hydroxybenzaldehyde (5 mmol). 
0.93g, 70% yield;  1H NMR (300 MHz CDCl3)  ppm 9.95 (s, 1H, CHO), 7.48 (t, 
J=1.1 Hz, 1H), 7.40 (t, J=7.5 Hz, 1H), 7.33 (t, J=2.6 Hz, 1H), 7.10 (q, J=1.1 Hz, 1H), 






3, 5- Di (tert-Butyldimethylsilyloxy) benzaldehyde (S17) 
Four equivalents (2.58 g) of DIEA and two equivalents (3.58 g) of tert-
butyldimethylsilyl chloride were reacted with 3, 5-dihydroxybenzaldehyde (5 mmol) 
as described earlier.  0.97g, 58% yield; 1H NMR (300 MHz CDCl3)  ppm 9.86 (s, 1H, 
CHO), 6.96 (d, J=2.3 Hz, 2H), 6.59 (t, J=2.3 Hz, 1H), 0.99 (s, 18H, C (CH3)3), 0.22 (s, 
12H, Si (CH3)2). 
 
 3-(Tert-Butyldimethylsilyloxy)-4-methoxy benzaldehyde (S18)  
Two equivalents (1.29 g) of DIEA and two equivalents (1.79 g) of tert-
butyldimethylsilylchloride were reacted with 3-hydroxy-4-methoxybenzaldehyde (5 
mmol) as described earlier. Yield: 1.07g, 80%; 1H NMR (300 MHz CDCl3)  ppm 
9.82 (s, 1H, CHO), 7.48 (q, J=1.9 Hz, 1H), 7.37 (d, J=1.9 Hz, 1H), 6.96 (d, J=8.3 Hz, 
2H), 3.89 (s, 3H, OCH3), 1.00 (s, 9H, C (CH3)3), 0.17 (s, 6H, Si (CH3)2). 
 
General procedure for the synthesis of silyloxystilbenes (S19-S21) 
Equimolar quantitites (5 mmol) of benzaldehyde (S16, S17 or S18) and 4-
methoxybenzyl triphenyl phosphonium bromide S2 were reacted in the presence of n-
butyllithium and tetrahydrofuran as solvent as described earlier. Stilbenes S19 and 
S20 were obtained as Z isomers. The E isomer was obtained by refluxing a solution of 
the Z isomer (5 mmol) in heptane (20 ml) in the presence of a catalytic amount of 
iodine (1 crystal) for 16 h. The reaction mixture was diluted with 20 ml ether and 
washed with saturated aqueous sodium bisulfite (40 ml) and brine (2 ×10 ml). The 
organic layer was dried over anhydrous MgSO4 and concentrated in vacuo to give the 
trans isomer in 90-92% yields. Stilbene S21 was obtained as a mixture of Z and E 
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isomers that were separated by flash column chromatography. The melting points, 
nominal mass and NMR data of S19-S21 are given in the Appendix 2. 
 
General procedure for deprotection of silyoxystilbenes (S19-S21) 
Tetrabutylammonium fluoride was added to a solution of the cis or trans 
silyloxy-protected stilbene in anhydrous tetrahydrofuran (20 ml). The pale yellow 
solution was stirred for 45 min, poured into water, and extracted with 
dichloromethane, from which removal of the solvent in vacuo provided a clear oil in 
80-90% yield. The oil was separated by flash column chromatography (hexane/ethyl 
acetate 9:1) to give the product. The melting points, nominal mass and NMR data of 
the resulting stilbenes S12, S13, S14 are given in the Appendix 2. 
 
E-2,2'-Dimethoxystilbene (S15) 
Two equivalents of titanium tetrachloride in dichloromethane (1.5 M) was 
added dropwise to powdered zinc (2.5 equivalents) in a round bottom flask that was 
charged with N2 gas and cooled in an ice water bath. About 50 ml of THF was then 
added and the mixture was brought to reflux for 2 h. It was then cooled to room 
temperature and a solution of 2-methoxybenzaldehyde (5 mmol) in THF was added 
dropwise. The mixture was then refluxed for 12 h. The reaction mixture was extracted 
with dichloromethane (3 times) and the organic layer was washed with brine and 
dried over anhydrous MgSO4. The organic solvent was removed in vacuo and the 
residue was purified by column chromatography (hexane/ethyl acetate 99:1). The 
product was obtained as a mixture of Z and E isomers, and converted to the E isomer 
by refluxing in heptane in the presence of iodine. The E isomer was obtained in 10% 
yield. The melting points, nominal mass and NMR data are given in the Appendix 2. 
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2.3. 3-Substituted Indolin-2-ones 
2.3.1. Rationale of drug design 
           As described in Section 1.6, the decision to focus on the indolin-2-one moiety 
was based on the known bioisoteric relationship between this fragment and phenol. 
(57)  Two possible ways of attaching the indolin-2-one moiety to ring A of resveratrol 
were considered, namely a route that would result in 5-substituted indolin-2-ones and 
another that would give 3-substituted indolin-2-ones. The latter was favoured for the 
following reasons: 
(i) The lower lipophilicity of the 3-substituted indolin-2-one, compared to the 5- 
substituted indolin-2-one. It is always a good strategy to start from a compound with 
lower lipophilicity because larger and more lipophilic molecules tend to result during 
the course of structural modifications. 
(ii) 3-Substituted indolin-2-ones are associated with antiproliferative activities (60, 61) 
which may contribute to chemopreventive activity. 
(iii) Presence of a Michael reaction acceptor moiety in the indolin-2-one moiety 
which may predispose this template to chemopreventive activity. 
 61 compounds were synthesized. They were organized into four classes. The 
1st class (Table 2-2) consisted of 3-benzylideneindolin-2-ones with different 
substituents on the phenyl ring B. To probe the hydrophobic and electronic demands 
of the phenyl ring B, various substitutents were introduced. Selection was based on 
the Craig Plot to ensure representation of electron-donating/withdrawing and 
lipophilic/hydrophilic groups. (68) Steric factors were addressed by replacing the 
phenyl ring with naphthalene, indole or pyridine. In addition, the compounds were 




















Compound R' Compound R' 
1 H 20 4'-CH3 
2 2'-OCH3 21 4'-C2H5 
3 3'-OCH3 22 2'-F 
4 4'-OCH3 23 3'-F 
5 2'-OCH3, 4' –OCH3 24 4'-F 
6 2'-OCH3, 5' –OCH3 25 2'-F, 4'-F 
7 2'-OCH3, 6' –OCH3 26 3'-Cl 
8 3'-OCH3, 5' –OCH3 27 4'-Cl 
9 3'-OCH3, 4' –OCH3, 5' –OCH3 28 2'-Cl, 4'-Cl 
10 3'-O-C6H5 29 2'-Cl, 4'-F 
11 2'-OH 30 2'-CF3 
12 3'-OH 31 3'-CF3 
13 2'-OH, 5' –OH 32 4'-CF3 
14 3'-OH, 5' –OH   33 1 4'-CN 
15 2'-OH, 4' –OCH3   34 1 2'-pyridinyl 
16 3'-OH, 4' –OCH3   35 1 4'-pyridinyl 
17 3'-OCH3, 4' –OH   36 1 3'-indolyl 
18 2'-CH3   37 1 1'-napthalenyl 
19 3'-CH3   38 1 2'-napthalenyl 
 
1 Ring B is replaced by the pyridine, indole or naphthalene. 
 
Class 2 compounds were substituted on both rings A and B (Table 2-3). Three 
representative groups on ring B were chosen: 3'-methoxy, 3'-hydroxy-4'-methoxy, and 
3'-trifluoromethyl. These groups were chosen because the Class 2 compounds were 
decided after the Class 1 compounds were evaluated for NQO1 induction activity. 
The more active compounds in Class 1 were associated with these substituents. For 
each ring B substituent, three different ring A groups were investigated (6-fluoro, 6-
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chloro, 6-methoxy). In this case, selection was based on the commercial availability 
of the starting reagents. 
Table 2-3: Structures of 3-substituted indolin-2-ones (39-48) with substituents 
on ring A (Class 2 compounds) 




















6-F 44 3'-OH, 4' –
OCH3 
6-Cl 
40 5-Cl 45 6- OCH3 
41 6- Cl 46  
3'-CF3 
6-F 
42 6- OCH3 47 6-Cl 
43 3'-OH, 4' –
OCH3 
6-F 48 6- OCH3 
   
Class 3 compounds (Table 2-4) consisted of the following modifications: (i) 
N-methylation of the indolin-2-one nitrogen (49, 50); (ii) reduction of the exocyclic 
double bond (51, 52) and (iii) a shift in the positions of the carbonyl and exocyclic 
double bonds to give the regioisomeric 2-benzylideneindolin-3-ones (53, 54). 
Compounds 49, 51 and 53 would give interesting SAR comparisons to 3 because they 
have the same ring B (3'-OCH3).  Similarly, 50 and 54 could be compared to 16, and 
52 to 20.   The 2-benzylideneindolin-3-one moiety is also known as “aza-aurone” 
because of its resemblance to aurones (2-benzylidenebenzofuran-3-ones), a class of 
minor flavonoids. (69) The structural modifications in Class 3 would cast light on the 
SAR of the 3-benzylideneindolin-2-one template. 
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Table 2-4: Structures of 3-benzylidine-1-methylindolin-2-ones (49, 50), 3-
benzylindolin-2-ones (51, 52) and 2-benzylidineindolin-3-ones (53, 54) (Class 3 
compounds)  
                  
 
 
49:  R' = 3'-OCH3                              51: R' = 3'-OCH3                               53: R' = 3'-OCH3    




Class 4 consisted of isoindigos (3,3'-bisindoles) which may be viewed as two 
indolin-2-ones linked through a double bond at their respective C3 positions. The 
isoindigos are larger in size and more lipophilic, but a check on their molecular 
weights (262- 365) and calculated logP values (CLogP: 2.1 - 3.7) showed that they 
did not exceed the threshold values of the “Rule of Five”. (59) The isoindigos were also 
interesting because two nitrogen-linked Michael acceptor moieties are embedded in 
the ring. Substituents were introduced on one or both rings and the choice of 
substituents was determined primarily by the commercially availability of the starting 








Table2-5: Structures of isoindigos (55-61) (Class 4 compounds) 
 




















Number R R' Number R R' 





56 6-F 60 5-F 
57 5-Cl 61 5-Cl 
58 6-Cl 
 
2.3.2. Chemical considerations 
The Class 1 and 2 compounds (1-50) were synthesized by a Knoevenagel-type 
reaction between an aldehyde and oxindole (Scheme 2-6). 
 




Reagents and conditions: (a) piperidine (cat.), ethanol, microwave, 140 ℃, 15 min or 
reflux, 18 h.  R2 = Methyl for 49 and 50. Substituted benzaldehydes replaced by 




In the typical Knoevenagel reaction, the carbonyl group of an aldehyde or 
ketone reacts with a carbanion under basic conditions. An aldol is formed which 
undergoes dehydration to give an ,β-unsaturated enone as product. The synthesis of 
the 3-substituted indolin-2-ones (1-48) was carried out in the presence of the base 
piperidine as catalyst. Under these conditions, the enol tautomer of oxindole forms the 




















The aldehyde (substituted benzaldehydes or the carboxaldehydes of pyridine, 






















The iminium intermediate reacted with the enolate anion to form an 






















The N-methylated 3-benzylideneindolin-2-ones 49-50 were obtained in a 
similar way but starting from the N-methylated oxindole. The condensation between 
the aldehyde and oxindole was carried out in ethanol as solvent and piperidine as 
catalyst by conventional heating or in a microwave reactor. 
The 2-benzylindolin-2-ones 51 and 52 were synthesized by catalytic 
hydrogenation of the exocyclic double bond of the benzylidineindolin-2-ones 41 and 





The 2-benzylidineindolin-3-ones (53, 54) were obtained by an acid catalyzed aldol 








Reagents and conditions: (a) 50% aqueous ethanol, concentrated hydrochloric acid, 
reflux 2h 
 
The N-acetyl group of 1-(3-hydroxy-1H-indol-1-yl) ethanone was removed in 
































1H-indol-3-ol                                                     
 
















1H-Indol-3-ol reacted with the carbocation to form an aldol which lost water 







































The isoindigos (55-61) were obtained by an acid catalyzed reaction between 
an oxindole and an isatin (Scheme 2-8). 
 




Reagents and conditions: (a) glacial acetic acid, concentrated hydrochloric acid, 
reflux 16h 
The mechanism is also an acid catalyzed aldol condensation. The oxindole 
was protonated on the carbonyl oxygen, followed by the loss of the C3-H proton to 













Oxindole (keto tautomer) Enol tautomer  
The isatin was protonated at the non-amide carbonyl oxygen and the electron-
withdrawing effect of the protonated oxygen generated an electron deficient centre on 


















Reaction between the enolic tautomer of the oxindole and the electron poor carbon of 












































2.3.3. Assignment of configuration 
The 3-substituted indolin-2-ones may exist as either Z or E isomer. These 
isomers are distinguishable by nuclear Overhauser effect (NOE). In the E isomer, 
irradiation of the proton at C4 (H-4) of ring A leads to nuclear Overhauser 
enhancement of the signals attributed to the aromatic protons of ring B (in particular 
the ortho protons H-2' and H-6'). In the Z isomer, irradiation of H-4 of ring A results 
in the enhancement of the vinyl proton signal, as shown in Figure 2-1 























 As a result of these interactions, the chemical shifts of H-2' and/or H-6' on the 
phenyl ring (B) of 3-(benzylidene) indolin-2-ones were found at 7.85 -8.53 ppm for 
the Z isomer, and 7.45-7.84 ppm for the E isomer. (60, 70) This was explained in the 
following way: (70) In the Z isomer, the aromatic proton (H-2' or H-6') was deshielded 
by the carbonyl functionality. In the E isomer, the proton was shielded by the phenyl 
ring of the indolin-2-one core structure. Thus, analysis of the chemical shifts of the 
aromatic protons of ring B (in particular H-2' and H-6') provided a useful means of 
assigning the Z/E configuration of the compound. 
The 1H and 13C NMR spectra of the synthesized compounds (except 51, 52 
which had no exocyclic double bond) showed that they were obtained as a single 
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isomer (E or Z). Various means were used to assign their configuration as described 
in the following paragraphs. 
(i) The x ray structures of 21 (4'-ethyl on ring B) and 37 (1'-napthalenyl) in the solid 
states were obtained (Figure 2-2). Both compounds were found to have the E 
configuration. This led us to assign the same configuration to other 3-(benzylidene) 
indolin-2-ones with 4' substituents (4, 24, 27, and 33). Compound 38 is a regioisomer 
of 37 and both compounds have very similar chemical shifts in the aromatic region. 
Since x-ray analysis showed that 37 had the E configuration, a similar assignment was 
made for 38.  
Figure 2-2: X-ray structures of 21 and 37 
 
 




(ii) Compound 7 has methoxy groups on both the 2' and 6' positions of ring B. It was 
not possible to assign its configuration based on the chemical shifts of the aromatic 
protons on ring B. Thus, 2D NOESY analysis of 7 was used. The chemical shifts of 7 


































The protons of the 2' and 6' methoxy groups appeared as a singlet at 3.73 ppm. 
The NH proton and vinyl proton were observed as singlets at 10.49 ppm and 7.43 
ppm respectively. The ring B protons were represented as a triplet (7.39-7.42 ppm, H-
4') and a doublet (6.74-6.76 ppm, H-3' and H-5') due to cross coupling. The ring A 
protons appeared in two clusters: a triplet at 7.13-7.16 ppm that was assigned to H-6 
and a multiplet at 6-77-6.83 ppm that was assigned to the remaining protons (H-4, H-












 If 7 was present as the Z isomer, NOESY analysis would reveal interactions 
between the vinylic proton and H-4. This was not observed in the spectrum (Figure 2-
3).  Instead interactions were observed between NH and H-7, the meta and para 
protons of ring B, and the protons on ring A (H6 and H4, H5, H7). Hence, it was 
concluded that 7 was present as the E isomer. 
(iii) Several compounds in the library had been reported in the literature and they 
were assigned the E configuration. These were 1, 2, 5, 6, 8, 9, 11, 12, 16, 17, 20, 26, 
28, 34-36 (references are given in Appendix 2). When the 1H chemical shifts of the 
synthesized compounds were compared to the reported values, a good agreement was 
observed. Hence, they were assigned the E configuration. 
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(iv) The syntheses of compounds (23, 29, 32, 46, and 47) gave a mixture of E and Z 
isomers, with one predominant isomer. Both isomers were separated, purified by 
column chromatography and their 1H spectra examined. The chemical shifts of H-2' 
and H-6' were found at 7.90-8.01 ppm for the predominant isomer, and at 8.4-8.5 ppm 
for the minor isomer. Hence, the E configuration was assigned to the predominant 
isomer and the Z configuration to the minor isomer. However, only the E isomer was 
used for biological testing. 
(v) The syntheses of compounds 3, 10, 13-15, 18, 19, 22, 25, 30, 31, 39-45, 48-50 
gave only one isomer. The chemical shifts of the H-2' and/ or H-6' were found at 7.45-
7.84 ppm which were typical of E isomers. There were no literature values for 
comparison and unlike (iv) only one isomer was obtained from the synthesis. In spite 
of these issues, an assignment of E configuration was made for these compounds, 
since the chemical shifts of the aromatic protons fell within the range of the E isomers 
of 3-substituted indolin-2-ones.  
 Compounds 51 and 52 were obtained from the catalytic hydrogenation of 41 
and 20. They have no exocyclic double bond but a chiral centre is present at C3. 
Catalytic hydrogenation is not generally known to be stereoselective and thus, it was 
assumed that 51 and 52 were a mixture of R and S isomers and were used as such for 
biological testing. 
In contrast to the 3-benzylideneindolin-2-ones discussed earlier, the 2-
benzylideneindolin-3-ones 53 and 54 were assigned a Z configuration. 53 was 
reported in literature to be a Z isomer (71) and a comparison of the reported 13C 
chemical shifts with the synthesized compound showed a good agreement. 54 has not 
been previously reported. Both 53 and 54 are structurally very similar and their 13C 
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and 1H chemical shifts in the aromatic region were found to be largely the same. Thus, 
54 was also assigned a Z configuration. 
   Figure 2-4: E and Z isomers of isoindigos 
 















E and Z forms of the isoindigos 55-61 are possible (Figure 2-4). The E isomer 
is thermodynamically more stable because in this configuration, the electrostatic 
repulsion between the carbonyl oxygen atoms is avoided. Isoindigo (compound 55) 
was reported in the literature to have an E configuration. (72) It was used as a reference 
compound and its 13C and 1H chemical shifts were compared with those of the other 
isoindigos in the library. No significant differences were observed and hence, the 
same configuration (E) was assigned to the other isoindigos. 
 
2.3.4. Experimental methods 
General Procedure for synthesis of 3-substituted indolin-2-ones (1-48) 
Equimolar amounts (0.5 mmol) of the oxindole and aldehyde were dissolved 
in ethanol (10 ml), a drop of piperidine (20µl) was added and the mixture heated in a 
sealed vessel (10 ml) which was flushed with argon. The vessel was heated to 140℃ 
for 15 min in a microwave synthesizer (Biotage Initator ®). A few compounds (1, 2, 3, 
4, 5, 7, 8, 9, 14, 18, 22, 20, 24, 27, 33, 34, 35, 36) were synthesized by conventional 
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heating (reflux, 18 h) using the same quantities of reactants dissolved in a larger 
volume (20 ml) of ethanol.  The reaction mixture was then cooled to room 
temperature and the resulting precipitate removed by filtration, carefully washed with 
cold ethanol and recrystallized at least once from ethanol to give the desired product. 
Some compounds (2, 5, 6, 9, 12, 13, and 22) were not sufficiently soluble in ethanol 
to permit recrystallization. These compounds were washed many times with ethanol 
until TLC showed a single spot. In the case of compound 14, it did not precipitate 
from the reaction mixture on cooling. The solvent was then removed under vacuum 
and the oil purified by flash column chromatography (hexane: ethylacetate = 4:1) until 
TLC gave a single spot. 
 
General Procedure for synthesis of substituted 3-benzylindolin-2-ones (51, 52) 
Compound 20 or 41 (100 mg) was dissolved in ethanol (15ml), 10 mg Pd/C 
(10%) was added and the mixture was reacted with H2 in a shaking Parr hydrogenator 
at 50 psi, 16 h, and room temperature (30℃). The catalyst was filtered off and the 
solvent removed in vacuo to give the crude product which was purified by flash 
column chromatography (51 hexane: ethylacetate = 3:1) or recrystallization from 
ethanol (52)  
 
General Procedure for synthesis of substituted 2-benzylidene indolin-3-ones (53, 54)  
The method of Daisley et al with modification (73, 74) was followed. Briefly, 1-
(3-hydroxy-1H-indol-1-yl)ethanone (5mmol) was dissolved in 50% aqueous ethanol 
(25 ml) containing concentrated HCl (0.5ml) and heated to reflux for 1 h under 
protection of argon. The corresponding aldehyde (5mmol) in ethanol was then added 
and heating was continued for another 2 h. The reaction mixture was cooled to room 
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temperature, after which the solvent was removed under reduced pressure and the 
residue purified by flash column chromatography (hexane: ethyl acetate = 4:1). 
 
General Procedure for synthesis of isoindigos (55-61) 
The method of Papageorgiou et al was followed. (75) Briefly, a solution of the 
substituted indolin-2-one (oxindole) (0.5mmol) and (isatin) indoline-2,3-dione 
(0.5mmol) in glacial acetic acid (20ml) and concentrated hydrochloric acid (0.5ml) 
was heated to reflux for 16h under argon protection. The reaction mixture was cooled 
to room temperature and the precipitate removed by vacuum filtration and washed 
liberally with ethyl acetate until a single spot was detected on TLC. 
 
X-ray Crystallography 
Crystals of 21 and 37 were grown in ethanol and mounted on glass fibres. X-
ray data were collected with a Bruker AXS SMART APEX diffractometer, using Mo-
Kα radiation at 223K, with the SMART suite of Programs (SMART version 5.628 
(200), Bruker AXS Inc., Madison, WI). Data were processed and corrected for 
Lorentz and polarisation effects with SAINT (SAINT+ version 6.22a (2001) Bruker 
AXS Inc., Madison, WI), and for absorption effect with SADABS (SADABS, version 
2.10 (2001), University of Göttingen). Structural solution and refinement were carried 
out with the SHELXTL, suite of programs (SHELXTL, Version 6.14 (2000), Bruker 
AXS Inc., Madison, WI). The structure was solved by direct methods to locate the 
heavy atoms, followed by difference maps for the light, non-hydrogen atoms. All non-
hydrogen atoms were generally given anisotropic displacement parameters in the final 
model whereas H-atoms were placed at calculated positions. X-ray crystal data for 21 




            The synthesis of 84 compounds was successfully achieved by standard 
synthetic procedures. Of the 23 methoxystilbenes, the syntheses of 5 compounds (S6Z, 
S6E, S9E, S12Z, and S14Z) have not been reported before based on a search with on 
SciFinder. In the same way, it was found that 13 out of 61 compounds in the 2nd 
library were novel.  These were 14, 15, 39, 43, 45, 46, 48, 51, 54, 56, 59, 60 and 61. 
The purity of the compounds was determined by reversed phase HPLC with two 
different mobile phases and found to be at least 96 % pure based on this analysis. 
Assignment of E/Z configuration was made by NMR, x-ray analysis or by comparison 











Chapter 3 Induction of NQO1 Activity by Methoxystilbenes 
 
3.1. Introduction 
            In this chapter, the methoxylated stilbenes were investigated for their abilities 
to induce NQO1 activity. NQO1 is commonly used as a biomarker for identifying 
compounds with Phase II enzyme induction properties. (76) An earlier report by Heo et 
al (2001) showed that methoxylated stilbenes related to resveratrol induced NQO1 
activity but only to a modest extent. (55) The most active analogue was 2',3,4,4',5-
pentamethoxystilbene (Figure 1-2) and it caused a modest 2.6 fold induction at 
150M (compared to a 2 fold induction at 25 M resveratrol). The aim of this chapter 
is to determine the effect on NQO1 induction brought about by systematically varying 
the number and position of the methoxy groups on the stilbene framework and to 
assess the contribution of E and Z isomers to this activity. Since NQO1 induction may 
help to maintain the antioxidant function of cells, (56) the compounds were also tested 
for their radical quenching properties in the ABTS (2,2'-azino-3-ethylbenzothiazoline-
6-sulfonic acid) decolorization assay. (77) 
 
3.2. Experimental Methods 
3.2.1. Materials  
            Menadione, digitonin, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT),  β-naphthoflavone (BNF), resveratrol, trolox (6-hydroxy-2, 5, 7, 8-
tetramethylchroman-2-carboxylic acid), dicoumarol, ABTS [2,2'-azino-3-ethylbenzo- 
thiazoline  -6-sulfonic acid], salicylamide, 7-ethoxyresorufin and sulforaphane were 
purchased from Sigma-Aldrich (St Louis, MO). Pinosylvin was purchased from 
Sequuoia Research Products (Pangbourne, United Kingdom). 2,3,7,8-
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tetrachlorodibenzo-p-dioxin (TCDD) was purchased from AccuStandard (New Haven, 
USA). Other reagents were of analytical grade. 
 
3.2.2. Cell lines 
Hepa1c1c7 murine hepatoma cells and a mutant (c1, CRL-2716) that was 
defective in the expression of the enzyme aryl hydrocarbon hydroxylase (CYP1A1) 
were purchased from American Type Culture Collection (Rockville, MD). Hepa1c1c7 
and c1 cells were cultured in alpha-minimum essential medium (α-MEM) without 
nucleosides, and containing  10%(v/v) heat- and charcoal-treated fetal calf serum (1 g 
of charcoal per 100 ml of serum; 90 min at 55℃), 0.15% sodium bicarbonate, 0.01% 
penicillin G, 0.01% streptomycin sulfate in an humidified atmosphere of 5% CO2 at 
37℃. Cells were sub cultured when they reached 80-90% confluency and used within 
6–17 passages for determinations. Total protein content was assessed by the Bradford 
assay. (78) Total protein content of Hepa1c1c7 cells was 0.036mg/well. 
 
3.2.3.   MTT assay for determination of cell viability 
Cell viability was determined on Hepa1c1c7 cells using the microculture 
tetrazolium (MTT) assay. (79) The cells were plated at a density of 104 cells per well in 
a 96-well plate and cultured for 24 h. The test compounds were prepared in DMSO 
and serially diluted with medium. Not more than 1% DMSO (final concentration) was 
present in each well. The test compounds were incubated with the cells for 48 h, after 
which 100 µl MTT (0.5 mg/ml in 1×PBS) was added for 3 h and the cells lysed to 
release the formazan product. The latter was dissolved in DMSO (150 µl) and 
absorbance determined within 30 min at 590 nm on a microtitre plate reader. Cell 
survival was given by the expression: 
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Cell survival (%) = A cells + test compound – A blank / A untreated cells – A blank x 100 
where A is the absorbance of formazan measured at 590 nm in the test (A cells + test 
compound), control (A untreated cells) or blank (A blank)wells. Each concentration of test 
compound was evaluated on 3 separate occasions. The IC50 was determined from the 
sigmoidal curve obtained by plotting % surviving cells versus concentration using 
OriginPro 7.5 SR1 (Version V7.5776 B776), OriginLab Corporation, MA.  
 
3.2.4. Determination of NQO1 activity 
The method of Prochaska et al was adopted with some modifications. (80) 
Hepa1c1c7 or c1 cells were grown in 96-well plates (104 per well) for 24 h in α-MEM 
as described in 3.2.2. Stock solutions of test compounds were prepared in DMSO and 
aliquots were added to each well to give the desired final concentrations. The final 
concentration of DMSO in each well was kept at 0.5% v/v or lower. After incubation 
for 48 h, the media was decanted and the cells were lyzed by treating them with a 
solution containing 0.8% w/v digitonin and 2 mM EDTA for 10 min at 37℃. The 
plates were gently agitated on an orbital shaker for 10 min at 23 ℃. An aliquot 
(200µl) of a solution ("complete reaction mixture") was then added to each well. This 
solution was freshly prepared prior to use and consisted of 7.5ml 0.5M Tris-Cl 
(pH=7.4), 100mg  bovine serum, 1ml 1.5% Tween-20, 0.1ml 7.5mM FAD, 1ml 
150mM glucose 6-phosphate, 90µl 50mM NADP, 300 units  yeast glucose-6-
phosphate dehydrogenase, 45mg  MTT and deionized water made up to a final 
volume of 150 ml. Menadione (1 µl of 50 mM menadione dissolved in acetonitrile for 
every milliliter of reaction mixture) was added just before the mixture was dispensed 
into the wells. After addition, the plate was gently agitated for 5 min and the  reaction 
was quenched by addition of a solution (50µl) of 0.3mM dicoumarol in 0.5% DMSO 
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and 5mM potassium phosphate, pH=7.4. A blue color due to the formation of 
formazan was observed in each well and its absorbance was measured at 590 nm on a 
plate reader. Wells with no cells (“blank”) and wells with Hepa 1c1c 7 cells and 
medium containing 0.5% DMSO but without the test compound (“control”) were used 
as controls. NQO1 induction of test compound at a given concentration was 
determined from the equation: 
Degree of induction = A test compound – A blank / A control – A blank 
where A is absorbance of formazan measured at 590 nm in the various wells. 
Reference compounds (sulforaphane, BNF) were determined under similar conditions.   
Each concentration of test compound was determined on three separate occasions. 
Induction was determined over a range of concentrations (10 fold or more) and results 
were plotted using OriginPro 7.5 SR1. The concentration required to bring about a 2-
fold increase in the basal activity of NQO1 (CD) was determined from the plot for 
each compound. 
 
3.2.5.   Quenching of ABTS radical cation 
The method of Re et al was used. (77) Briefly, stock solutions of ABTS (7mM) 
and potassium persulfate (0.245 M) were prepared in distilled water. Aliquots of 
ABTS (1 ml) and potassium persulfate (10 l) were mixed to give a stock solution 
that was kept in the dark at 23℃for 16h to optimize the production of the radical 
cation (ABTS•+). The solution was then diluted with PBS (pH 7.4) to an absorbance 
of 0.70 (±0.02) at 734 nm. An aliquot of the test sample (10 l), freshly prepared in 
80% ethanol) was mixed with the ABTS•+ solution (990 l) in a 1 ml cuvette and 
absorbance was recorded over a period of 5min. At least three concentrations of test 
compound and a known antioxidant (trolox) were determined over the concentration  
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range of 2.5–15 M. Scavenging ability was determined from the reduction in the 
absorbance of ABTS•+ after 5min at a specific concentration of test compound.  
% scavenging activity = 1 – [(A ABTS+ - A ABTS+ + Test compound) / A ABTS+] x 
100 
At least three separate determinations were made for each concentration. The 
plot of % scavenging activity versus concentration of test compound gave a straight 
line, the slope of which was determined and compared with that obtained for trolox 
under similar conditions. The “trolox equivalent antioxidant capacity” (TEAC) of the 
test compound was determined as follows: TEAC = Slope test compound / Slope trolox 
A value of 2 indicated that the test compound was twice as active as trolox in 
quenching ABTS•+.  
 
3.2.6. Measurement of 7-ethoxyresorufin O-deethylase (EROD) activity in 
Hepa1c1c7 cells 
    The method of Marchand et al was used. (37) Hepa1c1c7 cells were plated at a 
density of 10 4 cells per well in a 96-well plate and cultured for 24 h. A stock solution 
of test compound was prepared in DMSO and serially diluted with medium to give the 
desired concentration in the well. The concentration of DMSO was 0.5 % v/v. The 
cells were incubated with test compound for 48 h. After this time, the medium was 
removed, and the well washed with 200µl of 1×phosphate-buffered saline solution 
(PBS) and then incubated with 5 µM 7-ethoxyresorufin and 2 mM salicylamide in 
200µl of medium at 37℃ for 40 min. 7-Ethoxyresorufin (non-fluorescent) is de-
ethylated in the presence of the enzyme EROD to give 7-hydroxy-3H-phenoxazin-3-
one whose fluorescence was monitored in this assay. Salicylamide was added to 
inhibit the further metabolism of 7-hydroxy-3H-phenoxazin-3-one by phase II 
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enzymes. Readings were taken at excitation of 530 nm and emission of 590 nm on a 
Tecan Infinite M200 fluorometer. Fluorescence (if any) of the test compound was 
determined at the same wavelengths to take into account its contribution to the 
observed readings. Readings of empty wells (no cells, “blank”) and wells with 
Hepa1c1c7 cells in medium containing 0.5% DMSO but without test compound 
(“control”) were also determined. TCDD, a stronger inducer of CYP1A1 activity was 
used as positive control.    
CYP1A1 induction activity was given by the expression: 
  Degree of induction = F Cells + test compound – F Blank / F Control – F Blank  
  
3.2.7. In silico determination of log P 
The test compounds were drawn and geometry minimized using the 
Hamiltonian forcefield MMFF94x in MOE ® (Chemical Computing Group, Montreal, 
Canada).  Calculated log P (octanol/water) values were collated using the QuaSAR 
module. 
 
3.2.8. Statistical analysis 
            Data was analyzed for statistical significance with one-way ANOVA followed 
by Tukey post-hoc test. Spearman correlation analysis was carried out to establish 
correlation between parameters. Both determinations were carried out on SPSS 15.0 
for Windows, Chicago, IL. by Spearman (SPSS 15.0). A level of probability of 0.05 






3.3. Results  
3.3.1. Growth inhibitory effects of methoxystilbenes on Hepa1c1c7 cells 
            Growth inhibitory effects of methoxystilbenes were determined primarily to 
ensure that the concentration range used for the NQO1 induction experiments would 
not affect survival of the Hepa1c1c7 cells. IC50 values of the stilbenes were 
determined by the microculture tetrazolium (MTT) assay. (79) Briefly, this assay 
evaluated the ability of viable cells to reduce MTT to purple formazan crystals. 
Compounds with growth inhibitory effects would cause less formazan to be formed. 
IC50 values are given in Table 3-1. Based on these results, some deductions could be 
made on the SAR for antiproliferative activity.   
The unsubstituted stilbenes (Z and E) had weak antiproliferative activities. 
When one or more hydroxyl groups were introduced into the stilbene framework, 
activity remained poor (IC50 > 25 M), as seen from resveratrol, pinosylvin, S11E, 
S12E, S12Z, S13E, S13Z, S14E, S14Z. A comparison of the activities of resveratrol, 
pinosylvin and 13E was instructive because these compounds had similar groups (3,5-
OH) on ring A but different groups on ring B (4'-OH in resveratrol, no substitutent in 
pinosylvin and 4'-OCH3 in S13E). Notwithstanding their similar rings A, these 
compounds had poor antiproliferative activities which implied that modifications on 
ring B had little effect on activity. On the other hand, when the hydroxyl groups on 
ring A of S13E were methoxylated, the resulting compound S8E showed a marked 
improvement in activity (IC50 5.2 M). This trend was also observed in other 
compounds (S3Z, S4Z, S6Z, S7Z, S8Z, and S10Z) that had methoxy groups on ring 
A. The potent activities of S10E and S10Z which had three methoxy groups on ring A 
were particularly notable.   
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A striking difference in activities of Z and E isomers was also observed for 
stilbenes S3, S4, S6, S7, S8 and S10, with greater activity associated with the Z 
isomer. 
Among the isomeric stilbenes with one methoxy group on ring A (S3Z, S4Z, 
S5Z), the 4-methoxy isomer (S5Z) stood out for its significantly lower activity 
compared to the 2-methoxy (S3Z) and 3-methoxy (S4Z) analogues. When two 
methoxy groups were introduced on ring A, the resulting compounds were more 
active, including compounds with a 4-methoxy substituent (S6Z: ring A = 2,4-OCH3, 
IC50 8.1 M; S7Z: ring A = 3,4-OCH3, IC50 5.1 M ). But the isomer without 4-
methoxy group (S8Z: 3,5-OCH3, IC50 0.59 M) had  significantly better activity than 
its isomers S6Z, S7Z, which may imply that there are preferred positions for methoxy 
groups on ring A.  
 The calculated log P values of the stilbenes are given in Table 3-1. It is noted 
that the in silico generated log P values could not distinguish between the Z and E 
isomers.  A visual inspection of log P and growth inhibitory IC50 values did not show 
any apparent correlation between the two parameters and this was confirmed by a 










Table 3-1: IC50, CD values and calculated log P (octanol/water) of methoxystilbenes 



















CD (M)2 Log P3
S3E 2-OCH3 4'-OCH3 >25 0.85 4.42 
S3Z 2-OCH3 4'-OCH3 11.5 No Induction at IC504 4.42 
S4E 3-OCH3 4'-OCH3 >25 3.1 4.46 
S4Z 3-OCH3 4'-OCH3 9.7 No Induction at IC504 4.46 
S5E 4-OCH3 4'-OCH3 >25 >205 4.42 
S5Z 4-OCH3 4'-OCH3 >25 >205 4.42 
S6E 2,4-OCH3 4'-OCH3 >25 5.0 4.41 
S6Z 2,4-OCH3 4'-OCH3 8.1 No Induction at IC504 4.41 
S7E 3,4-OCH3 4'-OCH3 >25 >205 4.16 
S7Z 3,4-OCH3 4'-OCH3 5.1 No Induction at IC504 4.16 
S8E 3,5-OCH3 4'-OCH3 5.2 No Induction at IC504 4.49 
S8Z 3,5-OCH3 4'-OCH3 0.59 No Induction at IC504 4.49 
S9E 2,6-OCH3 4'-OCH3 10.3 2.0 4.37 
S10E 3,4,5-OCH3 4'-OCH3 1.0 No Induction at IC504 3.91 
S10Z 3,4,5-OCH3 4'-OCH3 0.034 No Induction at IC504 3.91 
S11E 2-OH 4'-OCH3 >25 >205 4.16 
S12E 3-OH 4'-OCH3 >25 >205 4.20 
S12Z 3-OH 4'-OCH3 >25 >205 4.20 
S13E 3,5-OH 4'-OCH3 >25 >205 3.96 
S13Z 3,5-OH 4'-OCH3 >25 >205 3.96 
S14E 3-OH, 4-
OCH3 






4'-OCH3 >25 > 205 
4.15 
S15E 2-OCH3 2'-OCH3 >25 2.5 4.42 
Resveratrol 3,5-OH 4'-OH >25 >205 3.70 
Pinosylvin 3,5-OH H >25 >205 4.01 
Stilbene (E) H H >25 17.7 4.85 
Stilbene (Z) H H >25 >205 4.85 
 
1 Concentration required to reduce cell survival of Hepa1c1c7 cells by 50%. Mean of 
three determinations.  2 Concentration required to increase NQO1 induction activity 
by 2-fold compared to basal levels observed in untreated Hepa1c1c7 cells.  Mean of 
three determinations. CD of reference compounds sulphorane and BNF were 0.15 M 
and 0.013 M respectively. 3 Log P (octanol/water) was determined with MOE ® 
(Chemical Computing Group, Montreal, Canada). 4  No induction observed at 
concentrations  IC50 . 
5 CD was not determined because 2-fold induction was not observed at 20 M.  
 
3.3.2. Induction of NQO1 activity by methoxystilbenes 
The NQO1 induction assay is based on the generation of NADPH when 
glucose-6-phosphate is reduced by glucose-6-phosphate dehydrogenase in the 
presence of its co-factor NADP. NADPH is formed and it serves as an electron donor 
for the NQO1- mediated reduction of menadione to menadiol. Menadiol in turn 
reduces MTT to purple formazan whose formation is monitored at 590 nm. Both 
NADP and menadione are regenerated during the catalytic cycle and need not be 
replenished during the course of the assay. An inducer of NQO1 will increase the rate 
at which menadiol is generated, leading to more formazan being formed. Reference 
compounds were sulforaphane and BNF and their CD values were found to be 0.15 
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M and 0.013 M respectively. These values were close to those reported in the 
literature. (16) 
Having established the IC50 values in Section 3.3.1, the compounds were 
tested for induction at concentrations that would not result in cell death. As seen from 
Table 3-1, CD values were obtained for only a few compounds. One reason was that 
compounds with strong antiproliferative activities (S3Z, S4Z, S6Z, S7Z, S8E, S8Z, 
S10E, and S10Z) did not induce NQO1 at concentrations that did not kill the cells. 
Other compounds (S11- S14, resveratrol, pinosylvin, Z-stilbene) did not induce 
NQO1 activity at the highest concentration (20 M) tested and were not pursued 
further. For compounds with CD values, induction activity was ranked as follows: 
S3E (CD 0.85 M) > S9E, S15E, S4E > S6E > E-stilbene (CD 17.7 M). 
The stilbene S3E (2,4'-dimethoxystilbene) was found to be the most active 
inducer of NQO1 activity in the Hepa1c1c7 cells. It was also tested on the mutant c1 
cells that do not express CYP1A1. As seen in Figure 3-1, S3E had negligible NQO1 
induction activity in the c1 cells. This would imply that an active metabolite (s) of 
S3E was involved in NQO1 induction and that CYP1A1 was involved in the 
formation of these metabolites. CYP1A1 catalyzes the hydroxylation of aromatic 









Figure 3-1:  NQO1 induction activities of S3E tested at different concentrations on 































Since S3E induced NQO1 activity, it was of interest to determine if it also 
induced CYP1A1 activity. Thus its effect on the O-deethylation of 7-ethoxyresorufin 
was investigated in the EROD assay. EROD (7-ethoxyresorufin de-ethylase) is the 
enzyme that mediates the O-deethylation of 7-ethoxyresorufin.  It is widely used to 
assess the bioactivation capacity of CYP1A1. (81) S3E was tested at 5 M, a 
concentration that was equivalent to 4 times its CD value for NQO1 induction.  At 
this concentration, S3E increased CYP1A1 activity by 1.2 fold, compared to 3.4 fold 
for the known inducer TCDD which was tested at 10 nM. The level of NQO1 
induction at the same concentration (4 x CD) was 4.9, which meant that S3E 









3.3.3. Radical quenching activity of  methoxystilbenes 
The ABTS decolorisation assay was based on the ability of the test compound 
to scavenge the stable radical cation of ABTS (ABTS+). The nitrogen radical of this 
species imparted a deep purple color at 734 nm which was lost when quenched by an 
antioxidant.  Radical quenching activity was compared to that of a reference 
antioxidant (trolox) and given as a ratio TEAC. A compound with a higher TEAC has 
stronger radical quenching properties. TEAC of the test compounds are given in Table 
3-2. 
 













1 Compounds S3- S11, S15 had no radical quenching properties.  2 Mean ( SD, n 
=3). 
Compound 1 R on Ring A R' on Ring B TEAC 2 
S11E 2-OH 4'-OCH3 1.49(0.05) 
S12 E 3-OH 4'-OCH3 1.04 (0.05) 
S12 Z 3-OH 4'-OCH3 1.11 (0.03) 
S13E 3,5-OH 4'-OCH3 1.86 (0.03) 
S13Z 3,5-OH 4'-OCH3 2.49 (0.06) 
S14E 3-OH, 4-OCH3 4'-OCH3 1.11 (0.02) 
S14Z 3-OH, 4-OCH3 4'-OCH3 1.29 (0.06) 
Resveratrol 3,5-OH 4'-OH 2.74 (0.09) 
Pinosylvin 3,5-OH H 2.04 (0.06) 
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Resveratrol was found to have a TEAC of 2.74 and pinosylvin which did not 
have a 4'-OH on ring B, had a lower TEAC value of 2.04.  Interestingly, S13E with a 
4'-methoxy group on ring B and the same ring A substituents as resveratrol and 
pinosylvin (3, 5-OH) had a TEAC of 2.49. Thus, the antioxidant activity of resveratrol 
owed little to the presence of the 4'-hydroxyl on ring B, as it could be methoxylated or 
omitted altogether with little effect on antioxidant activity.  In contrast, the hydroxyl 
groups on ring A of resveratrol were important for antioxidant activity. This was 
evident from the following observations: 
(i) Removal of one of the hydroxyl groups from ring A of S13E (3,5-OH) gave S12E 
(3-OH) which had a lower TEAC (1.04).   
(ii) Replacing both hydroxyl groups of S13E with methoxy groups (S8E, 3,5-OCH3) 
completely abolished scavenging activity.   
(iii) The quenching activities of S14E and S14Z which had both hydroxyl and 
methoxy groups on ring A were not markedly different from compounds with only 
one hydroxyl group (S11E, S12 E/Z). 
Thus, rings A and B of the stilbene framework had different substitution 
requirements: Ring A must have at least two hydroxyl groups but ring B need not be 
hydroxylated for radical quenching activity. The role of Z and E isomers could not be 
fully established since only two examples were available.  
 
3.4. Discussion 
            Resveratrol was reported to be an inducer of NQO1 in Hepa1c1c7 cells with a 
CD of 21 M. (52) It had an identical induction profile on the mutant BPrc1 cells that 
lacked a functional AhR receptor. This implied that resveratrol was a monofunctional 
inducer, acting via the Nrf2 pathway to bring about NQO1 induction. Resveratrol also 
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inhibited human CYP1A1 and CYP1A2. (53) CYP1A1 is involved in the hydroxylation 
of polycyclic aromatic hydrocarbons. Many polycyclic aromatic hydrocarbons are 
procarcinogens and hydroxylation results in the formation of the carcinogenic species.  
Thus, CYP1A1 is one of the most important enzymes involved in tumor initiation.  
CYP1A2 is the major P4501A subfamily protein and catalyzes the dealkylation of O-
ethers. Although EROD is a CYP1A2 enzyme, an increase in EROD activity is taken 
to reflect the induction of CYP1A1 activity. (81) The antioxidant activity of resveratrol 
has been widely reported (82, 83, 84) and ascribed to the phenolic character of resveratrol. 
 The growth inhibitory activities of the compounds were determined on the 
murine Hepa1c1c7 cells to facilitate the NQO1 induction experiments which were 
done on the same cell line.  Neverthess, some SAR trends were apparent, namely that 
a Z configuration and presence of methoxy groups, particularly on ring A were 
features that enhanced antiproliferative activity. 
Resveratrol was found to be a weak NQO1 inducer with CD > 20 M. 
Stilbenes with 4'-methoxy group on ring B and hydroxyl groups on ring A also 
showed poor NQO1 induction activity but stilbenes that were methoxylated on both 
rings (S3E, S4E, S6E, S9E) showed a strong induction effect. The association of 
induction activity with the E isomer would be more convincing if more isomeric pairs 
were available for comparison. Presently only three pairs of isomers (S3E/Z, S4E/Z, 
S6E/Z) were evaluated. The most active NQO1 inducer in this library was S3E with a 
CD of 0.85 M. The induction activity of S3E may be due to an active metabolite 
produced by CYP1A1 metabolism. It was also a bifunctional inducer, but has a 4-fold 
selectivity for NQO1 which is an advantageous feature. The results from the EROD 
assay could be due to the inhibition of CYP1A1 by S3E but this aspect was not 
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investigated. If this is proven true in future investigations, it would not be undesirable 
as inhibition of CYP1A1 would prevent activation of procarcinogens.  
Most of the methoxystilbenes had negligible radical quenching activity. SAR 
pointed to the presence of hydroxyl groups on ring A for this property. Since this 
structural feature strongly diminished NQO1 induction and antiproliferative properties, 
it would seem that antioxidant activity (evaluated by the present assay) contributed 
little to either property. On the other hand, results from non-cell based antioxidant 
assays (such as the ABTS decolorization assay) are generally difficult to interpret and 
extrapolate to a biological context and confirmation from cell based assays would be 
necessary if this investigation is to be pursued in future. 
 
3.5. Conclusion 
           A series of methoxystilbenes related to resveratrol were investigated for their 
effects on NQO1 induction and growth inhibition on the murine hepatoma cells. Both 
activities were enhanced in compounds with methoxy groups on both rings A and B. 
On the other hand, antioxidant activity (measured by quenching of ABTS radical 
cation) was abolished by the same modification. The association of Z isomers with 
strong growth inhibitory properties was observed for many compounds but the other 
activities did not manifest a preference for either isomer. The most promising 
compound was S3E for NQO1 induction. S3E had a bifunctional profile but exhibited 
selectivity for NQO induction compared to CYP1A1 induction. Thus it may still be 




Chapter 4 Induction of NQO1 Activity by Indolinones and Related Compounds 
 
4.1. Introduction 
            In this chapter, the NQO1 induction properties of 3-substituted indolin-2-ones 
and related compounds were investigated. The rationale for the design of this series of 
compounds was the bioisosteric relationship between the phenolic and indolin-2-one 
moieties. 3-Benzylideneindolin-2-one has a nitrogen linked Michael acceptor 
fragment, that is unlike conventional Michael acceptors which are unsaturated carbon 
bonds conjugated to electron withdrawing groups. The aim of this chapter was to test 
the hypothesis that 3-benzylidene indolin-2-ones are NQO1 inducers and that the 
nitrogen- linked Michael acceptor moiety present in these molecules contributed to 
this activity. The hypothesis was investigated by evaluating NQO1 induction in 
Hepa1c1c7 and mutant c1 cells, and induction of CYP1A1 by the EROD assay. 
 
4.2. Experimental Methods 
4.2.1 Materials and cell lines 
            The descriptions in 3.2.1 and 3.2.2 are applicable.   
4.2.2 MTT assay for determination of cell viability 
            The method described in 3.2.3 was followed. 
4.2.3 Determination of NQO1 activity 
           The method described in 3.2.4 was followed. 
4.2.4 Measurement of 7-ethoxyresorufin O-deethylase (EROD) activity in 
Hepa1c1c7 cells 





4.2.5 Statistical analysis 
Data was analyzed for statistical significance by one-way ANOVA followed 
by Tukey HSD as post-hoc test on SPSS 15.0 for Windows, Chicago, IL. Spearman's 
correlation analysis was carried out on the same software. A level of probability of 
0.05 was used as the criterion for significance. 
 
4.3 Results 
4.3.1.   Induction of NQO1 activity in Hepa1c1c7 cells 
 The compounds were initially screened for growth inhibitory activity on 
Hepa1c1c7 cells in order to determine the concentration range to be used for the 
NQO1 induction assay. A fixed concentration of 25 M was used and compounds that 
reduced cell survival by less than 50% were earmarked for IC50 determination by the 
MTT assay.  These values are given in Table 4-1. The IC50 of the other compounds 
were not determined as the initial screening suggested that these values would be 
greater than 25 M.  The compounds were subsequently tested over a series of 
appropriate   concentrations to determine their CD values, which is the concentration 
required to bring about a 2-fold increase in the basal NQO1 activity. The CD values 










Table 4-1:  CD and IC50 of Class1-4 compounds 
NO. Ring A (R) Ring B (R') QR Induction of 






1 R = H R' =H 0.92±0.09 >25 
2 R = H R' =2'OCH3 0.25±0.06 >25 
3 R = H R' =3'OCH3 0.27±0.06 >25 
4 R = H R' =4'OCH3 0.87±0.11 >25 
5 R = H R' =2',4' (OCH3)2 >11 11.1 
6 R = H R' =2',5' (OCH3)2 0.013±0.003 >25 
7 R = H R' =2',6' (OCH3)2 >14 13.9 
8 R = H R' =3',5' (OCH3)2 >16 16.0 
9 R = H R' =3',4', 5' (OCH3)3 >25 >25 
10 R = H R' =3' OC6H5 1.7±0.4  10.8 
11 R = H R' =2'-OH 9.0±1.0 >25 
12 R = H R' =3'-OH 1.1±0.2 >25 
13 R = H R' =2',5' (OH)2 2.4±0.6 >25 
14 R = H R' =3',5' (OH)2 5.3±0.6 >25 
15 R = H R' =2'-OH, 4'OCH3 0.49±0.13 >25 
16 R = H R' =3'-OH, 4'OCH3 0.12±0.03 11.9 
17 R = H R' =3'OCH3, 4'OH 0.86±0.08 14.6 
18 R = H R' =2'CH3 0.85±0.07 >25 
19 R = H R' =3'CH3 0.27±0.05 >25 
20 R = H R' =4'CH3 1.6±0.2 >25 
21 R = H R' =4' C2H5 2.4±0.4 >25 
22 R = H R' =2'F 0.85±0.07 >25 
23 R = H R' =3'F 1.73±0.4 >25 
24 R = H R' = 4'F 5.1±0.7 >25 
25 R = H R' = 2', 4' (F)2 3.3±0.6 >25 
26 R = H R' =3'Cl 0.12±0.03 5.9 
27 R = H R' = 4'Cl 0.45±0.1 6.7 
28 R = H R' = 2', 4' (Cl)2 2.3±0.6 10.6 
29 R = H R' = 2'Cl, 4'F 0.33±0.08 >25 
30 R = H R' =2'CF3 4.5±0.6 >25 
31 R = H R' =3'CF3 0.027±0.006 3.9 
32 R = H R' =4'CF3 0.031±0.009 12.0 
33 R = H R' =4'CN 20.7±2.1 >25 
34 R = H 2'pyridinyl 2.7±0.5 19.9 
35 R = H 4'pyridinyl 14.4±1.3 >25 
36 R = H 3'indolyl 0.17±0.05 >25 
37 R = H 1' napthalenyl >19 18.6 
38 R = H 2' napthalenyl 0.42±0.06 >25 
CLASS 2 2a
39 R = 6F R' =3'OCH3 0.17±0.05 9.8 
40 R = 5-Cl R' =3'OCH3 0.36±0.06 17.5 
41 R = 6-Cl R' =3'OCH3 0.039±0.01 >25 
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42 R = 6-OCH3 R' =3'OCH3 0.13±0.05 9.8 
43 R = 6F R' =3'-OH, 4'OCH3 0.11±0.05 15.6 
44 R = 6-Cl R' =3'-OH, 4'OCH3 0.076±0.01 >25 
45 R = 6-OCH3 R' =3'-OH, 4'OCH3 0.24±0.08 9.8 
46 R = 6F R' =3'CF3 0.016±0.007 2.2 
47 R = 6-Cl R' =3'CF3 0.0041±0.0009 1.1 
48 R = 6-OCH3 R' =3'CF3 0.085±0.014 2.6 
CLASS 3 
49 2b - R' =3'OCH3 1.07±0.15 >25 
50 2b - R' =3'-OH, 4'OCH3 1.2±0.3 15.5 
51 2c - R' =3'OCH3 10.9±1.1 >25 
52 2c - R' =4'CH3 >25 >25 
53 2d - R' =3'OCH3 0.49±0.07 21.2 
54 2d - R' =3'-OH, 4'OCH3 1.9±0.2 >25 
CLASS 4 2e
55 R = H R' = H 0.025±0.008 >25 
56 R = 6F R' = H 0.0083±0.0016 >25 
57 R = 5Cl R' = H 0.0015±0.0007 20.5 
58 R = 6Cl R' = H 0.0017±0.00097 >25 
59 R= 6CF3 R' = H 0.00056±0.00021 >25 
60 R= 6CF3 R' = 5F 0.00096±0.00016 >25 
61 R= 6CF3 R' = 6Cl 0.00069±0.0002 9.8 
 


























(a) Class 1 and Class 2 (e)Class 4
R'





(c) Class 3 (51,52)
 
  Compounds 5, 7, 8 and 37 had no effect on NQO1 induction at concentrations 
below their IC50, and could not be tested at concentrations > IC50. Thus their CD 
values were recorded as > IC50, rounded up to the nearest unit. Compound 9 and 52 
were also found to be weak inducers when tested at the highest concentration of 25 
M. Thus, their CDs were listed as > 25 M in Table 4-1. Some interesting SAR 
trends were observed from the induction properties of each Class of compounds and 
these are discussed in the following paragraphs. 
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The 3-substituted indolin-2-ones of Class 1 (n = 38) showed an impressive 103 
fold difference in induction activity. Since modifications were only made on ring B, 
the nature of ring B was a critical determinant of activity. The compounds in Class 1 
may be classified as those that were monosubstituted on ring B (n = 19), di- or tri-
substituted on ring B (n = 13) or had a non-phenyl ring B (n= 5). 
Among the Class 1 compounds with monosubstituted ring B, the NQO1 
induction activities of compounds with 3' or 4' substituent were examined. For 
compounds with 4'-substituent, activity decreased in the order of 4'-CF3 (32, 0.031 
M) > 4'-Cl (27, 0.45 M ) > 4'-OCH3 (4, 0.87M), H (1, 0.92 M) >  4'-CH3 (20, 1.6 
M) > 4'-C2H5 (21, 2.4 M) > 4'-F (24, 5.1 M) > 4'-CN (33, 20.7 M). For 
compounds with 3'-substituent, the sequence was 3'-CF3 (31, 0.027 M) > 3'-Cl (26, 
0.12 M) > 3'-OCH3 (3, 0.27 M), 3'-CH3 (19, 0.27 M) > H (1, 0.92 M), 3'-OH (12, 
1.10 M) > 3'-F (23, 1.73 M), 3'-OC6H5 (10, 1.70 M). It was noted that better 
activity in both series was associated with the trifluoromethyl, chloro and methoxy 
groups. The Hansch  (indicative of lipophilicity) and Hammett  (indicative of 
electron donating/withdrawing character) values of the substituents were collated (85) 
and analyzed for correlation to CD (expressed as –log10 CD or pCD) using the 
Spearman's  coefficients. The results showed that activity was significantly 
correlated to  ( 0.42, p = 0.045, 2 tailed) but not to . Thus, the electron density of 
ring B was a more critical determinant of activity than its lipophilic character. The 
positive correlation to  indicated a preference for electron withdrawing groups like 
trifluoromethyl and halogens. 
When ring B was di- or tri-substituted, no clear trend on activity was observed.  
By contrast to the preference of electron withdrawing groups observed for mono-
substituted ring B, di-substitution of ring B with two halogens did not improve 
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activity. This was seen from a comparison of 28 (2',4'-Cl, CD 2.3 M) with 26 (3'-Cl, 
CD 0.12 M), 27 (4'-Cl, CD 0.45 M),  and  25 (2',4'-F, CD 3.3 M) with 22 (2'-F, 
CD 0.85 M) and  23 (3'-F, CD 1.73 M).  Thus, the correlation between induction 
activity and the electronic parameter  did not hold up when ring B had more than 
one substituent.   
Mention should be made of compound 14 because of its structural relationship 
to resveratrol based on the design strategy. Compound 14 had 3',5'-Dihydroxy groups 
on ring B which corresponded to ring A of resveratrol (circled groups in Figure 4-1). 
The phenolic ring B of resveratrol was replaced by the bioisoteric indolin-2-one 
moiety (groups in rectangles in Figure 4-1). Compared to resveratrol, 14 was a better 
NQO1 inducer (CD 5.3 M), an indication that the present design approach is viable.  
 













Resveratrol Compound 14   
 
When a non-phenyl ring was present as ring B, variable outcomes were again 
observed.  An interesting observation was the different induction potencies of the 
isomeric napthalenyl derivatives (37, 38).  The 1'-napthalenyl isomer (37, CD > 19 
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M) was significantly less active than the 2'-napthalenyl isomer (38, CD 0.42 M).  
The 2' and 4'-pyridinyl isomers (34, 35) also showed regioselectivity in their induction 
properties. 
The Class 2 compounds were 3-benzylideneindolin-2-ones with substituents 
on both rings A and B. Three types of groups were present on ring B: 3'-methoxy, 3'-
trifluoromethyl and 3'-hydroxy- 4'-methoxy. These groups were selected to reflect 
different  values (methoxy versus trifluromethyl) and to compare the effect of mono- 
and di-substitution on ring B. For each ring B substituent, ring A was substituted with 
6-fluoro, 6-chloro or 6-methoxy. Analysis of the results suggested that the effect on 
NQO1 induction was determined to a greater extent by the nature of ring B than the 
substitution pattern on ring A. This is illustrated by the following comparisons.  
When the CD of 3 (3'-OCH3 on ring B, no ring A substituent) was compared 
to 39-42 (3'-OCH3 on ring B, various substituents on ring A) by one-way ANOVA, 
greater induction was observed for 41 (6-Cl) and 42 (6-OCH3). In the case of 31 (3'-
CF3 on ring B, no ring A substituent) and 46-47 (3'-CF3 on ring B, various ring A 
substituents), only 47 (6-Cl) improved activity. But for 16 (3'-OH, 4'-OCH3 on ring B, 
no ring A substituent) and 43-45 (3'-OH- 4'-OCH3 on ring B, various ring A groups), 
none of the ring A substituent improved activity.  Clearly, activity was influenced to a 
greater degree by the group present on ring B and 3'-methoxy was the preferred group.  
Notwithstanding the lesser role played by ring A, 6-chloro on ring A gave better 
activity for 2 out of 3 different ring B substituents.  Further confirmation with more 
examples would be required.  
The activities of the Class 3 compounds were particularly informative because 
they shed light on the role of the nitrogen linked Michael acceptor in the 3-
benzylideneindolin-2-ones.  The results showed that it was important to retain an 
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unsubstituted ring nitrogen (N-methyl derivatives 49, 50 were less active) and to keep 
the carbon-carbon double bond intact.  Reduction of the double bond abolished the 
Michael acceptor moiety and this was accompanied by a significant drop in the 
activity of the reduced compounds (51, 52).  On the other hand, a change in the 
positions of the carbonyl and exocylic double bond (53, 54) gave mixed results, with 
reasonable activity in 53 (0.46 M compared to 0.27 M in 3) but decreased in 54 
(1.9 M compared to 0.12 M in 16).  Results from these compounds confirmed the 
importance of an intact Michael acceptor motif for NQO1 induction activity.   These 
findings are summarized in Figure 4-2: 
 





3'OCH3 or 3'OH 4'OCH3N-methylation
decreases activity
Saturation of double bond
decreases activity
Relocation of C=O and C=C:
Mixed effects on activity, depending




 The isoindigos in Class 4 resembled two fused indolinones. Thus, isoindigos 
were larger, more lipophilic and more rigid than the indolinones of Class 1-2. These 
features may have contributed to the strong induction properties of the isoindigos 
which yielded the most potent inducers in this study. Isoindigo (55) was reported as a 
potent NQO1 inducer in Hepa1c1c7 cells with an ED50 of 250 nM. (86) In our hands, it 
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had a CD of 25 nM. Substitution of one of the indole rings with various electron 
withdrawing groups (6F, 5Cl, 6Cl or 6-CF3) resulted in a significant improvement in 
activity. But introducing substituents on both rings did not improve activity further, as 
shown from a comparison of 59 (6-CF3 CD 0.56 nM) and its disubsituted analogues 
60 (6-CF3, 5'-F CD 0.96 nM) and 61 (6-CF3, 6'-Cl CD 0.69 nM). 
 
4.3.2. Induction of NQO1 activity in the mutant Hepa1c1c7 cell line (c1) 
 The mutant Hepa1c1c7 cell line c1 is defective in the expression of CYP1A1 
gene.  The CYP1A1 gene is part of the AhR gene battery, not the Nrf2 gene battery.  
If a compound induces NQO1 via the Nrf2 gene battery (mono-functional inducer), it 
would still induce NQO1 activity to the same extent in the mutant c1 cell line.  On the 
other hand, if it induces NQO1 activity via the AhR gene battery, a reduction in 
NQO1 induction on the mutant c1 cell line would be observed if CYP1A1 activity is 
required to convert the compound into an active metabolite that mediates the 
induction activity.  If this is not involved, NQO1 activity should theoretically be 
unchanged since the c1 cells lack the CYP1A1 gene but have functional AhR. 
Not all the compounds were tested for NQO1 induction on c1 cells. Thirty six 
compounds were selected based on their CD values ( 1M) on Hepa1c1c7 cells. 
Sulphoraphane and BNF were used as reference compounds. As seen from Figure 4-3, 
sulphoraphane induced NQO1 activity in Hepa1c1c7 and c1 cells to almost the same 
extent (CD 0.15 M on Hepa1c1c7 and 0.21 M on c1 cells), in keeping with its 
monofunctional profile. In the case of BNF which is a known bifunctional inducer, 
the CD value could not be determined on the mutant c1 cells because induction 




Figure 4-3:  NQO1 induction activities of (a) sulforaphane (b) BNF in Hepa1c1c7 
and c1 cells. 
 (a) Sulforaphane                                                    (b) BNF 
           
 Most of the test compounds showed the same profile as BNF on c1 cells. The 
CD of these compounds could not be determined because induction levels remained 
almost the same even at higher concentrations, as shown in their plots of induction 
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Figure 4-4:  Plots of NQO1 induction ratio versus concentrations for compounds 
whose CD could not be determined in c1 cells 
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A qualitatively different pattern was observed for the other compounds. The 
induction ratios of these compounds increased at higher concentrations, with some 
compounds (17, 45, 58) showing steep increases in their induction ratios at high 
concentrations (Figure 4-5). The CD values of these compounds could be determined 
and with the exception of 57 and 58, they were higher than the values obtained on the 
Hepa1c1c7 cells.  In the case of 57 and 58, CD values derived from c1 cells were 
actually lower than those derived from the wild type cells, but an examination of the 
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Figure 4-5:  Plots of NQO1 induction ratio versus concentrations for compounds 
whose CD values could be determined in c1 cells. Values in parentheses represent CD 
values (M, unless otherwise stated) in Hepa1c1c7 and c1 cells respectively. 
 
1 (0.92, 4.1)             2 (0.25, 1.0)                     3 (0.27, 1.9)     




 4 (0.87, 12.3)                    16 (0.12, 6.1)                    17 (0.86, 4.4) 
 
      
 
19 (0.27, 6.1)     22 (0.85, 7.0)      26 (0.12, 0.28) 
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27 (0.45, 4.4)               29 (0.33, 13.3)             31 (0.027, 0.24) 
 
  
   
 
 
  32 (0.031, 0.81)      39 (0.17, 3.9)                        43 (0.11, 2.4) 
 
   
 
44 (0.076, 0.8)        45 (0.24, 3.4)      53 (0.49, 1.02) 
      
 
      55 (25 nM, 57 nM)          56 (8.3 nM, 26 nM)              57 (1.5 nM, 0.2 nM)  
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58 (1.7 nM, 0.6 nM) 
 
Taken together, these results showed that most if not all the compounds were 
bifunctional inducers and that a prior metabolic activation by CYP1A1 was required 
for NQO1 induction. Hence, in the absence of CYP1A1 in the c1 cells, none of the 
compounds retained the induction profiles observed in Hepa1c1c7 cells. However, for 
those compounds whose CD values could be determined in c1 cells, the increase in 
induction ratios at high concentrations suggested that the un-modified compound also 
made a contribution to activity. But they were presumably less active than the putative 
metabolites and hence brought about induction of NQO1 activity only at high 
concentrations. 
In terms of structural trends among compounds that had measurable CD 
values in c1 cells, some interesting observations were made. 
(i) Among the Class 1 compounds 31 and 32 which were the most potent NQO1 
inducers in the Hepa1c1c7 cells did not show the increase in induction activity with 
concentration on the c1 cells. On the other hand, compounds that showed this pattern 
of increase on the c1 cells were those that had weaker NQO1 induction activities in 
Hepa1c1c7 cells. Compounds 1, 17 and 22 were some examples.   
(ii) Many isomeric compounds in Class 1 showed contrasting activities on the c1 cells 
in spite of their structural similarities. This was seen in the isomeric pairs: 4 (4'-
OCH3) and 3 (3'-OCH3), 17 (3'-OCH3-4'-OH) and 16 (3'-OH-4'-OCH3), 18 (2'-CH3) 
and 19 (3'-CH3), with greater activity observed in the 1st named isomer of each pair. 






10   Hepa1c1c7























(iii)  Among the disubstituted Class 2 compounds, only compounds with 3'-OH-4'-
OCH3 on ring B had measurable CD values on c1 cells. This was observed 
irrespective of the substituent on ring A. The other Class 2 compounds with 3'-
methoxy or 3'-trifluoromethyl group on ring B fared less well, including 47 and 48 
which had the most potent NQO1 induction activities among the Class 1 and 2 
compounds.  
(iv) The isoindigos of Class 4 were the most potent NQO1 inducers of Hepa1c1c7 
cells in the present library, with CD values in the nanomolar range. Isoindigo (55) was 
reported to be a bifunctional inducer (86) but it was not reported that an active 
metabolite(s) was involved in NQO1 induction. Our results showed that an active 
metabolite may be responsible for the NQO1 induction activity of 55, notwithstanding 
the intrinsic induction activity of 55. The only compound that had the same profile as 
55 on the c1 cells was 58 (6-Cl). The other monosubstituted isoindigos (56, 57) 
showed gentler increases in induction ratios with concentration (Fig. 4-5) while the 
disubstituted isoindigos (59-61) showed a consistent high basal level of NQO1 
induction ratio (2-3) over a wide concentration range but with limited increases at 
higher concentrations (Fig 4-4).  
 
4.3.3. Induction of CYP1A1 activity by indolinones and related compounds  
The preceding section showed that the compounds were not monofunctional 
inducers since NQO1 induction activities measured in c1 cells were reduced 
compared to those measured in the wild type Hepa1c1c7.  They were likely to be 
bifunctional inducers, that is, induction is brought about by activating AhR pathway 
and the activities of both phase I and II enzymes are induced.  Unfortunately, the c1 
cell line could not provide strong confirmation of bifunctional induction.  In this 
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section, investigations on the induction of CYP1A1 activity in Hepa1c1c7 cells are 
described.  Induction of CYP1A1 was determined at a fixed concentration of test 
compound using the EROD (7-ethoxyresorufin O-deethylase) assay. EROD activity 
describes the rate of CYP1A1-mediated deethylation of the substrate 7-
ethoxyresorufin to give resorufin (Figure 4-6). Both 7-ethoxyresorufin and resorufin 
are fluorescent compounds but have different excitation and emission wavelengths.  
The formation of resorufin is monitored in the assay. 











Briefly, the method involved incubating the test compound for 48 h with 
Hepa1c1c7 cells at a concentration that was close to 4 x CD value (in Hepa1c1c7 
cells). A fixed concentration was not used because it would be difficult to select this 
concentration in view of the > 10 4 fold variation in NQO1 induction activities of 
these compounds. If the compounds induced CYP1A1 activity, more 7-
ethoxyresorufin would be converted to resorufin, compared to control untreated 
Hepa1c1c7 cells. The ratio of resorufin fluorescence was monitored in treated and 
control cells for this purpose (Table 4-2). In order to evaluate the relative degrees to 
which CYP1A1 and NQO1 were induced at the same concentration, the quotient of 
the two induction ratios (NQO1 induction ratio / CYP1A1 induction ratio) was 





Table 4-2:  CYP1A1 and NQO1 induction ratios of test compounds  
 










1 (5 M) R = H R' =H 1.01±0.04 5.13 5.08 
2 (1 M) R = H R' =2'OCH3 2.48±0.09 4.03 1.63 
3 (1 M) R = H R' =3'OCH3 1.26±0.08 4.21 3.34 
4 (5 M) R = H R' =4'OCH3 1.04±0.01 4.50 4.3 
5 ( M) R = H R' =2',4'(OCH3)2 ND   
6 (0.05 M) R = H R'=2',5' (OCH3)2 3.08±0.31 3.32 1.08 
7  R = H R'=2',6' (OCH3)2 ND   
8  R = H R' =3',5' (OCH3)2 ND   
9  R = H R' =3',4',5' (OCH3)3 ND   
10 (7.5 M) R = H R' =3' OC6H5 1.08±0.02 3.34 3.09 
11 (20 M) R = H R' =2'-OH 1.02±0.02 3.35 3.28 
12 (5 M) R = H R' =3'-OH 1.11±0.03 3.94 3.55 
13 (10 M) R = H R' =2',5' (OH)2 2.87±0.25 7.69 2.68 
14 (20 M) R = H R' =3', 5' (OH)2 1.04±0.03 3.82 3.67 
15 (2.5 M) R = H R' =2'-OH, 4'OCH3 2.35±0.23 3.59 1.53 
16 (0.5 M) R = H R' =3'-OH, 4'OCH3 2.66±0.16 3.13 1.17 
17 (5 M) R = H R' =3'OCH3, 4'OH 1.32±0.10 4.00 3.03 
18 (5 M) R = H R' =2'CH3 1.66±0.10 4.45 2.68 
19 (1 M) R = H R' =3'CH3 1.08±0.05 4.04 3.74 
20 (7.5 M) R = H R' =4'CH3 1.07±0.04 3.05 2.85 
21 (7.5 M) R = H R'=4' C2H5 1.08±0.01 4.96 4.59 
22 (5 M) R = H R' =2'F 1.26±0.10 6.80 5.39 
23 (7.5 M) R = H R' =3'F 1.11±0.02 4.19 3.77 
24 (20 M) R = H R' = 4'F 1.64±0.09 5.69 3.47 
25 (15 M) R = H R' = 2', 4' (F)2 1.89±0.18 5.06 2.68 
26 (0.5 M) R = H R' =3'Cl 1.21±0.01 4.47 3.69 
27 (2.5 M) R = H R' = 4'Cl 1.06±0.03 3.67 3.46 
28 (10 M) R = H R' = 2', 4' (Cl)2 1.21±0.06 4.24 3.50 
29 (2.5 M) R = H R' = 2'Cl, 4'F 1.20±0.04 3.52 2.93 
30 (20 M) R = H R' =2'CF3 1.20±0.02 2.96 2.47 
31 (0.1 M) R = H R' =3'CF3 1.40±0.09 3.85 2.75 
32 (0.1 M) R = H R' =4'CF3 1.22±0.03 2.74 2.24 
33 (25 M) R = H R' =4'CN 1.03±0.04 2.20 2.13 
34 (10 M) R = H 2' pyridinyl 1.08±0.04 3.92 3.63 
35 (20 M) R = H 4' pyridinyl 1.01±0.01 2.08 2.06 
36 (1 M) R = H 3' indolyl 1.28±0.07 4.33 3.38 
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37  R = H 1' napthalenyl ND   
38 (2.5 M) R = H 2' napthalenyl 1.06±0.01 4.61 4.35 
CLASS 2 5a 
39 (1 M) R = 6F R' =3'OCH3 1.25±0.06 3.21 2.57 
40 (2.5 M) R = 5-Cl R' =3'OCH3 1.32±0.08 4.34 3.29 
41 (0.1 M) R = 6-Cl R' =3'OCH3 1.51±0.13 2.56 1.70 
42 (0.5 M) R = 6-OCH3 R' =3'OCH3 1.13±0.01 3.08 2.72 
43 (0.5 M) R = 6F R' =3'-OH, 4'OCH3 2.05±0.07 4.10 2.00 
44 (1 M) R = 6-Cl R' =3'-OH, 4'OCH3 2.33±0.13 5.09 2.18 
45 (1 M) R = 6-OCH3 R' =3'-OH, 4'OCH3 1.05±0.01 4.34 4.13 
46 (0.05 M) R = 6F R' =3'CF3 1.23±0.08 3.31 2.69 
47 (0.05 M) R = 6-Cl R' =3'CF3 2.40±0.27 5.20 2.17 
48 (0.5 M) R = 6-OCH3 R' =3'CF3 1.36±0.07 4.22 3.10 
CLASS 3 
49 5b  (5 M) - R' =3'OCH3 1.18±0.05 4.78 4.05 
50 5b  (5 M) - R' =3'-OH, 4'OCH3 1.08±0.03 2.64 2.44 
51 5c (20 M) - R' =3'OCH3 1.78±0.10 2.23 1.25 
52 5c - R' =4'CH3 ND   
53 5d (5 M) - R' =3'OCH3 1.13±0.07 3.88 3.43 
54 5d (7.5M) - R' =3'-OH, 4'OCH3 1.38±0.11 4.21 3.05 
CLASS 4 5e 
55 (0.1 M) R = H R' = H 1.44±0.11 2.80 1.94 
56 (5 nM) R = 6F R' = H 2.75±0.14 2.56 0.93 
57 (5 nM) R = 5Cl R' = H 2.31±0.15 2.42 1.05 
58 (50 nM) R = 6Cl R' = H 2.09±0.06 2.88 1.38 
59 (5 nM) R= 6CF3 R' = H 3.01±0.26 2.99 0.99 
60 (5 nM) R= 6CF3 R' = 5'F 3.72±0.20 3.09 0.83 
61 (5 nM) R= 6CF3 R' = 6'Cl 3.23±0.21 2.96 0.92 
BNF - - 2.73±0.14  9.75 3.57 
 
1 Compound number and concentration used in CYP1A1 induction assay ( 4 x CD 
for NQO1 activity) is given in parentheses. 
  2 Determined on Hepa1c1c7 cells at concentrations given in column 1. Mean  SD 
for n=3 separate determinations.  CYP1A1 induction ratio = Fluorescence Cells + Test 
Compound –F Blank / Fluorescence Control Cells –F Blank. 
3 Determined on Hepa1c1c7 cells at the same concentration forCYP1A1 induction 
ratio Values were read off from plot of induction ratio versus concentration.  
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  4 NQO1 induction activity / CYP1A1 induction activity. 

























(a) Class 1 and Class 2 (e)Class 4
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(c) Class 3 (51,52)
 
TCDD and BNF which were known inducers of CYP1A1, (87, 88, 89) were 
employed as positive controls in the EROD assay. At 5 nM, TCDD increased 
CYP1A1 activity of Hepa1c1c7 cells by 3 fold. BNF was tested at 1 M and it 
induced CYP1A1 by 2.7 fold.   
As seen from Table 4-2, the test compounds induced CYP1A1 activity to 
varying degrees. The isoindigos in Class 4 which were potent inducers of NQO1 
demonstrated strong CYP1A1 induction activities. Thus many members had poor 
selectivities, as seen from their NQO1/CYP1A1 quotients (1). This profile was 
particularly evident for mono- and di-substituted isoindigos (56-61). The 
unsubstituted isoindigo 55 had only moderate CYP1A1 induction (1.44) and retained 
approximately two fold selectivity for NQO1 (quotient = 1.94). It was noted that 55 
was also the least potent NQO1 inducer among the Class 4 compounds. 
Of the Class 1 compounds that were tested (n=33), only 5 (15%) induced 
CYP1A1 by more than two fold while the remaining compounds had negligible 
CYP1A1 induction. The strong CYP1A1 inducers had the following substitutions on 
ring B: one or two methoxy groups (2, 6), two hydroxyl groups (13) and both 
hydroxyl and methoxy groups (15, 16). Strong induction of CYP1A1 would translate 
to poor selectivity for NQO1 if the compound is a weak inducer of NQO1 and this 
was indeed found to be true for 2, 6, 15 and 16 which had quotients of 1.1 -1.6.  The 
exception was 13 (2',5'-OH) which retained modest selectivity (quotient = 2.68) 
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because it was a relatively weak inducer of NQO1 (CD 2.5 M) compared to the other 
compounds.  
2, 6, 15 and 16 had one or more regioisomers in Class 1 but the latter caused 
less CYP1A1 induction and were more selective towards NQO1. This was true for 3 
and 4 which were regioisomers of 2 and had larger selectivity quotients (3.3-4.3).  No 
comparison could be made for 6 because the CD values of the other dimethoxy 
analogues (5, 7-9) could not be determined due to their growth inhibitory effects on 
the Hepa1c1c7 cells. Hydroxyl and methoxy groups were present on ring B of 15, 16 
and 17, but only 17 was found to be a selective inducer of NQO1. These observations 
imply a certain degree of regioselectivity in the induction activities of the Class 1 
compounds. 
The Class 2 compounds did not appear to be more potent CYP1A1 inducers 
than the Class 1 compound. The most potent compound was 47 which induced 
CYP1A1 by 2.4 fold, but it induced NQO1 by 5.2 fold at the same concentration, and 
thus maintained modest selectivity for NQO1 (quotient = 2.17). It was interesting to 
note that the ring A substituent strongly influenced selectivity for the two proteins. 
Compounds with 6-methoxy group on ring A (42, 45, 48) were among the most 
selective NQO1 inducers. On the other hand, compounds with 6-chloro on ring A (41, 
44, 47) were ranked among the least selective NQO1 inducers. As in the case of 13 
and 55, this was due to the intrinsically weaker NQO1 induction activities of 
compounds with 6-methoxy group on ring A. 
As summarized in Figure 4-2, SAR derived from Class 3 showed the 
importance of an intact nitrogen linked Michael acceptor moiety for NQO1 induction.  
As to how these modifications affected CYP1A1 induction and selectivity for NQO1, 
it was seen that (i) the reduced analogue 51 induced CYP1A1 to a greater extent than 
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its counterpart 3 which had the intact Michael acceptor moiety. Lower selectivity for 
NQO1 was observed; (ii) The N-methylated derivatives 49 and 50 were relatively 
poor CYP1A1 inducers and had greater selectivity for NQO1 induction; (iii) The 
isomeric indolin-3-ones (53, 54) also had a desirable profile, but interestingly 
modifying 16 to give 54 resulted in preferential induction of NQO1, as compared to 
the same modification of 3 to give 53 (Figure 4-7). The difference may be attributed 
to the fact that 16 had high CYP1A1 induction and poor selectivity for NQO1 to start 
with, unlike 3 which had a more acceptable profile.  Thus modifying a “poor” 
candidate (16) gave a better outcome than making the same changes on a strong 
candidate (3).  
 
Figure 4-7: Comparison of NQO1 /CYP1A1 quotients (in brackets) of  




















3 (3.34) 53 (3.43)




There were several indications from the results that compounds with strong 
NQO1 induction activities were actually less selective inducers of NQO1. This was 
seen from the Class 4 compound (55) and the more potent NQO1 inducers in Class 1 
and 2 (13, 41, 44, 47). To quantify this trend, the compounds were categorized 
according to the concentrations used to determine the CYP1A1 and NQO1 induction 
activities. Since the compounds were used at  4xCD for NQO1 activity, weaker 
NQO1 inducers were tested at higher concentrations while strong NQO1 inducers 
were tested at lower concentrations. In all, 10 concentrations ranging from 20 M to 5 
nM were used. The compounds were grouped into four concentration ranges: (A): 15 
and 20 M (n = 8); (B) 5-10 M (n = 17) (C) 0.1-2.5 M (n = 21); (D) 5 and 50 nM 
(n = 9) and the NQO1/CYP1A1 quotients for each group were compared with other 
groups by one-way ANOVA with Tukey as post hoc test. The mean of the quotient 
for each concentration group is shown in Figure 4-8. The analysis showed that the 
quotients at all the concentration ranges were significantly different at p < 0.05, 
except for those at A (15, 20 M) and C (0.1 -2.5 M). Thus compounds tested at the 
5-10 M range (B) had significantly larger quotients than compounds tested at lower 
concentration ranges (C and D). These compounds at B were moderately potent 
NQO1 inducers but they demonstrated preferential induction of NQO1 compared to 
CYP1A1.  In contrast, the more potent inducers found in category D induced both 








Figure 4-8: NQO1/CYP1A1 Quotients for compounds tested at the following 
concentration range (A) 15 and 20 M; (B) 5-10 M; (C) 0.1-2.5 M; (D) 5 and 50 
nM. 
Quotients at concentration ranges were significantly different (p< 0.05, one-way 






























             The compounds in Class 1-4 were designed based on the premise that the 
indolinone moiety was a viable bioisotere of the phenolic group. The 3-substituted 
indolin-2-ones were thus atypical analogues of resveratrol. It was hypothesized that 
this class of compounds would have chemopreventive properties based on their 
isosteric relationship to resveratrol. Of particular interest was the presence of the 
nitrogen-linked Michael acceptor moiety in these compounds which had been 
associated with monofunctional NQO1 induction activity. In view of the scope of 
biological activities that encompassed chemoprevention, the investigations were 
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restricted to the induction of phase II enzymes, namely the induction of NQO1 
activity. 
The indolinones were found to be extremely potent inducers of NQO1 activity 
in Hepa1c1c7 cells. The variation in activity was quite remarkable. The 38 
compounds in Class 1 alone provided a 103 fold difference in induction activity and 
this arose from simple variations in ring B. When all the compounds in Class 1-4 were 
compared, the fold variation exceeded by 104, with CD values in the nanomolar range 
for the most potent inducers. The design strategy for this library of compounds had 
succeeded in producing compounds that were more potent NQO1 inducers than 
resveratrol. 
The nitrogen-linked Michael acceptor moiety in the indolinones and 
isoindigos was proposed to be a critical fragment for NQO1 induction. Analysis of 
SAR within the Class 3 compounds provided the necessary confirmation. The 
reduction of the exocyclic double bond which effectively abolished the Michael 
acceptor feature resulted in a significant lowering of activity whereas modifications 
that left this feature intact, like N-methylation and switching the positions of the 
carbonyl and double bond to give isomeric 2-substituted indolin-3-ones, retained 
activity.  
The isoindigos (Class 4) may be viewed as indolin-2-ones linked by an 
exocyclic double bond.  These compounds were extremely potent NQO1 inducers and 
it is tempting to relate this to the presence of Michael reaction moieties embedded in 
the isoindigo template. However, modifications that led to the loss of this moiety in 
the isoindigo ring were not explored and thus no conclusion can be reached at this 
stage.   Isoindigos have a very different physiochemical profile from the 3-substituted 
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indolin-2-ones and differences in size, lipophilicity and conformational rigidity would 
influence activity as well. 
Having established a structural role for the Michael acceptor moiety, the next 
step was to investigate its functional role in NQO1 induction.    Two investigations 
were carried out for this purpose – NQO1 induction in c1 cells that lacked a 
functional CYP1A1 gene, and induction of CYP1A1 activity in wild type Hepa 1c1c7 
cells. Not all the compounds were tested on c1 cells but those tested showed only 
limited induction of NQO1 activity. This was ascribed to the involvement of an active 
metabolite(s) generated by CYP1A1 for induction activity. However, some 
compounds (generally those with lower CD values) were able to induce NQO1 
activity in c1 cells at higher concentrations, which was interpreted to mean that these 
compounds possessed intrinsic induction activity, but were possibly less potent than 
the putative metabolites. 
The compounds induced CYP1A1 activity in Hepa1c1c7 cells but to varying 
degrees. An interesting observation to emerge from these results was the association 
of preferential NQO1 induction with compounds that were moderate (CD  1-2 M) 
rather than potent inducers (CD in nanomolar range) of NQO1.  What this meant was 
that moderate NQO1 inducers (CD  1-2 M) had a better balance of potency and 
selectivity than very potent but non-selective NQO1 inducers. A word of caution 
would be that these compounds could be inhibitors of CYP1A1 activity. However, if 
this is found to be true in future investigations, it will not negate the value of these 
compounds as chemopreventive agents.  In fact, inhibition of CYP1A1 activity may 
be desirable as it limits the processing of pre-carcinogens into carcinogens.   
Although the Michael acceptor moiety in indolinones is an essential fragment 
for NQO1 induction activity, the compounds behaved more like bi-functional 
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inducers (induction of both NQO1 and CYP1A1), in contrast to the mono-functional 
induction profile normally associated with compounds with this moiety.  Further 
confirmation of this profile may be obtained by measuring NQO1 induction in another 
mutant Hepa1c1c7 cell line that lacked a functional AhR receptor. (16) 
Recent investigations suggested that the distinction between mono- and bi-
functional inducers may not be so clear-cut.  There is growing evidence of interaction 
between the AhR/XRE and Nrf2/ARE signaling pathways and it is widely thought 
that the expression of NQO1 is regulated by this interaction. (35) Proposed links 
between the AhR and Nrf2 gene batteries may involve three (interrelated) scenarios. 
First, Nrf2 is a down-stream target of AhR. Activation of AhR results in an increase 
in the expression of CYP450 enzymes as well as Nrf2, which will in turn activate 
phase II enzymes like NQO1. (36) The 2nd possibility is that reactive oxygen species 
and electrophiles are increased in the course of CYP450 mediated reactions, and these 
serve as indirect triggers of Nrf2 activity. (37) The 3rd scenario proposes a direct 
interaction of AhR/XRE and Nrf2/ARE signaling due to the close proximity of the 
XRE and ARE sequences in the regulatory region of NQO1. (38) Taken together, the 
coordinate regulation of phase I and II xenobiotic metabolisms by the AhR and Nrf2 
would result in more effective xenobiotic and carcinogen detoxification. It may also 
imply that the perceived advantages of mono-functional over bi-functional inducers 








4.5. Conclusion  
           A library of indolinones and isoindigos were found to be potent inducers of 
NQO1 activity in the mouse hepatoma Hepa1c1c7 cell line. There was a large 
variation in activity ( 104 fold) which permitted some qualitative SAR to be 
proposed. These were the importance of (i) electron withdrawing groups on ring B for 
the monosubstituted Class 1 compounds, (ii) retaining the nitrogen-linked Michael 
acceptor moiety in the indolinone template, (iii) the relative importance of ring B 
substitution compared to ring A substitution in Class 2 compounds, and (iv) the 
activity enhancing effect of disubstitution of the isoindigo ring system with electron 
withdrawing groups. 
The compounds were found to induce CYP1A1 activity in the EROD assay 
and were classified as bifunctional inducers of NQO1. Involvement of a metabolite 
for NQO1 induction was a likely possibility. However, several compounds induced 
NQO1 to a greater extent than CYP1A1. It was shown that preferential induction of 
NQO1 was associated with compounds that were moderate inducers of NQO1. 
Compounds that were very potent NQO1 inducers were found to discriminate poorly 




Chapter 5 Structure Activity Relationships of NQO1 Induction by Indolinones 
and Related Compounds 
 
5.1 Introduction 
       In this chapter, the NQO1 induction properties of Class 1-4 compounds were 
analyzed to reveal trends in structure activity relationships. As mentioned earlier, a 
large variation in induction activity (>104 fold) was observed among the compounds 
The compounds were also designed to have lead-like features with respect to the 
number of hydrogen (H) bond donor and acceptor groups, rotatable bonds and 
molecular weights. (90)  In the case of some members in Class 1, the choice of groups 
on ring B was made with reference to the Craig Plot.   Hence, the database has several 
promising features for SAR analysis and the deductions drawn from this exercise 
would serve to give a better understanding of the physicochemical descriptors 
influencing NQO1 induction activity and provide useful inputs for the design of 
improved candidates. In this study, principal component analysis (PCA) and 
projection to latent structures by partial least squares analysis (PLS) were used to 
reveal trends in structure activity relationships. (91, 92) 
The utility of PCA resides in its ability to summarize and collate information 
residing in a large data matrix into a form that is readily analyzed. The original 
multidimensional space defined by a large number of variables is contracted into a 
few descriptive dimensions called principal components (PC) which now represent 
the main variation in the data. PLS is used to connect the information in two blocks of 
variables (dependent and independent variables) to each other. Thus, it is a regression 
extension of PCA.  PLS is particularly well suited to handle variables that are 
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correlated to each other, a feature that often leads to the breakdown of simple 
regression analysis. 
 
5.2 Experimental Methods 
Structures of Class 1-4 compounds were drawn and geometry minimized using 
the Hamiltonian forcefield MMFF94x in MOE ® (Chemical Computing Group, 
Montreal, Canada). The following molecular descriptors were collected for the 
compounds using the QuaSAR component of MOE ®: HOMO and LUMO energies, 
molecular weight (MW) , molar refractivity (MR), dipole moment (DM),  number of 
rotatable bonds (Rotbond), number of H bond donors (HD) and acceptors (HA), 
calculated log P in octanol/water (Log P), sum of atom polarizabilities (AtomPol), van 
der Waals' (VDW )surface areas of H bond acceptors (vdwHA) and donors (vdwHD), 
VDW surface areas of OH and NH groups (PSA), total hydrophobic VDW surface 
area (VDWH), VDW volume (VDW Vol) topological polar surface area (TPSA), 
water accessible surface area (H2OSA).  The chemical shift of the carbonyl carbon 
(Delatcarbonyl) was determined from the 13C NMR spectra of the compounds. 
Biological activity was expressed as pCD which is the logarithm of the reciprocal of 
CD (concentration required to increase by two fold NQO1 induction activity in 
Hepa1c1c7 cells, expressed in molar units). The descriptors of the compounds are 
given in Appendix 4.  PCA and PLS were run on SIMCA-P 11 (Umetrics AB, Umea, 
Sweden) with default settings. Spearman rank correlation coefficients for the data set 






5.3 Results and Discussion 
Eighteen descriptors were used to characterize the compounds. These descriptors  
were categorized as (i) constitutional - molecular weight, number of rotatable bonds, 
number of H bond donor atoms, number of H bond acceptor atoms; (ii) molecular 
orbital related - HOMO and LUMO energies; (iii) lipophilic - calculated Log P in 
octanol/water; (iv) geometrical - VDW surface areas of H bond acceptors and donors, 
water accessible surface area, VDW volume, total hydrophobic VDW surface area, 
topological polar surface area, polar surface area (equivalent to the VDW surface 
areas of OH and NH groups); (iv) electronic - dipole moment, molar refractivity, sum 
of atom polarizabilities, chemical shift of carbonyl carbon. Significant correlations 
among descriptors were noted when analyzed by non-parametric (Spearman) 
correlation (Appendix 5).    
 PCA on the complete data set identified a significant three component model 
with R2X = 0.783 and Q2 = 0.559. Most of the information in a PCA is found in the 1st 
two components and thus only the 1st and 2nd PCs were considered. The first two 
components reflected 61% (R2X = 0.605) of the variation, with 36% predictability (Q2 
=0.355). The score plot is shown in Figure 5-1. Nearly ¾ of the Class 1 compounds 
(n=27) were found on the left quadrant. The remaining compounds were located on 
the right quadrant and these were compounds with alkyoxy groups (di- and 
trimethoxy, methoxy and hydroxy, phenoxy) and naphthalene as ring B. In contrast, 
the Class 2 compounds were more evenly distributed in the plot, with most of the 
compounds clustered around the origin. The Class 3 compounds were modifications 
of 3 (3'-OCH3) and 16 (3'-OH-4'-OCH3). Although not depicted very clearly on the 
plot, the corresponding indolin-3-ones (53, 54) were in close proximity to their 
respective indolin-2-one isomers (3 and 16), indicating that this modification retained 
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many physicochemical similarities. The N-methyl and reduced analogues of 3 were 
further displaced from it, suggesting greater differences (defined by the PCs) among 
them. The Class 4 compounds were found at the lower quadrant of the score plot, 
implying special characteristics inherent in this class. Notwithstanding their 
separation from the compounds in Class 1-3, the Class 4 compounds were not tightly 
clustered. Isoindigos with 6-trifluoromethyl on ring A (59-61) were found together on 
the far right quadrant, separated from other members in Class 4. 
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Figure 5-1: PCA score Plot of t[1] (1st PC) versus t[2] (2nd PC) for 61 compounds and 18 descriptors.   Compounds 1-38 (Class 1, ); 
Compounds 39-48 (Class 2,  Δ);  Compounds 49-54 (Class 3, red ); Compounds 55-61 (Class 4,)  The ellipse corresponds to the 95% 


















R2X[1] = 0.357372            R2X[2] = 0.248004            
Ellipse: Hotelling T2 (0.95) 











































SIMCA-P 11 - 7/18/2008 2:31:57 PM  
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The loadings plot of the components was next examined to provide an understanding 
of the distribution pattern in the score plot (Figure 5-2). The contribution (or loading) 
of the variables to the PC is given in the loadings plot. Variables that were clustered 
were strongly correlated to each other and possibly, one of them could be used to 
represent the rest. Variables that were isolated were unique and not correlated to other 
parameters. Variables found at the extremes of the 4 quadrants were the most 
important because they contributed significantly to the respective PCs. For the 1st PC, 
the parameters with strong loadings were those related to size (VDW volume, total 
hydrophobic VDW surface area) and polarity (water accessible surface area, atom 
polarizabilities, molar refractivity). In the case of the 2nd component, these were the 
number of H bond donors, VDW surface areas of H bond donors and acceptors, and 
LUMO energies. Variables like the chemical shift of the carbonyl carbon that lie close 
















Figure 5-2: PCA loading plot of the loadings of the 1st two principal components (p2 
versus p1) of 61 compounds and 18 variables. The boxed parameters on the right are 
VDWH (total hydrophobic VDW surface area), VDWVol (VDW volume), H2OSA 
(water accessible polar surface area), AtomPol (sum of atom polarizabilities), MR 
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The loadings of the variables explained the distribution of the compounds in 
the score plot. The Class 1 compounds were broadly clustered in the left and right 
quadrants due to the size and polarity descriptors.  Thus, compounds that were 
oxygenated (two or more methoxy groups 5-9, phenoxy 10, or methoxy and hydroxyl 
groups 15-17) were larger molecules with greater VDW surface areas (more carbon 
atoms) and  water accessible surfaces areas (larger number of oxygen atoms). The 
napthalenyl derivatives (37, 38) were also larger molecules. Compounds with these 
characteristics were found in the right quadrant.  
The segregation of the isoindigos in Class 4 was explained by the interplay of 
two variables in the 2nd PC, namely the number of H bond donors and VDW surface 
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area of these donors, and the LUMO energies. Each isoindigo has 2 donor (NH) and 2 
acceptor (=O) groups. They also had significantly lower LUMO energies (large 
negative values) than other compounds.  Within the series, several compounds had 2 
or more H bond donors (11-17) but they did not have the low LUMO energies of the 
isoindigos. Interestingly, a check on the HOMO energies of all compounds showed 
that their values fall within a narrow range (-8.47 to -9.06 eV) compared to the 
LUMO energies (-0.02 to -2.05 eV), which would explain why HOMO was not 
identified with either PC. The number of H bond acceptors was also not significantly 
associated with either PC. 
In the next step of the analysis, PLS was carried out to find a correlation 
between NQO1 induction activity (pCD) of Class 1-4 and the available descriptors. 
The separation of Class 4 compounds in the PCA score plot implied that they should 
be analyzed separately from the other Classes. When this was attempted, a statistically 
poor model was obtained. Thus, PLS was applied to all four classes of compounds. 
The outcome was a significant one-component model with R2Y = 0.540 and Q2 = 
0.445. The parameters that contributed significantly to the model were identified from 
the VIP (variable influence on projection) parameter which was a weighted sum of 
squares of the PLS weights taking into account the amount of explained Y-variance of 
each dimension.  In a nut-shell, descriptors with a large VIP (>1) were the most 
influential for the model.  Six descriptors were selected based on their VIP values (> 
1) and these were used in the subsequent PLS analysis. The resulting PLS model was 
statistically better than the 1st model. It was a significant one-component model which 
could explain 56% of the variability in the data (R2Y = 0.563) with a prediction level 
of 53% (Q2 = 0.532). The coefficient plot showed the ranking of the parameters based 
on their relative contribution to the model (length of bar) as well as their correlation 
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(positive for direct correlation, negative for inverse correlation) to activity (Figure 5-
3). 
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The parameters that contributed significantly to the model were LUMO 
energies (most influential), molecular weight, VDW surface area of H bond donors, 
number of rotatable bonds, VDW surface area of H bond acceptors and HOMO (least 
influential). Parameters with positive coefficients were directly correlated to pCD 
(molecular weight, VDW surface areas of H bond donors and acceptors) while 
parameters with negative coefficients were inversely related (LUMO, HOMO, 
number of rotatable bonds). Taken together, a profile for good induction activity was 
proposed: A rigid compound (few rotatable bonds) with low (more negative) LUMO 
and HOMO energies, a molecular weight in the higher end of the present range of 
221-364 Daltons and a large polar surface area associated with H bonding groups. 
   
The HOMO energy represents the energy required to detach an electron from a 
molecule in the dilute gas phase, while the LUMO energy is the energy released when 
an electron is accepted by a molecule in the dilute gas phase. (93)  Low LUMO 
energies imply that a compound accepts electrons readily. By the same token, low 
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HOMO energies imply that a compound donates electrons less readily. These 
characteristics would be found in ring structures that have electron withdrawing 
groups. The ring structure would be electron poor and predisposed to accepting 
electrons (favoured by low LUMO) rather than to donate electrons (associated with 
high HOMO).  Indeed, the most active compounds in Class 1 and 2 (31, 32, 46, 47) 
had one or more electron withdrawing groups. Moreover, as mentioned in Section 
4.3.1., when the Hansch  and Hammett  values of Class 1 compounds with 3' or 4'-
substituents (CF3, Cl, F, OCH3, OH, CH3, OC6H5,CN) were analyzed for correlation 
to pCD,  induction activity was significantly correlated to  (Spearman's  = 0.42, p = 
0.045, 2 tailed) and not . 
Low LUMO energies were also found for the Class 4 isoindigos (55-61).  
Compounds 56-61 had electron withdrawing groups (Cl, F, CF3) and low LUMO 
energies which would be expected. Interestingly, the unsubstituted isoindigo 55 also 
had a low LUMO energy although it had no electron withdrawing substituent. An 
examination of the LUMO energies of all the compounds showed that the reduced 
compounds 51 and 52 had the highest LUMO energies. By contrast, their non-reduced 
counterparts 3 and 21 had lower LUMO energies (Figure 5-4). Thus, it was deduced 
that LUMO energies could be influenced by conformational flexibility.  The loss of 
the double bond in 51 and 52 resulted in a more flexible side chain at position 3, as 
compared to the fixed configuration (E) of the 3-benzylidene side chains of 3 and 21.  
It may be that the rigidity of isoindigo and the extended conjugated system found in 






Figure 5-4:  LUMO energies of 3-substituted indolin-2-ones (3, 20) and their reduced 
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 Zoete and coworkers found a strong correlation between NQO1 induction 
potencies of 34 phenylpropenoids and their synthetic analogs and their HOMO 
energies. (94) Potent inducers had larger (less negative) HOMO energies which implied 
that the compounds were good electron donors (strong reducing agents). This 
relationship was linked to the monofunctional induction profile of the 
phenylpropenoids.  Induction of NQO1 involved disruption of the Keap1/Nrf2 
complex.  Keap 1 is a sulfhydryl rich protein which is oxidized by 
oxidative/electrophilic stress, thereby uncoupling the association between Keap1 and 
Nrf2.  Thus it is logical that inducers that disrupt the Keap1/Nrf2 complex should be 
strong reducing agents (large HOMO energies).  The present series of compounds 
were found to induce CYP1A1 activity in Hepa1c1c7 cells to varying degrees.  Thus 
they differed from the phenylpropenoids and a different physicochemical profile 
would be required for good activity.   
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In order to validate the PLS model, a training set of compounds was randomly 
selected from the existing library and used to predict the activity of the remaining 
compounds (test set). The training set comprised 40 compounds and the “best” 6 
descriptors identified by VIP. The resulting model was statistically significant (one 
component) with R2Y = 0.687 and Q2 = 0.664. The test set was made up of 19 
compounds (6 and 33 were removed because of their large residuals, > 2 log units).    
The activities of the test set were predicted based on the training set. A modest level 
of prediction was obtained, with a root mean square error of prediction = 0.687 
(Figure 5-5). 
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5.4.   Conclusion and Summary 
        The SAR of NQO1 induction in Hepa1c1c7 cells by a series of 3-substituted 
indolin-2-ones, isoindigos and related compounds were analyzed by PCA and PLS. 
Descriptors that encompassed the constitutive, geometric, lipophilic, molecular 
orbital-related and electronic characteristics of these compounds were used in the 
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analysis. In terms of physicochemical properties, the 3-substituted indolin-2-ones in 
Class 2 were more homogenous than those in Class 1, as revealed in the score plot. 
The isoindigos were distinct from the other compounds. The descriptors that 
contributed to these differences were found in two PCs: the 1st PC had contributions 
from geometric (VDW volume, total hydrophobic VDW surface area, water 
accessible surface area) and electronic (molar refractivity, atom polarizability) 
properties. Differences in Class 1 indolin-2-ones were traced to 1st PC (size, polarity) 
whereas the segregation of the isoindigos from the other classes of compounds was 
attributed to the 2nd PC which had contributions from the number and VDW surface 
areas of H bond donors, and LUMO energies. The regression of NQO1 induction 
activity against the descriptors by PLS gave a modestly predictive model that 
highlighted LUMO energies, size (molecular weight), VDW surface areas of H bond 
donors and acceptors, rigidity (number of rotatable bonds) as the five most influential 
parameters. This was a significant finding because it highlighted properties that would 
give rise to compounds that had strong NQO1 induction but discriminated poorly 
between CYP1A1 and NQO1.  However, the present model could not conclusively 
describe the properties required of preferential NQO1 inducers, except to propose that 
features found in potent inducers should be avoided.  With some caution, this could 
mean that 3-benzylidene-indolin-2-ones with desirable potency and selectivity for 
NQO1 induction should have a mix of electron withdrawing and donating substituents, 
molecular weights < 300, total number of H bond donors and acceptors not exceeding 




Chapter 6 Antiproliferative Activities of Methoxystilbenes and Class 1-4 
Indolinones and Related Compounds 
 
6.1. Introduction 
In the earlier chapters, the methoxystilbenes and Class 1-4 compounds 
(isoindigos, indolinones and related compounds) were investigated for induction of 
phase II enzymes and some members had demonstrated promising activity. The 
current understanding of chemoprevention indicated that several cellular phenomena 
may work in concert to bring about chemoprevention. (6) A compound may have the 
ability to impede the initiation stage of carcinogenesis (blocking agent) as well as 
arrest or reverse the promotion and progression of the process (suppressing agent). In 
this chapter, the antiproliferative activities of the test compounds were investigated. 
The presence of such an activity brought about by either disrupting the cell cycle or 
apoptosis would greatly enhance the potential of these compounds as 
chemopreventive agents. 
 
6.2. Experimental Methods 
6.2.1. Determination of antiproliferative activity by the microculture tetrazolium 
(MTT) assay. 
The antiproliferative activity of the test compounds were determined by the 
MTT assay (79) on the following cell lines: MCF7 (human breast cancer cell line), 
HCT116 (human colon cancer cell line), and CCL186 (normal human diploid 
embryonic lung fibroblast). The cell lines were purchased from American Type 
Culture Collection (Rockville, MD). MCF7 and CCL186 cells were cultured in 
Eagle's Minimum Essential Medium (EMEM) with 1mM sodium pyruvate, 1.5 g/L 
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sodium bicarbonate, 2mM L-glutamine supplemented with10% FBS and 0.01% 
antibiotics. HCT116 cells were cultured in McCoy's 5A Medium with 2.2 g/L sodium 
bicarbonate supplemented with10% FBS and 0.01% antibiotics. Cells were plated at 
the following densities: 10000 cells/well (MCF7), 4000 cells/well (HCT116), 5000 
cells/well (CCL186) and grown for 24 h in a 96-well plate, with 100µl of 
corresponding medium in each well. The test compounds were prepared in DMSO 
and diluted to a series of concentrations with medium. Not more than 1% DMSO 
(final concentration) was present in each well. The test compounds were incubated 
with the cells for 72 h, after which 100 µl MTT solution (0.5 mg/ml in1× PBS) was 
added for 3 h and the cells lysed to release the formazan product. The latter was 
dissolved in DMSO (150 µl) and absorbance determined within 30 min at 590 nm on 
a microtitre plate reader. Cell survival was given by the expression: 
Cell survival (%) = A cells + test compound – A blank / A untreated cells – A blank x 100  
where A is the absorbance of formazan measured at 590 nm in the test, control or 
blank wells. Each concentration of test compound was evaluated on 3 separate 
occasions. The concentration (IC50) that inhibited 50% of cell growth was determined 
from the sigmoidal curve obtained by plotting % surviving cells versus concentration 
using OriginPro 7.5 SR1 (Version V7.5776 B776), OriginLab Corporation, MA.  
 
6.2.2. Determination of the effects of test compounds (5-7, 9, 10, 37, 42, 45-48) on 
the cell cycle of HCT116 cells by cell cytometry 
     Human colon carcinoma cells (HCT116) were grown to confluence and 
maintained in this state for at least 5 days without change of media. The serum starved 
cells were then trypsinized and subcultured at densities of 5x105 cells/well in six-well 
plates. Growth media contained 10% fetal calf serum. The test compound was added 
107 
 
either immediately to cells synchronized at G1 phase, or 24 h later when cells were 
synchronized at G2 phase. The cells were incubated with test compound for 24 h from 
the time of addition. After this time, the cells were harvested, trypsinized and fixed in 
70% ice-cold ethanol for a minimum of 24 h. After centrifugation, the supernatant 
was discarded and the pellet was treated with RNase A (200 µg/ml, Sigma Chemical 
Co, USA) for 30 min at room temperature, followed by cell staining using propidium 
iodide (Sigma Chemical Co, USA) at a final concentration of 20 µg/ml. The stained 
cells were then analyzed for cell cycle distribution in the G0/G1, S and G2/M phases 
on a Dako Cytomation Cyan LX (Dako Colorado, Fort Collins, CO, USA) equipped 
with an argon solid state laser (488nm) using the Summit (version 4.3) software. 
Compounds were tested at a concentration of 1.5 x IC50, with IC50 determined by the 
MTT assay on HCT116 cells. 
 
6.3. Results  
6.3.1. Antiproliferative activity of methoxystilbenes on MCF7, HCT116 and 
CCL186 cell lines 
The methoxystilbenes were initially screened on the MCF7 and HCT116 cells 
at a fixed concentration of 10 M. Only 9 compounds were found to reduce cell 
survival on both cell lines by more than 50% at this concentration. The IC50 of these 
compounds were then determined on HCT116, MCF7 and CCL186 cells. The results 
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1 IC50 value is given as mean  SD for n=3 determinations. Values in bold and italics 




In Chapter 3, the methoxystilbenes were screened for growth inhibitory 
activities on a mouse hepatoma (Hepa1c1c7) cell line. The main findings were that 
good activity was associated with methoxy groups on ring A and the presence of a Z 
configuration for the double bond. The most potent compound was S10Z (IC50 0.03 
M) which had 3 methoxy groups on ring B.  
Similar structural requirements were found for the antiproliferative activities 
of the stilbenes on human cancer cell lines HCT116 and MCF7. The importance of 
the Z configuration was apparent from the negligible effects of S3E, S4E, S6E, S7E 
and S14E on cell survival at 10 M, even though their IC50 values were not 
determined. Of the two isomeric pairs evaluated for IC50 (S8E/Z and S10E/Z), the Z 
isomer was at least 10 times more potent than the E isomer, with a greater difference 
noted on HCT116 cells compared to MCF7 cells. The importance of methoxy groups 
on ring A was underscored by the observation that none of the hydroxylated 
compounds (S11, S12, and S13) were shortlisted for IC50 determination (Figure 6-1). 
The only compound with a ring A hydroxy group that had reasonable antiproliferative 
activity was S14Z but it also had a methoxy group on ring A. 
 







The most potent compound was S10Z which had 3,4,5-trimethoxy groups on 
ring A (IC50 0.015-0.020 M). Compound S8Z with 3,5-dimethoxy groups on ring A 
was reasonably potent (IC50 0.12 -0.22 M) but its isomers S6Z (2,4-OCH3) and S7Z 
(3,4-OCH3) were at least 10 times weaker on the same cell lines. This may imply a 
preference for the 3 and 5 positions on ring A for activity but would require further 
confirmation. Among the ring A mono-methoxy analogues (S3Z, S4Z, S5Z), the 2-
methoxy (S3Z) and 3-methoxy (S4Z) analogues had equivalent activities (IC50 4.4-5.9 
M) but the 4-methoxy S5Z (a symmetrical molecule) had lower activity (IC50 > 10 
M, not determined) 
In terms of selective antiproliferative activity, the methoxystilbenes did not 
fare well. The most  selective member (S7Z) was only 3 times more selective against 
cancer cells and the most potent member (S10Z) did not discriminate against the 
cancer and non-cancer cell lines. 
 
6.3.2. Antiproliferative activity of indolinones on MCF7, HCT116 and CCL186 cell 
lines 
The indolinones and related compounds of Class 1-4 were also screened at a 
fixed concentration of 10 M on HCT116 and MCF7 cells. Only a small number of 
compounds caused cell death by more than 50% at this concentration and the IC50 








Table 6-2: IC50 and Selectivity Ratios of 3-substituted Indoline-2-ones on MCF7, 




Ring A (R) Ring B (R') IC50 (M)1 
MCF7 HCT116 CCL186 


























































1 IC50 value is given as mean  SD for n=3 determinations. Values in bold and italics 
represent the selectivity ratio: IC50 CCL186 /IC50 MCF7 or IC50 CCL186 /IC50 HCT116 
 
Only the Class 1 and 2 compounds were short-listed for IC50 determination 
(Table 6-2).   They showed comparable antiproliferative activities on both cancer cell 
lines, with IC50 values ranging from 1.2 to 19.6 M.  When these activities were 
compared to those obtained on a normal cell line (human lung fibroblasts), modest 
selectivities (approximately 2-fold on average) were observed although some 
compounds like 5, 46, and 47 discriminated poorly between cancerous and normal 
cells and had selectivity ratios that were close to 1.  Some structural trends were 
observed among the active compounds and these are summarized in Figure 6-2. 
 












-Dimethoxy at 2',4'; 2',5'; 2',6'
but not 3',5'.
-Trimethoxy at 3',4',5' (bulky)
-Phenoxy at 4' (bulky)





Preferred to 3'-OCH3 or 3'-OH-4'-OCH3
irrespective of ring A substitution pattern
Preferred to 6-F, 6-Cl irrespective







For compounds from Class 1, the presence of two or more methoxy groups on 
ring B strongly favored activity. Compounds 5, 6 and 7 were regioisomers with 
dimethoxy groups on ring B. Another regioisomer (8 with 3',5'-OCH3 on ring B) was 
less potent. This may imply that there were preferred positions for dimethoxy groups 
on ring B. Compounds 9, 10 and 37 had in common the presence of bulky substituents 
on ring B or a bulky ring B.   Compound 9 had three methoxy groups on ring B 
(3',4',5'-OCH3) and a 4'-phenoxy group was present in 10.  In 37, ring B was replaced 
by 1'-napthalenyl.    
Among the Class 2 compounds, a 6-OCH3 on ring A consistently resulted in 
better activity compared to other substituents. In the same way, the 3'-trifluoromethyl 
group on ring B appeared to be more advantageous than other ring B groups. 
Among the compounds that had weaker antiproliferative activities (IC50 > 10 
uM) and not listed in Table 4 were those from Class 3 that had modified Michael 
acceptor motifs.  An intact Michael acceptor moiety was thus important for 
antiproliferative activity.   
As for compounds that combined good antiproliferative activity with 
preferential induction of NQO1, some promising candidates were identified.  These 
were the Class 2 compounds (42, 45-48) and only 10 from Class 1.   Compounds 10 
(quotient 3.09), 45 (quotient 4.13) and 48 (quotient 3.10) were particularly notable in 
this respect.   
 
6.3.3. Effect of selected class 1 and 2 compounds on cell cycle of HCT116 cell line 
            The antiproliferative activities of the Class 1 and 2 compounds listed in Table 
6-2 may stem from effects on the cell cycle or other mechanisms like autophagy or 
necrosis. 3-Substituted indolin-2-ones are noted tyrosine kinase inhibitors (70) and one 
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such compound from this class is sunitinib which is used in the clinics as a 
multitargeted tyrosine kinase inhibitor with antiangiogenic activity.  Among the 
compounds in Table 6-2, 9 was reported by Andreani and coworkers (60) to have 
antiproliferative activities on a panel of cell lines. The authors proposed that multiple 
mechanisms may be involved in the activity of this class of compounds. To have a 
better understanding of the mechanisms underlying the antiproliferative activities of 
the compounds in Table 6-2, their effects on the cell cycle was investigated by 
fluorescence-activated cell sorter (FACS) analysis using flow cytometry. The 
experiments were designed to examine the effects of the test compounds on 
synchronized cell populations at the G1 or G2/M phase. G1 synchronized cells were 
obtained by growing cells to confluence for up to 5 days and then stimulating their re-
entry into the cell cycle by sub-culturing at lower densities. After 24 hours of growth, 
these cells would be aligned at the G2/M phase.  
Cells released from the G1-block were exposed to a fixed concentration ( 1.5 
x IC50 on HCT116 cells) of test compound for 24 h, after which the distribution of 
cells at the different phases were determined, and compared to control untreated cells. 
Cells aligned at the G2/M phase were similarly treated.   Figure 6-3 shows a 
representative FACS diagram of control cells just released from G1 block (a) and 24 
hours later (b). After 24 hours, the proportion of cells in G1 was sharply reduced and 
more cells were found in the S and G2 phases. If a compound arrested the cell cycle at 
the G1 phase, this transition would not be observed and the proportion of cells in G1 
would remain high. The remaining plots in Figure 6-3 depict the effects of the test 
compounds (5-7, 9, 10, 37, 42, 45-48) on the G1  G2/M transition. 
Figure 6-4 shows a representative FACS diagram of control cells just released 
from G2/M block (a) and 24 hours later (b). After 24 hours, the proportion of cells in 
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G2/M would decrease and more cells were found in G1 phase. If a compound arrested 
the cell cycle at the G2/M phase, the proportion of cells in G1 phase would not 
increase and the profile observed would be similar to that obtained at 0 hour. Figure 
6-4 (c-m) shows the effects of the test compounds on the G2/MG1 transition.  In 
order to have a more quantitative assessment of the proportion of cells in each phase, 






















Figure 6-3: FACS diagrams of test compounds (concentration given in bracket) on 


















Figure 6-4: FACS diagrams of test compounds (concentration given in bracket) on 

















Analysis of the results showed that the compounds could be placed into two 
groups. The 1st group of compounds caused G1 arrest and comprised of compounds 
46, 47, 9 and 10. As seen from Figure 6-3 (k, l), cells treated with 46 and 47 were 
retained in the G1 phase with minimal increases in the G2/M phase. There were, 
however, notable increases in apoptotic cells in the sub-G1 phase. When treated with 
cells synchronized at the G2/M phase, 46 and 47 had no effect on cell progression, 
and after 24 hours, the treated cells showed the same profile as untreated cells (Figure 
6-4 k, l). Compounds 9 and 10 showed a largely similar profile except that the 
proportion of G1 cells decreased to a greater degree and more cells were found in the 
S phase (Figure 6-3 f, g; Table 6-3). The pre-G1 phase also showed fewer apoptotic 

















Table 6-3: Effect of Test compounds on various phases of cell cycle 
HCT 116 cells released from G1 Block1
 Sub-G1 G1 S G2/M 
Control (0 h) 0.46 80.19 6.8 11.57 
Control (24 h) 1.94 34.03 14.90 49.47 
5 (5 M) 2.64 26.14 12.37 58.82 
6 (10 M) 2.64 24.24 26.68 46.51 
7 (10 M) 3.52 20.86 16.00 59.63 
9 (15 M) 3.78 56.85 21.42 18.54 
10 (15 M) 3.62 55.93 21.83 18.98 
37 (30 M) 2.96 32.69 26.91 38.42 
42 (2.5 M) 4.22 10.56 13.81 71.54 
45 (15 M) 5.26 17.49 21.13 56.49 
46 (15 M) 12.68 64.93 8.04 14.58 
47 (15 M) 12.39 65.55 7.10 15.13 
48 (5 M) 4.39 17.50 19.12 59.16 
HCT 116 cells released from G2 Block1
 Sub-G1 G1 S G2/M 
Control (0 h) 1.17 31.12 12.11 55.97 
Control (24 h) 1.24 55.88 14.93 27.90 
5 (5 M) 12.49 34.66 13.43 39.43 
6 (10 M) 9.83 39.33 16.68 34.26 
7 (10 M) 9.51 32.97 12.42 44.99 
9 (15 M) 4.13 42.06 16.84 36.45 
10 (15 M) 2.16 63.51 13.10 21.09 
37 (30 M)  5.68 51.32 14.61 28.26 
42 (2.5 M) 30.54 26.01 15.36 43.57 
45 (15 M) 15.54 26.01 15.36 43.57 
46 (15 M) 2.49 64.15 8.82 25.00 
47 (15 M) 10.62 53.47 8.05 28.39 




1 Concentration used is indicated in brackets. Proportion of cells in each phase was 
the mean of 3 separate determinations. 
 
The 2nd class of compounds arrested the cell cycle at the G2/M phase. This 
was observed for 5-7 and 42, 45, 48. As seen in Figure 6-4 (c, d, e, i, j, m), these 
compounds did not cause the expected increases in the G1 phase after 24 h. Cells in 
G2/M did show some decrease but to a limited extent. There were large numbers of 
cells in the sub-G1 phase that was suggestive of apoptosis for 42, 45 and 48. When 
investigated for their effects on cells released from G1 arrest, the compounds showed 
minimal effects on the G1G2/M transition. 
The only compound that did not fit well into either class was 37. It did not 
seem to affect the cell cycle. The only noticeable features were the increase in 
apoptotic cells in the sub-G1 phase of cells released from G2 arrest, and the increase 
in cells in the S phase when released from G1 arrest.  
A structural trend was observed among the compounds that caused G1 or G2 
arrest.  Compounds (5-7, 42, 45, and 48) that caused G2 arrest had in common the 
presence of one or two methoxy groups on ring A or B. Compounds 5-7 were 
regioisomers with two methoxy groups on ring B. Compounds 42, 45 and 48 had 6-
methoxy on ring A. Rings B of 42 and 45 were also methoxylated. By contrast, 
greater structural diversity was noted in compounds (9, 10, 46, and 47) that caused G1 
arrest.  Compounds 46 and 47 had halogenated groups on rings A and B while 9 and 
10 had bulkier substituents on ring B.  The outlier status of 37 could be anticipated 






Some of the methoxy stilbenes in Table 6-1 had been reported to have 
antiproliferative properties. These were S8Z, S10E and S10Z. Cushman et al 
identified S10Z as a potent cytotoxic agent, targeting tubulin, the major component of 
microtubules to bring about arrest of cell growth. (95)  They showed that the exact 
location of the four methoxy groups on S10Z was a crucial feature for activity and 
that changes in their locations resulted in decreased potency. The association of potent 
antiproliferative activity with the Z isomer was not unexpected.  Combrestatin A4 (Z - 
3,4,5-trimethoxy-3'-hydroxy-4'-methoxystilbene) is a classical example of a Z stilbene 
with potent antiproliferative activity. Interestingly, S10E retained good 
antiproliferative activity in spite of its E configuration and has been the focus of many 
investigations. Gossiau et al found that S10E selectively induced the activation of 
mitochondrial apoptotic pathway in transformed fibroblasts. (51) S10E had a more 
favourable pharmacokinetic profile than resveratrol in terms of better distribution in 
the brain, intestinal and colonic mucosa. (44) The antiproliferative activity of S8Z on 4 
cancer cell lines has also been reported. (96) 
A comparison of the antiproliferative and NQO1 induction profiles of the 
methoxystilbenes showed limited overlap of activities because NQO1 induction was 
found among the E isomers whereas proliferative activities were found predominantly 
among the Z isomers. Thus, potent antiproliferative agents caused negligible NQO1 
induction and the reverse was also true, as seen from S3E (most promising NQO1 
inducer) which had weak antiproliferative activity. 
The 3-substituted indolin-2-ones had been widely investigated for 
antiproliferative activity. Many of them were found to inhibit different receptor 
tyrosine kinases (RTKs) and thus regarded as mutli-targeted inhibitors. The attraction 
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of these compounds is their perceived ability to reduce the formation of resistant cell 
clones by inhibiting two unrelated oncogenic mechanisms. For example, targeting the 
desired oncogenic kinase as well as vascular endothelial growth factor (VEGF) and 
Platelet-derived growth factor (PDGF) receptors involved in the formation of new 
blood vessels is hypothesized to enhance anti-tumour effect. (97)  
When tested for antiproliferative activities on MCF7 and HCT116 cells, only a 
small number of compounds (11 out of 61, 18%) reduced cell survival by  50% at 10 
M and were short listed for IC50 determination. No Class 3 or 4 compound was 
included in this short list.  For those compounds evaluated, activity was modest with 
IC50 values in the low micromolar range. An attempt was made to analyze the SAR 
with PCA and PLS but no significant model could be obtained. However, a qualitative 
SAR could be deduced. Features associated with good antiproliferative activity are 
summarized in Figure 6-2.  They were (i) two methoxy groups on ring A and B, (ii) 
bulky alkoxy groups on ring B, such as phenoxy and 3,4,5-trimethoxy, and (iii) chloro, 
fluoro and trifluoromethyl groups on rings A and B. An unexpected finding was how 
these structural features were linked with their effects on cell cycle progression. 
Compounds with at least two methoxy groups on rings A and B (5-7, 42, 45) were 
found to cause G2 arrest, whereas compounds with bulky substituents (trimethoxy, 
phenoxy) on ring B (9,10) and halogenated groups on both rings (46-48) caused G1 
arrest.  Evidence of apoptosis was also observed for these compounds.  Compound 37 
did not disrupt the cell cycle at either phase. Structurally, it was an outlier that did not 
fit into either category.  These structural trends would require further verification with 
more examples. At present, they serve to highlight how seemingly small variations on 
the ring structure could affect biological responses.    
125 
 
One of the aims of this work is to identify 3-substituted indolinones that 
NQO1 induction (cytoprotective to normal cells) and antiproliferative activity 
(targeting cancer cells).  A comparison of the two activities showed that there was 
some overlap in the structural requirements for the two activities, particularly for the 
Class 2 compounds but less so for Class 1. In Class 2, strong NQO1 induction was 
associated with 3'-trifluoromethyl on ring B, a feature also associated with good 
antiproliferative activity (46, 47, and 48).  In Class 1, the SAR for NQO1 induction 
activity was noted to be less clear-cut although among mono-substituted members, 
good activity was associated with electron withdrawing groups on ring B.  The 
requirements for antiproliferative activity in Class 1 were quite different and centered 
on the presence of alkoxy groups (dimethoxy, trimethoxy, phenoxy) on ring B (5-7, 9, 
10).  Most of these compounds were weak to moderate inducers of NQO1.  Since 
strong NQO1 inducers were frequently non-selective in their induction of CYP1A1 
and NQO1, candidates that preferentially induced NQO1 (rather than potent NQO1 
inducers) would be more useful.  Three promising members were identified – 10, 45 
and 48.  They had NQO1/CYP1A1 induction ratios of 3-4 and IC50 values ranging 
from 1-8 M on the cancer cell lines. These results are summarized in Table 6-4, 









Table 6-4: NQO1 induction and antiproliferative profile of selected Class 1, 2 
compounds 
 









9 > 25 ND 5 > 11 ND 
10 1.7 3.09 6 0.013 1.08 
46 0.016 2.68 7 > 14 ND 
47 0.0041 2.17 42 0.13 2.72 
   45 0.24 4.13 
   48 0.085 3.10 
 
1 CD for induction of NQO1 in Hepa1c1c7 cells. From Table 4-1 
2 From Table 4-2 
 
6.5. Conclusion and Summary 
            For the methoxystilbenes, greater antiproliferative activity was associated with 
the Z isomer. With a 4'-methoxy group on ring B, stilbenes with methoxy groups on 
ring A showed better activity. The tetramethoxylated stilbene, S10Z was the most 
potent member in the series.  Its good antiproliferative activity had been reported in 
the literature. Unfortunately features that promoted antiproliferative activity were not 
associated with phase II induction activity.  
In the case of the indolinones and isoindigos, selected members of Class 1 and 
2 had antiproliferative activities, with IC50 values in the range of  10M or less on at 
least one cell line. The antiproliferative effects were due to interference with the cell 
cycle (G1 or G2 arrest), although this may not be the only mechanism of action. 
Compounds 10, 45, 48 were identified to have both good /selective NQO1 induction 
and antiproliferative activities. 
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Chapter 7 Conclusions and Future Work 
  The aim of the thesis was to test the hypothesis that targeted structural 
modifications of the phytoalexin resveratrol would result in compounds with greater 
phase II enzyme induction activity. To address this hypothesis, two structural 
modifications were proposed. The first involved replacement of the phenolic hydroxy 
groups of resveratrol with methoxy groups and was investigated through the synthesis 
and characterization of a limited series of 23 methoxystilbenes. The second approach 
involved replacing the phenolic ring B of resveratrol with a bioisosteric indolin-2-one 
moiety. A larger series of 61 compounds, organized into 4 classes (Class 1, 2: 3-
substituted indolin-2-ones; Class 3: miscellaneous compounds; Class 4: isoindigos), 
were synthesized and characterized. Both series were evaluated for induction of the 
phase II enzyme NQO1 and antiproliferative activity on two human cancer cell lines. 
 The methoxystilbenes were found to have lesser potential as chemopreventive 
agents. Notwithstanding the fact that some members were more potent NQO1 
inducers than resveratrol on the Hepa1c1c7 cell model, the library had only a narrow 
range of induction activity ( 25 fold). The main reason for this limited range was that 
the CD values of many compounds could not be determined because of their growth 
inhibitory effects on the Hepa1c1c7 cells. The most active compound (S3E, CD 0.85 
M) induced both NQO1 and CYP1A1 – a bifunctional profile, in contrast to the 
monofunctional character of resveratrol, but S3E had fairly good selective induction 
of NQO1. From the few examples available, E-methoxystilbenes had stronger 
induction properties than their Z counterparts but the antiproliferative properties of 
methoxystilbenes were strongly associated with the Z isomers. This dichotomy meant 
that a useful merger of both properties could not be found in the same molecule. 
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Hence, the methoxystilbenes offered limited scope for future structural variation and 
there are no plans for more investigations in this area.   
 The 3-substituted indolin-2-ones and isoindigos of the 2nd series were found to 
be more promising for the same reasons that the methoxystilbenes were not.  This 
series showed a remarkable 104 fold variation in NQO1 induction activity, with 
nanomolar potencies for all Class 4 compounds (isoindigos). Even among the 3-
substituted indolin-2-ones, an approximate 103 fold variation was observed. The large 
variation in potency emphasized the potential of the indolinone template as promising 
lead structures for NQO1 induction activity. The importance of the nitrogen-linked 
Michael acceptor moiety in this template was verified by relevant comparisons with 
the Class 3 compounds in the series. Unfortunately, the presence of this moiety did 
not give rise to the anticipated monofunctional induction as reported in literature. (25) 
Instead, a bifunctional profile was observed but several members demonstrated 
stronger induction of NQO1 than CYP1A1. An interesting observation that emerged 
was that potent NQO1 inducers like the isoindigos induced both NQO1 and CYP1A1 
to the same extent. In contrast, compounds that were moderately active NQO1 
inducers (CD 1- 2.5 M) were more selective inducers of NQO1 than CYP1A1.  
A QSAR analysis was carried out on the NQO1 induction activities of this 2nd 
series using PCA and PLS. This analysis provided two important findings. First, the 
isoindigos were distinguished from the 3-substituted indolin-2-ones and other 
compounds by certain key descriptors like the number of H bond donors, VDW 
surface area of these donors and LUMO energies. Second, potent induction properties 
were associated with a suite of physicochemical descriptors – LUMO energy, size, 
VDW surface area of H bond donors and number of rotatable bonds.  Since good 
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NQO1 inducers were also non-selective, the presence of these properties in a 
molecule designed for phase II induction should be carefully considered. 
 Promising chemopreventive agents are generally multi-targeting agents.  
Resveratrol provides a good example. Its chemopreventive properties have been 
attributed to its antioxidant activity, induction of apoptosis and induction of phase II 
enzymes, to name a few.  Hence, the Class1-4 compounds were screened for 
antiproliferative activities. In sharp contrast to NQO1 induction activity, only a 
handful of compounds had anti-proliferative activities with IC50 values in the low 
micromolar range (1-10 M). Among these were found three promising members (10, 
45, 48) that combined  reasonably potent and selective NQO1 induction activities (CD 
0.08 – 1.7 M, NQO1/CYP1A1 quotient > 3) with potent antiproliferative activity 
(IC50 on two cancer cell lines 1 -8 M). Cell cycle analysis showed that 10 caused G1 
arrest, while 45, 48 arrested cells at the G2/M to G1 transition. 
The present findings showed that the bioisosteric replacement of the phenolic 
ring in resveratrol to give 3-substituted indolin-2-ones is a viable means of improving 
NQO1 induction activity. In addition, a small number of compounds from this series 
combined NQO1 induction with interference with cell cycle progression, a promising 
combination for effective chemoprevention. Non-dietary chemopreventive agents are 
generally considered with some skepticism and it would be difficult to persuade 
healthy persons to consume drugs for the purpose of preventing cancer. This presents 
some problems with respect to the future of synthesized compounds as 
chemopreventive agents. Perhaps the focus should be on their antiproliferative 




The present work has also raised some interesting questions and issues that 
may be further pursued. Some promising lead structures have emerged from this 
investigation and these could be probed further by structural modifications to give a 
better understanding of the pharmacophore for selective NQO1 induction activity. 
The mechanisms by which the 3-substituted indolin-2-ones and isoindigos induced 
NQO1 activity should be investigated in greater detail. An obvious omission in this 
thesis was the absence of investigations of a cell line that lacked a functional AhR 
receptor. In addition, the emerging evidence of cross-talk between the AhR/XRE and 
Keap2-Nrf2-ARE pathways suggest that it may be timely to determine if these 
compounds are mixed AhR/Nrf2 activators – that is, do they act as both AhR agonists 
and Keap1 activators? Further investigations on an Nrf2 reporter gene assay and Nrf2 
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Appendix 1: Determination of compound purity by HPLC for target compounds 
The purity of compounds was assessed by reverse phase high pressure column 
chromatography. Determinations were carried out on a Waters Delta 600 liquid 
chromatography system, using Agilent Zorbax Eclipse XDB-C18 column (4.6 mm × 
150 mm, 5 m). The isocratic mode was employed using two solvent systems (A: 
methanol-water and B: acetonitrile-water in the ratio of 4:1). Flow rate was fixed at 1 
ml /min and UV detection at dual wavelengths (278 nm and 305 nm) was employed. 
The area under the main peak was determined and expressed as a % of total peak area 
during a 20 min run. All compounds were purified until their chromatograms showed 
a main peak with areas > 96% on both solvent systems. The retention time (Rt) of the 
principal peak in two solvent system was determined in minutes (min). 
 
Compound Solvent system A Solvent system B 
tR (min) PHPLC tR (min) PHPLC 
3E 6.6 98.6% 4.5 97.6% 
3Z 6.7 99.1% 4.2 98.3% 
4E 8.3 97.2% 4.1 98.4% 
4Z 7.5 97.9% 4.4 98.5% 
5E 8.2 97.8% 4.1 99.8% 
5Z 7.7 96.5% 4.4 98.9% 
6E 8.1 97.4% 4.1 97.4% 
6Z 6.2 97.4% 4.0 98.0% 
7E 4.7 99.1% 3.1 98.1% 
7Z 4.8 98.2% 3.4 98.8% 
8E 7.0 97.9% 3.8 99.0% 
8Z 6.6 97.7% 4.0 98.1% 
10E 4.2 97.1% 3.0 99.2% 
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10Z 4.3 98.1% 3.3 99.0% 
12E 3.2 98.3% 2.3 98.5% 
12Z 3.2 97.9% 2.4 98.1% 
13E 2.1 98.5% 1.7 98.1% 
13Z 2.1 96.3% 1.8 98.7% 
14E 3.2 97.6% 2.4 96.0% 
14Z 3.3 98.2% 2.6 97.5% 
9E 7.2 99.0% 4.8 98.1% 
11E 3.5 97.9% 2.5 97.8% 
15E 7.7 99.1% 4.7 98.0% 
1 3.6 98.6% 2.3 97.5% 
2 3.3 97.1% 2.3 96.2% 
3 3.4 96.8% 2.3 97.3% 
4 3.6 98.1% 2.2 99.0% 
5 3.5 96.9% 2.2 98.0% 
6 3.2 99.1% 2.2 97.8% 
7 2.7 97.9% 2.1 98.6% 
8 3.9 99.0% 2.3 97.1% 
9 3.3 98.4% 2.2 98.1% 
10 7.7 97.5% 3.3 98.4% 
11 2.6 99.1% 1.8 97.3% 
12 2.3 98.6% 1.7 99.0% 
13 1.7 96.7% 1.6 97.2% 
14 1.7 98.2% 1.6 97.5% 
15 2.6 98.7% 1.8 97.8% 
16 2.1 96.1% 1.7 97.9% 
17 2.8 98.6% 1.9 97.4% 
18 4.4 98.3% 2.6 96.4% 
19 4.7 96.8% 2.7 97.7% 
20 4.8 98.5% 2.7 98.0% 
21 6.3 99.1% 3.3 98.4% 
22 3.3 97.4% 2.2 98.3% 
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23 3.6 97.6% 2.3 96.7% 
24 3.6 98.3% 2.3 99.0% 
25 3.5 96.8% 2.3 97.1% 
26 5.0 98.8% 2.8 98.2% 
27 5.3 99.1% 2.8 98.6% 
28 6.9 99.3% 3.5 97.8% 
29 4.4 97.5% 2.7 99.7% 
30 3.3 97.8% 2.5 97.9% 
31 4.7 96.8% 2.7 98.7% 
32 4.9 99.6% 2.8 97.3% 
33 2.5 96.8% 2.0 97.5% 
34 2.4 98.4% 2.0 98.2% 
35 2.1 97.3% 1.7 98.4% 
36 2.6 99.7% 1.8 98.1% 
37 5.7 97.7% 2.9 98.6% 
38 6.5 97.8% 3.1 98.1% 
39 3.9 97.4% 2.4 98.0% 
40 5.4 98.3% 2.9 97.9% 
41 5.9 97.5% 2.9 98.0% 
42 3.7 98.5% 2.2 98.3% 
43 2.2 99.6% 1.8 98.7% 
44 2.8 99.1% 1.9 97.5% 
45 2.1 98.0% 1.7 96.6% 
46 5.0 96.5% 2.8 99.1% 
47 7.1 98.2% 3.4 97.4% 
48 4.8 98.4% 2.7 96.8% 
49 4.5 97.6% 3.0 99.4% 
50 2.5 99.3% 2.0 98.5% 
51 2.6 97.3% 2.0 98.0% 
52 3.3 98.1% 2.2 97.6% 
53 3.3 97.6% 2.5 98.7% 
54 2.2 99.0% 1.8 97.5% 
148 
 
55 2.8 98.4% 1.9 97.9% 
56 3.1 99.1% 2.0 98.3% 
57 3.7 98.5% 2.2 97.4% 
58 4.1 97.7% 2.2 99.4% 
59 4.3 97.8% 2.3 98.5% 
60 4.8 99.7% 2.4 98.6% 























Appendix 2: Spectroscopic data, melting points, nominal mass, yields of 
synthesized compounds 
2, 4'-Dimethoxystilbene S3  
0.72 g (Yield 60%) S3Z1 (0.54 g); MS-APCI: [M+H]+ 241.2 (240.1); 1H NMR 
(300 MHz CDCl3)  ppm 7.22 (d, J=7.2 Hz, 2H), 7.17 (d, J=8.7 Hz, 2H), 6.90 (d, 
J=8.3 Hz, 1H), 6.70-6.78 (m, 3H), 6.57 (s, 2H), 3.77 (s, 3H, OCH3), 3.83 (s, 3H, 
OCH3). 
S3E2 (0.18 g), mp 85-87 ℃; lit. 85-86 ℃ ; MS-APCI: [M+H]+ 241.2 (240.1); 
1H NMR (300 MHz CDCl3)  ppm 7.57 (d, J=7.5 Hz, 1H), 7.47 (d, J=8.7 Hz, 2H), 
7.35 (d, J=16.2 Hz, 1H), 7.21 (d, J=6.9 Hz, 1H), 7.06 (d, J=16.5 Hz, 1H), 6.88-6.98 
(m, 4H), 3.89 (s, 3H, OCH3), 3.83 (s, 3H, OCH3). 
  3, 4'-Dimethoxystilbene S4 
0.86 g (72% yield) S4Z1 (0.64 g, oil); MS-APCI: [M+H]+ 241.2 (240.1); 1H 
NMR (300 MHz CDCl3)  ppm 7.20 (d, J=8.7 Hz, 2H), 7.15 (d, J=7.9 Hz, 1H), 6.83-
6.88 (m, 2H), 6.73-6.79(m, 3H), 6.54 (d, J=12.4 Hz, 1H), 6.48 (d, J=12.4 Hz, 1H), 
3.79 (s, 3H, OCH3), 3.69 (s, 3H, OCH3). 
S4E3 (0.22 g) mp 106-109 ℃; lit 107-108 ℃; MS-APCI: [M+H]+ 241.2 
(240.1); 1H NMR (300 MHz CDCl3)  ppm 7.45 (d, J=8.7 Hz, 2H), 7.26 (t, J=8.3 Hz, 
1H), 7.04-7.10 (m, 3H), 6.89-6.97 (m, 3H), 6.80 (q, J=1.9 Hz, 1H), 3.85 (s, 3H, 
OCH3), 3.83 (s, 3H, OCH3). 
 4, 4'-Dimethoxystilbene S5 
0.99 g (72% yield) S5Z4 (0.69 g, oil); MS-APCI: [M+H]+ 241.2 (240.1);  1H 
NMR (300 MHz CDCl3)  ppm 7.20 (d, J=9.0 Hz, 4H), 6.77 (d, J=9.0 Hz, 4H), 6.45 
(s, 2H), 3.79 (s, 6H, OCH3). 
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S5E5 (0.3 g) mp 214-215 ℃; lit 214-216 ℃; MS-APCI: [M+H]+ 241.3 
(240.1); 1H NMR (300 MHz CDCl3)  ppm 7.43 (d, J=9.0 Hz, 4H), 6.93(s, 2H), 6.89 
(d, J=9.0 Hz, 4H), 3.83 (s, 6H, OCH3). 
 2, 4, 4'-Trimethoxystilbene S6 
1.03 g (84% yield) S6Z (0.7 g, oil);  MS-APCI: [M+H]+ 271.2 (270.1);  1H 
NMR (300 MHz CDCl3)  ppm 7.12-7.20 (m, 3H), 6.73 (d, J=8.6 Hz, 2H), 6.49 (d, 
J=1.5 Hz, 2H), 6.46 (d, J=2.3 Hz, 1H), 6.33 (q, J=2.6 Hz, 1H), 3.81 (s, 3H, OCH3), 
3.80 (s, 3H, OCH3), 3.77 (s, 3H, OCH3); 13C NMR (75 MHz, CDCl3) δ ppm 160.11, 
158.30, 158.19, 130.39, 130.10, 129.94, 128.51, 123.65, 119.08, 113.35, 104.20, 
98.24, 55.39, 55.20, 55.05. 
S6E (0.33 g) mp 87-89 ℃; MS-APCI: [M+H]+ 271.2 (270.1); 1H NMR (300 
MHz CDCl3)  ppm 7.43-7.50 (m, 3H), 7.25 (d, J=16.2Hz, 1H), 6.95 (d, J=16.6 Hz, 
1H), 6.88 (d, J=8.7 Hz, 2H), 6.52 (q, J=2.3 Hz, 1H), 6.47 (d, J=2.3 Hz, 1H), 3.86 (s, 
3H, OCH3), 3.83 (s, 3H, OCH3), 3.82 (s, 3H, OCH3); 13C NMR (75 MHz, CDCl3) δ 
ppm 160.16, 158.77, 157.77, 131.10, 127.39, 126.86, 126.54, 121.16, 119.80, 113.94, 
104.88, 98.43, 55.42, 55.31, 55.21. 
 3, 4, 4'-Trimethoxystilbene S7 
0.94 g (77 % yield) S7Z6 ; (0.66 g, oil), MS-APCI: [M+H]+ 271.2 (270.1); 1H 
NMR (300 MHz CDCl3)  ppm 7.21-7.26 (m, 3H), 6.74-6.84 (m, 4H), 6.48 (d, J=12.0 
Hz, 1H), 6.43 (d, J=12.1 Hz, 1H), 3.87 (s, 3H, OCH3), 3.79 (s, 3H, OCH3), 3.65 (s, 
3H, OCH3). 
S7E7 (0.28 g) mp 136-137 ℃; lit mp 136-138 ℃; MS-APCI: [M+H]+ 271.2 
(270.1); 1H NMR (300 MHz CDCl3)  ppm 7.44 (d, J=8.7 Hz, 2H), 6.84-7.05 (m, 7H), 
3.95 (s, 3H, OCH3), 3.90 (s, 3H, OCH3), 3.83 (s, 3H, OCH3). 
 3, 4', 5 -Trimethoxystilbene S8 
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0.74 g (60% yield); S8Z8 (0.55 g); MS-APCI: [M+H]+ 271.3 (270.1); 1H NMR 
(300 MHz CDCl3)  ppm 7.21 (d, J=8.7 Hz, 2H), 6.77 (d, J=8.7 Hz, 2H), 6.53 (d, 
J=12.4 Hz, 1H), 6.44 (d, J=12.0 Hz, 1H), 6.43 (d, J=2.3 Hz 2H), 6.32 (t, J=2.3 Hz, 
1H), 3.78 (s, 3H, OCH3), 3.67 (s, 6H, OCH3).  
 S8E9 (0.19 g):  mp 49-54 ℃; lit mp 50 ℃; MS-APCI: [M+H]+ 271.3 (270.1); 
1H NMR (300 MHz CDCl3)  ppm 7.45 (d, J=8.6 Hz, 2H), 7.04 (d, J=16.2 Hz, 1H), 
6.902 (d, J=16.6 Hz, 1H), 6.90 (d, J=9.1 Hz, 2H), 6.65 (d, J= 2.3 Hz, 2H), 6.38 (t, J= 
2.3 Hz, 1H), 3.83 (s, 9H, OCH3). 
2, 4', 6- Trimethoxystilbene S9 
S9E (0.65 g, 48% yield) mp 79-80 ℃; MS-APCI: [M+H]+ 271.3 (270.1); 1H 
NMR (300 MHz CDCl3)  ppm 7.52 (d, J=16.6 Hz, 1H), 7.47 (d, J=9.1 Hz, 2H), 7.31 
(d, J=16.6 Hz, 1H), 7.14 (t, J=8.3 Hz, 1H), 6.88 (d, J=8.6 Hz, 2H), 6.59 (d, J=8.3 Hz, 
2H), 3.89 (s, 6H, OCH3), 3.82 (s, 3H, OCH3); 13C NMR (75 MHz, CDCl3) δ ppm 
158.83, 158.44, 132.08, 131.92, 127.60, 127.52, 117.82, 115.06, 113.88, 104.01, 
55.77, 55.25. 
 3, 4, 5, 4'-Tetramethoxystilbene S10 
1.2 g (80% yield); S10Z10 (0.8 g, oil); MS-APCI: [M+H]+ 301.2 (300.1); 1H 
NMR (300 MHz CDCl3)  ppm 7.24 (d, J=8.7 Hz, 2H), 6.79 (d, J=8.7 Hz, 2H), 6.52 
(d, J=12.1 Hz, 1H), 6.50 (s, 2H,), 6.42 (d, J=12.1 Hz, 1H), 3.84 (s, 3H, OCH3), 3.79 (s, 
3H, OCH3), 3.69 (s, 6H, OCH3). 
  S10E11  (0.4 g) mp 158-159 ℃; lit mp 157 ℃; MS-APCI: [M+H]+ 301.2 
(300.1); 1H NMR (300 MHz CDCl3)  ppm 7.44 (d, J=8.6 Hz, 2H), 6.98 (d, J=16.2 
Hz, 1H), 6.90 (d, J=9.4 Hz, 2H), 6.89 (d, J=16.2 Hz, 1H), 6.72 (s, 2H), 3.92 (s, 6H, 
OCH3), 3.87 (s, 3H, OCH3), 3.84 (s, 3H, OCH3). 
 2-Hydroxy-4'-methoxystilbene S11 
152 
 
S11E12 (0.023 g, 2% yield); mp 141-143 ℃; lit mp 145-147 ℃; 1H NMR (300 
MHz DMSO-d6)  ppm 9.66 (s, 1H, OH), 7.53 (d, J=7.9Hz, 1H), 7.49 (d, J=8.7 Hz 
2H), 7.26 (d, J=16.6 Hz, 1H), 7.13(d, J=16.6 Hz, 1H), 7.04-7.09(m, 1H), 6.94(d, 
J=8.67Hz, 2H), 6.78-6.86(m, 2H), 3.77 (s, 3H, OCH3). 
3-Hydroxy-4'-methoxystilbene (S12) 
S12Z (80% yield); MS-APCI: [M+H]+ 227.3 (226.1); 1H NMR (300 MHz 
CDCl3)  ppm 7.19 (d, J=8.7 Hz, 2H), 7.11 (t, J=7.7 Hz, 1H), 6.84 (d, J=7.5 Hz, 1H), 
6.73-6.78 (m, 3H), 6.68 (q, J=2.64 Hz, 1H), 6.52 (d, J=12.4Hz, 1H), 6.44 (d, J=12.1 
Hz, 1H), 3.78 (s, 3H, OCH3); 13C NMR (75 MHz, CDCl3) δ ppm 158.48, 155.37, 
139.10, 130.16, 129.96, 129.58, 129.47, 128.33, 121.34, 115.32, 113.97, 113.56, 
55.14. 
S12E13 (91 % yield) mp 157-160 ℃; lit mp 159-160 ℃; MS-APCI: [M+H]+ 
227.3 (226.1);  1H NMR (300 MHz DMSO-d6)  ppm 9.39 (s, 1H, OH), 7.53 (d, J=8.6 
Hz, 2H), 7.07-7.17 (m, 2H), 6.93-7.02 (m, 5H), 6.65 (q, J=1.9 Hz, 1H), 3.78 (s, 3H, 
OCH3). 
 3, 5-Dihydroxy-4'-methoxystilbene S13 
S13Z14 (94% yield); MS-APCI: [M+H]+ 243.2 (242.1); 1H NMR (300 MHz 
CDCl3)  ppm 7.20 (d, J=8.7Hz, 2H), 6.76 (d, J=8.7 Hz, 2H), 6.50 (d, J=12.0 Hz, 1H), 
6.37 (d, J=12.0 Hz, 1H), 6.31 (d, J=2.3Hz, 2H), 6.22 (t, J=2.3Hz, 1H), 3.78 (s, 3H, 
OCH3). 
  S13E15 (82% yield), mp 164-167 ℃; lit mp 158-166 ℃; MS-APCI: [M+H]+ 
243.3 (242.1); 1H NMR (300 MHz DMSO-d6)  ppm 9.21 (s, 2H, OH), 7.52 (d, J=8.7 
Hz, 2H), 6.86-7.01 (m, 4H,), 6.40 (d, J=1.9 Hz, 2H), 6.13 (t, J=3.7 Hz, 1H), 3.77 (s, 
3H, OCH3). 
 3-Hydroxy-4, 4'-dimethoxystilbene S14 
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S14Z (94 % yield) mp 77 – 79 ℃; MS-APCI: [M+H]+ 257.2 (256.1);  1H 
NMR (300 MHz CDCl3)  ppm 7.21 (d, J = 8.7 Hz, 2H), 6.86 (d, J=1.9 Hz, 1H), 
6.70-6.78 (m, 4H), 6.45 (d, J=12.0 Hz, 1H), 6.39 (d, J=12.1 Hz, 1H), 5.49 (s, 1H, OH), 
3.87 (s, 3H, OCH3), 3.79 (s, 3H, OCH3); 13C NMR (75 MHz, CDCl3) δ ppm 158.49, 
145.56, 145.15, 130.90, 130.01, 129.77, 128.69, 128.29, 120.87, 114.85, 113.54, 
110.32, 55.80, 55.11. 
  S14E16 (92 % yield) mp 192-193 ℃; MS-APCI: [M+H]+ 257.2 (256.1); 1H 
NMR (300 MHz DMSO-d6)  ppm 8.95 (s, 1H, OH), 7.49 (d, J=8.7 Hz, 2H), 7.01 (d, 
J=1.9 Hz, 1H), 6.88-6.96 (m, 6H), 3.78 (s, 3H, OCH3), 3.77 (s, 3H, OCH3). 
S15E17 (10% yield) mp: 135-136 ℃; lit mp 135-136 ℃; MS-APCI: [M+H]+ 
241.1 (240.1); 1H NMR (300 MHz CDCl3)  ppm 7.63-7.66 (m, 2H), 7.47 (s, 2H), 
7.20-7.23 (m, 2H), 6.87-6.98 (m, 4H), 3.88 (s, 6H, OCH3). 
              3-(Tert-Butyldimethylsilyloxy)-4'methoxystilbene S19 
S19Z:  Clear oil 76% yield; 1H NMR (300 MHz CDCl3)  ppm 7.18 (d, J=9.1 
Hz, 2H), 7.09 (d, J=7.9 Hz, 2H), 6.82-6.99 (m, 3H), 6.75 (d, J=9.0 Hz, 1H), 6.52 (d, 
J=12.1 Hz, 1H), 6.45 (d, J=12.1 Hz, 1H), 3.78 (s, 3H, OCH3), 0.93 (s, 9H, C (CH3)3), 
0.10 (s, 6H, Si(CH3)2). 
S19E: 1H NMR (300 MHz CDCl3)  ppm 7.45 (d, J=8.7 Hz, 2H), 7.19 (d, 
J=15.8 Hz, 1H), 7.08 (d, J=15.8 Hz, 1H), 6.88-6.99 (m, 5H), 6.72 (q, J=2.3 Hz, 1H), 
3.83 (s, 3H, OCH3), 1.00 (s, 9H, C (CH3)3), 0.22 (s, 6H, Si(CH3)2). 
              3, 5-Di-(Tert-Butyldimethylsilyloxy)-4'methoxystilbene S20 
S20Z: clear oil 68% yield; 1H NMR (300 MHz CDCl3)  ppm 7.17  (d, J=8.7 
Hz, 2H), 6.75 (d, J=8.6 Hz, 2H), 6.50 (d, J=12.4 Hz, 1H), 6.40 (d, J=12.1 Hz, 1H), 
6.36 (d, J=1.9 Hz, 2H), 6.19 (t, J=2.3 Hz, 1H), 3.77 (s, 3H, OCH3), 0.93 (s, 18H, C 
(CH3)3), 0.10 (s, 12H, Si(CH3)2). 
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S20E: 1H NMR (300 MHz CDCl3)  ppm 7.44 (d, J=8.7 Hz, 2H), 6.97 (d, 
J=16.6 Hz, 1H), 6.89 (d, J=8.6 Hz, 2H), 6.83 (d, J=16.2Hz, 1H), 6.60 (d, J=2.3Hz, 
2H), 6.24 (t, J=2.3Hz, 1H), 3.83 (s, 3H, OCH3), 0.99(s, 18H, C (CH3)3), 0.21 (s,12H, 
Si(CH3)2).  
             3-(Tert-Butyldimethylsilyloxy)-4, 4'-dimethoxystilbene S21 
1.32 g, 71 % yield. S21Z (0.8g); 1H NMR (300 MHz CDCl3)  ppm 7.19 (d, 
J=8.7 Hz, 2H), 6.70-6.83 (m, 5H), 6.44 (d, J=12.1 Hz, 1H), 6.39 (d, J=12.1 Hz, 1H), 
3.78 (s, 6H, OCH3), 0.93 (s, 9H, C (CH3)3), 0.06 (s, 6H, Si (CH3)2).  
S21E: (0.52 g); 1H NMR (300 MHz CDCl3)  ppm 7.42 (d, J=8.7 Hz, 2H), 
7.03 (d, J=7.9 Hz, 2H), 6.81-6.90 (m, 5H), 3.83 (s, 3H, OCH3), 3.82 (s, 3H, OCH3), 
1.02 (s, 9H, C (CH3)3), 0.18 (s, 6H, Si (CH3)2). 
(E)-3-Benzylideneindolin-2-one (1)18, Yield 68%, mp 179-180 ℃; lit. 175-
176 ℃; MS-APCI: [M+H]+ 222.2 (221.1); 1H NMR (300 MHz DMSO-d6)  ppm 
6.84 (dd, J=12.8, 7.9 Hz, 2 H), 7.22 (t, J=7.5 Hz, 1 H), 7.49 (m, 4H), 7.62 (s, 1 H), 
7.69 (d, J=7.2 Hz, 2 H), 10.59 (s, 1 H); 13C NMR (75 MHz, DMSO-d6) δ ppm 168.61, 
142.96, 135.75, 134.46, 130.15, 129.64, 129.23, 128.73, 127.68, 122.32, 121.08, 
120.87, 110.13. 
 (E)-3-(2-Methoxybenzylidene)indolin-2-one (2)19, Yield 82%, mp 221-
222 ℃; lit. 221-223 ℃; MS-APCI: [M+H]+ 252.3 (251.1); 1H NMR (300 MHz 
DMSO-d6)  ppm 3.84 (s, 3 H), 6.83 (dd, J=14.3, 7.5 Hz, 2 H), 7.07 (t, J=7.4 Hz, 1 H), 
7.18 (m, 2 H), 7.39 (d, J=7.5 Hz, 1 H), 7.48 (t, J=7.7 Hz, 1 H), 7.66 (m, 2 H), 10.57 (s, 
1 H); 13C NMR (75 MHz, DMSO-d6) δ ppm 168.63, 157.62, 142.74, 131.74, 131.70, 




 (E)-3-(3-Methoxybenzylidene)indolin-2-one (3)19, Yield 70%, mp 151-
152 ℃; lit. 152-153 ℃; MS-APCI: [M+H]+ 252.3 (251.1); 1H NMR (300 MHz 
DMSO-d6)  ppm 3.79 (s, 3 H), 6.85 (t, J=7.9 Hz, 2 H), 7.04 (dd, J=8.3, 2.3 Hz, 1 H), 
7.23 (m, 3 H), 7.43 (t, J=7.9 Hz, 1 H), 7.54 (d, J=7.5 Hz, 1 H), 7.59 (s, 1 H), 10.59 (s, 
1 H); 13C NMR (75 MHz, DMSO-d6) δ ppm 168.63, 159.31, 143.01, 135.78, 135.63, 
130.16, 129.86, 127.80, 122.53, 121.44, 121.08, 120.86, 115.53, 114.29, 110.15, 
55.17. 
 (E)-3-(4-Methoxybenzylidene)indolin-2-one (4)18, Yield 85%, mp 158-
159 ℃; lit. 156-157 ℃; MS-APCI: [M+H]+ 252.4 (251.1); 1H NMR (300 MHz 
DMSO-d6)  ppm 3.83 (s, 3 H), 6.86 (m, 2 H), 7.08 (d, J=8.7 Hz, 2 H), 7.21 (t, J=7.5 
Hz, 1 H), 7.57 (s, 1 H), 7.64 (d, J=7.9 Hz, 1 H), 7.70 (d, J=8.7 Hz, 2 H), 10.54 (s, 1 
H); 13C NMR (75 MHz, DMSO-d6) δ ppm 168.95, 160.52, 142.69, 136.00, 131.47, 
129.64, 126.62, 125.63, 122.06, 121.19, 120.99, 114.21, 110.02, 55.31. 
 (E)-3-(2,4-Dimethoxybenzylidene)indolin-2-one (5)20, Yield 78%, mp 210-
211 ℃; MS-APCI: [M+H]+ 282.2 (281.1); 1H NMR (300 MHz, DMSO-d6)  ppm 
3.85 (d, J=2.3 Hz, 6 H), 6.68 (d, J=6.8 Hz, 2 H), 6.84 (t, J=7.2 Hz, 2 H), 7.19 (t, J=7.5 
Hz, 1 H), 7.51 (d, J=7.5 Hz, 1 H), 7.61 (s, 1 H), 7.67 (d, J=9.0 Hz, 1 H), 10.51 (s, 1 
H); 13C NMR (75 MHz, DMSO-d6) δ ppm 169.05, 162.72, 159.45, 142.49, 131.79, 
130.65, 129.37, 125.25, 121.97, 121.46, 120.94, 115.42, 109.95, 105.23, 98.47, 55.71, 
55.47. 
(E)-3-(2,5-Dimethoxybenzylidene)indolin-2-one (6)21, Yield 69%, mp 189-
192 ℃; lit. 193-195 ℃;  MS-APCI: [M+H]+ 282.3 (281.1); 1H NMR (300 MHz 
DMSO-d6)  ppm 3.72 (s, 3 H), 3.79 (s, 3 H), 6.85 (dd, J=7.7, 4.7 Hz, 2 H), 7.06 (m, 
2 H), 7.21 (m, 2 H), 7.44 (d, J=7.9 Hz, 1 H), 7.60 (s, 1 H), 10.57 (s, 1 H); 13C NMR 
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(75 MHz, DMSO-d6) δ ppm 168.69, 152.59, 151.89, 142.89, 131.49, 129.94, 127.52, 
123.41, 122.47, 121.08, 121.03, 116.82, 114.44, 112.54, 110.11, 55.87, 55.47. 
 (E)-3-(2,6-Dimethoxybenzylidene)indolin-2-one (7), Yield 74%, mp 201-
202 ℃; MS-APCI: [M+H]+ 282.2 (281.1); 1H NMR (300 MHz DMSO-d6)  ppm 
3.74 (s, 6 H), 6.78 (m, 5 H), 7.15 (t, J=7.4 Hz, 1 H), 7.43 (m, 2 H), 10.47 (s, 1 H); 13C 
NMR (75 MHz, DMSO-d6) δ ppm 168.73, 157.95, 142.23, 131.33, 129.27, 129.03, 
127.15, 123.71, 122.22, 121.02, 111.66, 109.50, 103.91, 55.61. 
 (E)-3-(3,5-Dimethoxybenzylidene)indolin-2-one (8)20, Yield 70%, mp 160-
162 ℃; MS-APCI: [M+H]+ 282.2 (281.1); 1H NMR (300 MHz DMSO-d6)  ppm 
3.77 (s, 6 H), 6.59 (s, 1 H), 6.86 (m, 4 H), 7.22 (t, J=7.5 Hz, 1 H), 7.54 (s, 1 H), 7.57 
(d, J=8.3 Hz, 1 H), 10.59 (s, 1 H); 13C NMR (75 MHz, DMSO-d6) δ ppm 168.59, 
160.53, 143.04, 136.27, 135.66, 130.18, 127.89, 122.75, 121.11, 120.80, 110.16, 
106.95, 101.73, 55.36. 
(E)-3-(3,4,5-Trimethoxybenzylidene)indolin-2-one (9)22, Yield 90%, mp 
205-207 ℃; lit. 203-205 ℃; MS-APCI: [M+H]+ 312.4 (311.1); 1H NMR (300 MHz 
DMSO-d6)  ppm 3.74 (s, 3 H), 3.82 (d, J=10.6 Hz, 6 H), 6.83 (d, J=7.9 Hz, 1 H), 
6.98 (t, J=7.5 Hz, 1 H), 7.19 (t, J=7.5 Hz, 1 H), 7.67 (d, J=7.5 Hz, 1 H), 7.75 (s, 1 H), 
8.01 (s, 2 H), 10.57 (s, 1 H); 13C NMR (75 MHz, DMSO-d6) δ ppm 167.34, 152.28, 
140.47, 139.81, 137.33, 129.57, 128.62, 125.62, 125.24, 121.04, 119.40, 110.18, 
109.35, 60.16, 55.88. 
(E)-3-(3-Phenoxybenzylidene)indolin-2-one (10), Yield 28%, mp 139-
141 ℃; MS-APCI: [M+H]+ 314.2 (313.1); 1H NMR (300 MHz DMSO-d6)  ppm 
6.80 (m, 2 H), 7.16 (m, 6 H), 7.42 (m, 4 H), 7.53 (m, 2 H), 10.59 (s, 1 H); 13C NMR 
(75 MHz, DMSO-d6) δ ppm 168.54, 157.30, 156.11, 143.06, 136.27, 134.82, 130.56, 
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130.29, 130.21, 128.02, 124.50, 124.04, 122.53, 121.06, 120.62, 119.71, 119.40, 
118.18, 110.17. 
 (Z)-3-(2-Hydroxybenzylidene)indolin-2-one  (11)23, Yield 34%, mp 204-
205 ℃; lit. 195-196 ℃. MS-APCI: [M+H]+ 238.3 (237.1); 1H NMR (300 MHz 
DMSO-d6)  ppm 6.85 (q, J=8.0 Hz, 2 H), 6.94 (m, 2 H), 7.20 (t, J=7.5 Hz, 1 H), 7.30 
(t, J=7.4 Hz, 1 H), 7.48 (d, J=7.5 Hz, 1 H), 7.61 (d, J=7.2 Hz, 1 H), 7.67 (s, 1 H), 
10.53 (s, 1 H); 13C NMR (75 MHz, DMSO-d6) δ ppm 168.88, 156.52, 142.64, 132.53, 
131.61, 129.68, 129.58, 126.53, 122.37, 121.38, 121.02, 118.87, 116.03, 109.99. 
(E)-3-(3-Hydroxybenzylidene)indolin-2-one (12)20, Yield 71%, mp 268-
270 ℃; MS-APCI: [M+H]+ 238.2 (237.1); 1H NMR (300 MHz DMSO-d6)  ppm 
6.85 (m, 3 H), 7.09 (m, 2 H), 7.22 (t, J=7.5 Hz, 1 H), 7.31 (t, J=7.7 Hz, 1 H), 7.53 (s, 
1 H), 7.58 (d, J=7.9 Hz, 1 H), 9.72 (s, 1 H), 10.58 (s, 1 H); 13C NMR (75 MHz, 
DMSO-d6) δ ppm 168.77, 157.54, 142.96, 136.07, 135.68, 130.10, 129.93, 127.47, 
122.71, 121.13, 120.96, 120.22, 116.91, 115.61, 110.14. 
 (E)-3-(2,5-Dihydroxybenzylidene)indolin-2-one (13), Yield 86%, mp 
265 ℃ (decomposition temperature); MS-APCI: [M+H]+ 254.3 (253.1); 1H NMR 
(300 MHz DMSO-d6)  ppm 6.75 (m, 2 H), 6.87 (t, J=7.9 Hz, 2 H), 7.04 (d, J=2.3 Hz, 
1 H), 7.20 (t, J=7.5 Hz, 1 H), 7.60 (m, 2 H), 9.01 (s, 1 H), 9.46 (s, 1 H), 10.52 (s, 1 
H); 13C NMR (75 MHz, DMSO-d6) δ ppm 168.95, 149.45, 149.40, 142.60, 132.69, 
129.62, 126.09, 122.64, 121.51, 121.26, 121.02, 118.96, 116.85, 114.82, 109.93. 
(E)-3-(3,5-Dihydroxybenzylidene)indolin-2-one (14), Yield 82%, mp 253 ℃ 
(decomposition temperature); MS-APCI: [M+H]+ 254.2 (253.1); 1H NMR (300 MHz 
DMSO-d6)  ppm 6.32 (d, J=1.5 Hz, 1 H), 6.54 (s, 2 H), 6.87 (t, J=7.5 Hz, 2 H), 7.21 
(t, J=7.5 Hz, 1 H), 7.45 (s, 1 H), 7.66 (d, J=7.5 Hz, 1 H), 9.57 (s, 2 H), 10.57 (s, 1 H); 
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13C NMR (75 MHz, DMSO-d6) δ ppm 168.88, 158.72, 142.92, 136.52, 136.04, 
130.03, 127.26, 123.08, 121.14, 121.01, 110.11, 107.25, 104.14. 
 (E)-3-(2-Hydroxy-4-methoxybenzylidene)indolin-2-one (15), Yield 44%, 
mp 149-152 ℃; MS-APCI: [M+H]+ 268.3 (267.1); 1H NMR (300 MHz DMSO-d6)  
ppm 3.77 (s, 3 H), 6.54 (m, 2 H), 6.85 (dt, J=7.4, 3.6 Hz, 2 H), 7.18 (t, J=7.5 Hz, 1 H), 
7.61 (m, 3 H), 10.48 (s, 1 H); 13C NMR (75 MHz, DMSO-d6) δ ppm 169.21, 162.43, 
158.42, 142.30, 132.48, 130.75, 129.18, 124.33, 122.02, 121.64, 120.98, 114.26, 
109.90, 105.35, 101.28, 55.29. 
(E)-3-(3-Hydroxy-4-methoxybenzylidene)indolin-2-one (16)20, Yield 19%, 
mp 173-176 ℃; MS-APCI: [M+H]+ 268.2 (267.1); 1H NMR (300 MHz DMSO-d6)  
ppm 3.84 (s, 3 H), 6.88 (t, J=8.5 Hz, 2 H), 7.05 (d, J=8.7 Hz, 1 H), 7.20 (m, 3 H), 
7.48 (s, 1 H), 7.72 (d, J=7.5 Hz, 1 H), 9.39 (s, 1 H), 10.53 (s, 1 H); 13C NMR (75 MHz, 
DMSO-d6) δ ppm 168.99, 149.43, 146.44, 142.60, 136.47, 129.57, 126.86, 125.27, 
122.33, 122.20, 121.18, 120.98, 116.20, 112.06, 109.96, 55.63. 
 (E)-3-(4-Hydroxy-3-methoxybenzylidene)indolin-2-one (17)20, Yield 39%, 
mp 223-224 ℃; MS-APCI: [M+H]+ 268.3 (267.1); 1H NMR (300 MHz DMSO-d6)  
ppm 3.85 (s, 3 H), 6.84 (dd, J=11.9, 8.1 Hz, 2 H), 6.95 (t, J=7.4 Hz, 1 H), 7.15 (t, 
J=7.5 Hz, 1 H), 7.69 (m, 3 H), 8.69 (s, 1 H), 9.85 (s, 1 H), 10.52 (s, 1 H); 13C NMR 
(75 MHz, DMSO-d6) δ ppm 167.68, 149.87, 147.12, 140.10, 137.95, 128.11, 127.97, 
126.26, 125.72, 123.05, 120.96, 119.00, 115.84, 115.28, 109.27, 55.60. 
 (E)-3-(2-Methylbenzylidene)indolin-2-one (18), Yield 72%, mp 133-134 ℃; 
MS-APCI: [M+H]+ 236.2 (235.1); 1H NMR (300 MHz DMSO-d6)  ppm 2.29 (s, 3 
H), 6.76 (t, J=7.5 Hz, 1 H), 6.85 (d, J=7.9 Hz, 1 H), 7.07 (d, J=7.5 Hz, 1 H), 7.19 (t, 
J=7.5 Hz, 1 H), 7.32 (m, 3 H), 7.53 (d, J=7.2 Hz, 1 H), 7.67 (s, 1 H), 10.59 (s, 1 H); 
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13C NMR (75 MHz, DMSO-d6) δ ppm 168.42, 142.88, 136.79, 134.72, 133.87, 
130.42, 130.06, 129.44, 128.47, 128.26, 125.89, 122.36, 121.13, 110.11, 19.46. 
 (E)-3-(3-Methylbenzylidene)indolin-2-one (19), Yield 31%, mp 138-
139 ℃; MS-APCI: [M+H]+ 236.2 (235.1); 1H NMR (300 MHz DMSO-d6)  ppm 
2.35 (s, 3 H), 6.84 (dd, J=14.1, 7.4 Hz, 2 H), 7.23 (ddd, J=14.5, 7.5, 7.4 Hz, 2 H), 
7.39 (t, J=7.7 Hz, 1 H), 7.50 (m, 3 H), 7.59 (s, 1 H), 10.59 (s, 1 H); 13C NMR (75 
MHz, DMSO-d6) δ ppm 168.75, 143.00, 138.04, 135.97, 134.44, 130.32, 130.07, 
129.78, 128.61, 127.61, 126.29, 122.36, 121.10, 121.01, 110.17, 20.89. 
 (E)-3-(4-Methylbenzylidene)indolin-2-one (20)18, Yield 86%, mp 199-
200 ℃; lit. 195-196 ℃; MS-APCI: [M+H]+ 236.3 (235.1); 1H NMR (300 MHz 
DMSO-d6)  ppm 2.37 (s, 3 H), 6.84 (t, J=8.1 Hz, 2 H), 7.21 (t, J=7.5 Hz, 1 H), 7.33 
(d, J=7.9 Hz, 2 H), 7.59 (m, 4 H), 10.56 (s, 1 H); 13C NMR (75 MHz, DMSO-d6) δ 
ppm 168.74, 142.84, 139.64, 135.94, 131.54, 129.91, 129.37, 129.29, 126.93, 122.25, 
121.01, 110.07, 21.05. 
(E)-3-(4-Ethylbenzylidene)indolin-2-one (21), Yield 35%, mp 165-167 ℃; 
MS-APCI: [M+H]+ 250.3 (249.1); 1H NMR (300 MHz DMSO-d6)  ppm 1.21 (t, 
J=7.5 Hz, 3 H), 2.67 (q, J=7.5 Hz, 2 H), 6.85 (t, J=8.3 Hz, 2 H), 7.21 (t, J=7.7 Hz, 1 
H), 7.35 (d, J=7.5 Hz, 2 H), 7.60 (m, 3 H), 7.64 (s, 1 H), 10.58 (s, 1 H); 13C NMR (75 
MHz, DMSO-d6) δ ppm 168.83, 145.93, 142.87, 136.02, 131.81, 130.02, 129.55, 
128.18, 126.92, 122.30, 121.13, 121.03, 110.14, 28.18, 15.29. 
 (E)-3-(2-Fluorobenzylidene)indolin-2-one (22), Yield 88%, mp 218-220 ℃; 
MS-APCI: [M+H]+ 240.2 (239.1); 1H NMR (300 MHz DMSO-d6)  ppm 6.85 (m, 2 
H), 7.24 (dt, J=7.4, 3.6 Hz, 2 H), 7.37 (m, 2 H), 7.56 (m, 2 H), 7.75 (t, J=7.5 Hz, 1 H), 
10.65 (s, 1 H); 13C NMR (75 MHz, DMSO-d6) δ ppm 168.15, 161.36, 158.06, 143.17, 
132.02, 131.90, 130.58, 130.51, 129.86, 127.46, 127.42, 124.74, 124.69, 122.70, 
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122.43, 122.24, 121.31, 120.68, 116.19, 115.91, 110.24. * More C atoms detected in 
13C NMR data than expected. This is due to splitting by F substitutent in the 
compound. HPLC determination showed > 95% purity (Appendix 1). 
 (E)-3-(3-Fluorobenzylidene)indolin-2-one (23), Yield 29%, mp 166-167 ℃; 
MS-APCI: [M+H]+ 240.3 (239.1); 1H NMR (300 MHz DMSO-d6)  ppm 6.86 (m, 2 
H), 7.24 (t, J=7.5 Hz, 1 H), 7.30 (ddd, J=9.5, 6.9, 2.5 Hz, 1 H), 7.44 (d, J=7.5 Hz, 1 
H), 7.54 (m, 4 H), 10.63 (s, 1 H); 13C NMR (75 MHz, DMSO-d6) δ ppm 168.45, 
163.78, 160.54, 143.19, 136.97, 136.86, 134.15, 134.13, 130.93, 130.82, 130.53, 
128.69, 125.26, 125.23, 122.52, 121.25, 120.60, 116.54, 116.26, 116.04, 115.74, 
110.30. 23(Z), 1H NMR (300 MHz DMSO-d6)  ppm 6.82 (d, J=7.9 Hz, 1 H), 7.00 (t, 
J=7.5 Hz, 1 H), 7.27 (m, 2 H), 7.50 (m, 1 H), 7.70 (d, J=7.5 Hz, 1 H), 7.81 (s, 1 H), 
7.97 (d, J=7.9 Hz, 1 H), 8.52 (d, J=11.7 Hz, 1 H), 10.68 (s, 1 H).  * More C atoms 
detected in 13C NMR data than expected. This is due to splitting by F substitutent in 
the compound. HPLC determination showed > 95% purity (Appendix 1). 
 (E)-3-(4-Fluorobenzylidene)indolin-2-one (24)18, Yield 41%, mp 186-
189 ℃; lit. 189-190 ℃;  MS-APCI: [M+H]+ 240.2 (239.1); 1H NMR (300 MHz 
DMSO-d6)  ppm 6.85 (m, 2 H), 7.23 (t, J=7.5 Hz, 1 H), 7.35 (t, J=8.9 Hz, 2 H), 7.49 
(d, J=7.5 Hz, 1 H), 7.59 (s, 1 H), 7.76 (dd, J=8.3, 5.7 Hz, 2 H), 10.60 (s, 1 H); 13C 
NMR (75 MHz, DMSO-d6) δ ppm 168.61, 164.20, 160.91, 143.01, 134.68, 131.79, 
131.67, 130.92, 130.88, 130.20, 127.65, 122.30, 121.15, 120.78, 115.97, 115.68, 
110.19. * More C atoms detected in 13C NMR data than expected. This is due to 
splitting by F substitutent in the compound. HPLC determination showed > 95% 




 (E)-3-(2,4-Difluorobenzylidene)indolin-2-one (25), Yield 51%, mp 197-
200 ℃; MS-APCI: [M+H]+ 258.2 (257.1); 1H NMR (300 MHz DMSO-d6)  ppm 
6.85 (t, J=8.7 Hz, 2 H), 7.25 (m, 3 H), 7.44 (d, J=14.7 Hz, 2 H), 7.81 (m, 1 H), 10.66 
(s, 1 H); 13C NMR (75 MHz, DMSO-d6) δ ppm 168.08, 143.18, 131.96, 131.90, 
131.83, 131.78, 130.60, 129.90, 126.42, 122.70, 121.33, 120.56, 119.03, 118.99, 
118.84, 118.79, 112.31, 112.27, 112.02, 111.99, 110.22, 105.07, 104.72, 104.39. * 
More C atoms detected in 13C NMR data than expected. This is due to splitting by F 
substitutent in the compound. HPLC determination showed > 95% purity (Appendix 
1). 
(E)-3-(3-Chlorobenzylidene)indolin-2-one (26)20, Yield 29%, mp 169-
170 ℃; MS-APCI: [M+H]+ 256.3 (255.1); 1H NMR (300 MHz DMSO-d6)  ppm 
6.85 (m, 2 H), 7.23 (t, J=7.7 Hz, 1 H), 7.39 (d, J=7.9 Hz, 1 H), 7.55 (m, 3 H), 7.65 (d, 
J=4.5 Hz, 1 H), 7.72 (s, 1 H), 10.63 (s, 1 H); 13C NMR (75 MHz, DMSO-d6) δ ppm 
168.31, 143.17, 136.69, 133.86, 133.43, 130.58, 130.49, 129.24, 128.80, 128.76, 
127.57, 122.34, 121.17, 120.55, 110.26. 
(E)-3-(4-Chlorobenzylidene)indolin-2-one (27)18, Yield 70%, mp 189-
191 ℃; lit. 188-189 ℃; MS-APCI: [M+H]+ 256.2 (255.1); 1H NMR (300 MHz 
DMSO-d6)  ppm 6.85 (t, J=8.7 Hz, 2 H), 7.23 (t, J=7.5 Hz, 1 H), 7.47 (d, J=7.5 Hz, 1 
H), 7.58 (m, 3 H), 7.72 (d, J=8.3 Hz, 2 H), 10.61 (s, 1 H); 13C NMR (75 MHz, 
DMSO-d6) δ ppm 168.45, 143.06, 134.26, 134.11, 133.34, 131.09, 130.35, 128.82, 
128.19, 122.45, 121.20, 120.64, 110.19. 
 (E)-3-(2,4-Dichlorobenzylidene)indolin-2-one (28)20, Yield 65%, mp 218-
220 ℃; MS-APCI: [M+H]+ 290.3 (289.0); 1H NMR (300 MHz DMSO-d6)  ppm 
6.83 (m, 2 H), 7.13 (d, J=7.5 Hz, 1 H), 7.23 (t, J=7.5 Hz, 1 H), 7.49 (s, 1 H), 7.56 (dd, 
J=8.7, 1.9 Hz, 1 H), 7.78 (m, 2 H), 10.69 (s, 1 H); 13C NMR (75 MHz, DMSO-d6) δ 
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ppm 167.93, 143.26, 134.76, 133.96, 131.95, 131.53, 130.79, 130.10, 130.00, 129.39, 
127.70, 122.72, 121.34, 120.28, 110.30. 
(E)-3-(2-Chloro-4-fluorobenzylidene)indolin-2-one (29), Yield 61%, mp 
203-204 ℃; MS-APCI: [M+H]+ 274.2 (273.0); 1H NMR (300 MHz DMSO-d6)  ppm 
6.83 (m, 2 H), 7.12 (d, J=7.5 Hz, 1 H), 7.23 (t, J=7.5 Hz, 1 H), 7.37 (td, J=8.6, 2.5 Hz, 
1 H), 7.50 (s, 1 H), 7.65 (d, J=8.7 Hz, 1 H), 7.81 (dd, J=8.7, 6.4 Hz, 1 H), 10.68 (s, 1 
H); 13C NMR (75 MHz, DMSO-d6) δ ppm 168.08, 164.02, 160.70, 143.23, 134.22, 
134.08, 131.96, 131.85, 130.67, 130.44, 129.73, 129.52, 129.48, 122.61, 121.31, 
120.43, 117.47, 117.13, 115.06, 114.77, 110.32. 29(Z), 1H NMR (300 MHz DMSO-
d6)  ppm 6.81 (d, J=7.5 Hz, 1 H), 6.98 (t, J=7.5 Hz, 1 H), 7.26 (m, 2 H), 7.54 (dd, 
J=8.9, 2.5 Hz, 1 H), 7.72 (m, 2 H), 8.24 (dd, J=8.7, 6.4 Hz, 1 H), 10.59 (s, 1 H). * 
More C atoms detected in 13C NMR data than expected. This is due to splitting by F 
substitutent in the compound. HPLC determination showed > 95% purity (Appendix 
1). 
(E)-3-(2-(Trifluoromethyl)benzylidene)indolin-2-one (30), Yield 67%, mp 
175-177 ℃; MS-APCI: [M+H]+ 290.1 (289.1); 1H NMR (300 MHz DMSO-d6)  ppm 
6.75 (m, 2 H), 6.86 (d, J=7.9 Hz, 1 H), 7.21 (m, 1 H), 7.69 (m, 2 H), 7.79 (m, 2 H), 
7.91 (d, J=7.5 Hz, 1 H), 10.70 (s, 1 H); 13C NMR (75 MHz, DMSO-d6) δ ppm 167.93, 
143.27, 138.67, 133.27, 132.92, 130.93, 130.70, 130.43, 130.31, 129.73, 127.64, 
127.25, 126.86, 126.45, 126.39, 125.82, 122.66, 122.19, 121.32, 120.47, 118.56, 
110.37. * More C atoms detected in 13C NMR data than expected. This is due to 
splitting by CF3 substitutent in the compound. HPLC determination showed > 95% 
purity (Appendix 1). 
 (E)-3-(3-(Trifluoromethyl)benzylidene)indolin-2-one (31), Yield 57%, mp 
181-183 ℃; MS-APCI: [M+H]+ 290.1 (289.1); 1H NMR (300 MHz DMSO-d6)  ppm 
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6.85 (m, 2 H), 7.24 (t, J=7.7 Hz, 1 H), 7.33 (d, J=7.5 Hz, 1 H), 7.67 (s, 1 H), 7.78 (m, 
2 H), 8.00 (d, J=7.9 Hz, 2 H), 10.66 (s, 1 H); 13C NMR (75 MHz, DMSO-d6) δ ppm 
168.37, 143.32, 135.69, 133.84, 133.03, 130.74, 130.21, 130.00, 129.79, 129.45, 
129.36, 129.19, 128.94, 126.03, 125.98, 125.84, 122.23, 121.27, 120.53, 110.44. * 
More C atoms detected in 13C NMR data than expected. This is due to splitting by 
CF3 substitutent in the compound. HPLC determination showed > 95% purity 
(Appendix 1). 
 (E)-3-(4-(Trifluoromethyl)benzylidene)indolin-2-one (32), Yield 53%, mp 
186-189 ℃; MS-APCI: [M+H]+ 290.2 (289.1); 1H NMR (300 MHz DMSO-d6)  ppm 
6.85 (dd, J=16.2, 7.9 Hz, 2 H), 7.23 (t, J=7.7 Hz, 1 H), 7.39 (d, J=7.9 Hz, 1 H), 7.64 
(s, 1 H), 7.87 (m, 4 H), 10.66 (s, 1 H); 13C NMR (75 MHz, DMSO-d6) δ ppm 168.37, 
143.35, 138.82, 133.69, 130.76, 129.93, 129.60, 129.42, 129.18, 125.88, 125.67, 
125.63, 122.65, 122.28, 121.34, 120.47, 110.36. 32(Z), 1H NMR (300 MHz DMSO-
d6)  ppm 6.82 (d, J=7.5 Hz, 1 H), 7.00 (t, J=7.5 Hz, 1 H), 7.24 (t, J=7.5 Hz, 1 H), 
7.73 (d, J=7.5 Hz, 1 H), 7.80 (d, J=8.3 Hz, 2 H), 7.88 (s, 1 H), 8.45 (d, J=8.3 Hz, 2 H), 
10.68 (s, 1 H). * More C atoms detected in 13C NMR data than expected. This is due 
to splitting by CF3 substitutent in the compound. HPLC determination showed > 95% 
purity (Appendix 1). 
 (E)-4-((2-Oxoindolin-3-ylidene)methyl)benzonitrile (33)18, Yield 78%, mp 
237-239 ℃; lit. 242-243 ℃; MS-APCI: [M+H]+ 247.3 (246.1); 1H NMR (300 MHz 
DMSO-d6)  ppm 6.85 (dd, J=14.9, 7.7 Hz, 2 H), 7.25 (t, J=7.5 Hz, 1 H), 7.37 (d, 
J=7.9 Hz, 1 H), 7.62 (s, 1 H), 7.86 (d, J=7.9 Hz, 2 H), 7.97 (m, 2 H), 10.67 (s, 1 H); 
13C NMR (75 MHz, DMSO-d6) δ ppm 168.22, 143.39, 139.42, 133.34, 132.56, 
130.82, 129.92, 129.65, 122.68, 121.26, 120.34, 118.58, 111.61, 110.34. 
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 (E)-3-(Pyridin-2-ylmethylene)indolin-2-one (34)24, Yield 30%, mp 202-
203 ℃; lit. 205-207 ℃; MS-APCI: [M+H]+ 223.3 (222.1); 1H NMR (300 MHz 
DMSO-d6)  ppm 6.86 (d, J=7.5 Hz, 1 H), 6.98 (t, J=7.5 Hz, 1 H), 7.28 (t, J=7.4 Hz, 1 
H), 7.46 (m, 1 H), 7.55 (s, 1 H), 7.86 (d, J=7.5 Hz, 1 H), 7.95 (m, 1 H), 8.88 (d, J=4.1 
Hz, 1 H), 8.99 (d, J=7.9 Hz, 1 H), 10.61 (s, 1 H); 13C NMR (75 MHz, DMSO-d6) δ 
ppm 169.29, 153.23, 149.64, 143.60, 137.20, 133.65, 130.81, 129.28, 128.38, 127.94, 
124.09, 121.51, 121.22, 109.59. 
 (E)-3-(Pyridin-4-ylmethylene)indolin-2-one (35)21, Yield 83%, mp 222-
223 ℃; lit. 228-230 ℃;  MS-APCI: [M+H]+ 223.3 (222.1); 1H NMR (300 MHz 
DMSO-d6)  ppm 6.85 (dd, J=14.3, 7.5 Hz, 2 H), 7.25 (t, J=7.7 Hz, 1 H), 7.35 (d, 
J=7.5 Hz, 1 H), 7.54 (s, 1 H), 7.62 (d, J=5.7 Hz, 2 H), 8.71 (d, J=5.7 Hz, 2 H), 10.68 
(s, 1 H); 13C NMR (75 MHz, DMSO-d6) δ ppm 168.10, 150.18, 143.41, 142.35, 
132.22, 130.95, 130.30, 123.13, 122.91, 121.36, 120.28, 110.37. 
 (E)-3-((1H-indol-3-yl)methylene)indolin-2-one (36)25, Yield 24%, mp 231-
232 ℃; MS-APCI: [M+H]+ 261.4 (260.1); 1H NMR (300 MHz DMSO-d6)  ppm 
6.91 (m, 2 H), 7.22 (m, 3 H), 7.53 (d, J=7.9 Hz, 1 H), 7.64 (d, J=7.5 Hz, 1 H), 7.74 (d, 
J=7.5 Hz, 1 H), 7.87 (s, 1 H), 8.22 (s, 1 H), 10.46 (s, 1 H), 11.99 (s, 1 H); 13C NMR 
(75 MHz, DMSO-d6) δ ppm 169.68, 141.71, 136.33, 129.79, 128.30, 127.73, 127.22, 
122.71, 122.26, 122.22, 121.40, 120.91, 120.78, 118.92, 112.48, 110.46, 109.55. 
 (E)-3-(Naphthalen-1-ylmethylene)indolin-2-one (37), Yield 56%, mp 198-
199 ℃; MS-APCI: [M+H]+ 272.4 (271.1); 1H NMR (300 MHz DMSO-d6)  ppm 
6.67 (t, J=7.7 Hz, 1 H), 6.87 (dd, J=7.2, 4.1 Hz, 2 H), 7.17 (t, J=7.5 Hz, 1 H), 7.60 (m, 
3 H), 7.82 (d, J=7.2 Hz, 1 H), 7.91 (d, J=8.7 Hz, 1 H), 8.05 (m, 3 H), 10.67 (s, 1 H); 
13C NMR (75 MHz, CDCl3) δ ppm 170.08, 141.69, 135.47, 133.59, 132.11, 131.30, 
130.01, 129.87, 129.35, 128.64, 126.87, 126.74, 126.53, 125.13, 124.80, 123.33, 
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121.80, 110.21. * One less carbon detected in 13C NMR. This is attributed to an 
overlap of carbon peaks. 
 (E)-3-(Naphthalen-2-ylmethylene)indolin-2-one (38), Yield 51%, mp 193-
195 ℃; MS-APCI: [M+H]+ 272.3 (271.1); 1H NMR (300 MHz DMSO-d6)  ppm 
6.86 (m, 2 H), 7.23 (t, J=7.5 Hz, 1 H), 7.58 (m, 3 H), 7.80 (m, 2 H), 8.01 (m, 3 H), 
8.27 (s, 1 H), 10.64 (s, 1 H); 13C NMR (75 MHz, DMSO-d6) δ ppm 168.72, 143.08, 
135.75, 133.20, 132.64, 132.08, 130.22, 129.22, 128.37, 128.23, 127.94, 127.74, 
127.31, 126.83, 126.36, 122.36, 121.17, 120.98, 110.20. 
(E)-6-Fluoro-3-(3-methoxybenzylidene)indolin-2-one (39), Yield 29%, mp 
169-170 ℃; MS-APCI: [M+H]+ 270.3 (269.1); 1H NMR (300 MHz DMSO-d6)  ppm 
3.79 (s, 3 H), 6.68 (m, 2 H), 7.03 (dd, J=8.1, 2.1 Hz, 1 H), 7.24 (m, 2 H), 7.43 (t, 
J=7.9 Hz, 1 H), 7.54 (m, 2 H), 10.77 (s, 1 H); 13C NMR (75 MHz, DMSO-d6) δ ppm 
168.92, 164.80, 161.55, 159.36, 144.94, 144.78, 135.60, 135.35, 135.31, 130.01, 
126.75, 124.24, 124.10, 121.40, 117.35, 117.32, 115.69, 114.25, 107.74, 107.44, 
98.39, 98.02, 55.24. * More C atoms detected in 13C NMR data than expected. This is 
due to splitting by F substitutent in the compound. HPLC determination showed > 
95% purity (Appendix 1). 
 (E)-5-Chloro-3-(3-methoxybenzylidene)indolin-2-one (40), Yield 70%, mp 
212-214 ℃; MS-APCI: [M+H]+ 286.2 (285.1); 1H NMR (300 MHz DMSO-d6)  ppm 
3.80 (s, 3 H), 6.88 (d, J=8.7 Hz, 1 H), 7.07 (m, 1 H), 7.27 (m, 3 H), 7.46 (m, 2 H), 
7.68 (s, 1 H), 10.75 (s, 1 H); 13C NMR (75 MHz, DMSO-d6) δ ppm 168.31, 159.39, 
141.77, 137.55, 135.37, 130.05, 129.64, 127.02, 124.94, 122.51, 122.02, 121.50, 
116.15, 114.18, 111.54, 55.26. 
(E)-6-Chloro-3-(3-methoxybenzylidene)indolin-2-one (41), Yield 71%, mp 
198-200 ℃; MS-APCI: [M+H]+ 286.2 (285.1); 1H NMR (300 MHz DMSO-d6)  ppm 
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3.79 (s, 3 H), 6.91 (m, 2 H), 7.04 (dd, J=8.3, 2.3 Hz, 1 H), 7.24 (m, 2 H), 7.43 (t, 
J=7.9 Hz, 1 H), 7.52 (d, J=8.3 Hz, 1 H), 7.63 (s, 1 H), 10.76 (s, 1 H); 13C NMR (75 
MHz, DMSO-d6) δ ppm 168.60, 159.36, 144.33, 136.55, 135.50, 134.20, 130.02, 
126.71, 123.77, 121.52, 120.95, 119.80, 115.91, 114.28, 110.14, 55.24. 
 (E)-6-Methoxy-3-(3-methoxybenzylidene)indolin-2-one (42)26, Yield 31%, 
mp 161-163 ℃, lit. 162-163 ℃; MS-APCI: [M+H]+ 282.2 (281.1); 1H NMR (300 
MHz DMSO-d6)  ppm 3.77 (m, 6 H), 6.44 (m, 2 H), 7.01 (dd, J=8.1, 2.1 Hz, 1 H), 
7.22 (m, 2 H), 7.41 (m, 2 H), 7.49 (d, J=8.3 Hz, 1 H), 10.54 (s, 1 H); 13C NMR (75 
MHz, DMSO-d6) δ ppm 169.29, 161.15, 159.29, 144.77, 136.06, 132.32, 129.83, 
127.36, 123.80, 121.37, 115.20, 114.18, 113.63, 106.52, 96.50, 55.30, 55.17. 
 (E)-6-Fluoro-3-(3-hydroxy-4-methoxybenzylidene)indolin-2-one (43), 
Yield 33%, mp 225-227 ℃; MS-APCI: [M+H]+ 286.2 (285.1); 1H NMR (300 MHz 
DMSO-d6)  ppm 3.83 (s, 3 H), 6.69 (t, J=10.2 Hz, 2 H), 7.05 (m, 1 H), 7.16 (s, 2 H), 
7.47 (s, 1 H), 7.71 (dd, J=8.1, 5.8 Hz, 1 H), 9.41 (s, 1 H), 10.70 (s, 1 H); 13C NMR (75 
MHz, DMSO-d6) δ ppm 169.32, 164.48, 161.22, 149.50, 146.51, 144.52, 144.35, 
136.20, 136.16, 126.69, 124.27, 123.93, 123.81, 122.16, 117.69, 117.65, 116.14, 
112.13, 107.50, 107.20, 98.18, 97.82, 55.66. * More C atoms detected in 13C NMR 
data than expected. This is due to splitting by F substitutent in the compound. HPLC 
determination showed > 95% purity (Appendix 1). 
 (E)-6-Chloro-3-(3-hydroxy-4-methoxybenzylidene)indolin-2-one (44), 
Yield 53%, mp 220-223 ℃; MS-APCI: [M+H]+ 302.2 (301.1); 1H NMR (300 MHz 
DMSO-d6)  ppm 3.84 (s, 3 H), 6.87 (d, J=1.9 Hz, 1 H), 6.94 (dd, J=8.3, 1.9 Hz, 1 H), 
7.06 (d, J=9.0 Hz, 1 H), 7.18 (m, 2 H), 7.52 (s, 1 H), 7.70 (d, J=8.3 Hz, 1 H), 9.41 (s, 
1 H), 10.69 (s, 1 H); 13C NMR (75 MHz, DMSO-d6) δ ppm 169.02, 149.72, 146.55, 
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143.94, 137.45, 133.55, 126.64, 124.14, 123.53, 122.43, 120.77, 120.17, 116.30, 
112.12, 109.96, 55.68. 
 (E)-3-(3-Hydroxy-4-methoxybenzylidene)-6-methoxyindolin-2-one (45), 
Yield 38%, mp 184-186 ℃; MS-APCI: [M+H]+ 298.2 (297.1); 1H NMR (300 MHz 
DMSO-d6)  ppm 3.75 (s, 3 H), 3.83 (s, 3 H), 6.44 (m, 2 H), 7.03 (d, J=8.3 Hz, 1 H), 
7.13 (d, J=10.6 Hz, 2 H), 7.31 (s, 1 H), 7.64 (d, J=8.3 Hz, 1 H), 9.35 (s, 1 H), 10.49 (s, 
1 H); 13C NMR (75 MHz, DMSO-d6) δ ppm 169.72, 160.78, 149.11, 146.45, 144.38, 
133.30, 127.23, 125.04, 123.63, 121.90, 116.09, 114.07, 112.14, 106.42, 96.43, 55.67, 
55.34. 
 (E)-6-Fluoro-3-(3-(trifluoromethyl)benzylidene)indolin-2-one (46), Yield 
50%, mp 132-135 ℃; MS-APCI: [M+H]+ 308.1 (307.1);  1H NMR (300 MHz 
DMSO-d6)  ppm 6.66 (m, 2 H), 7.32 (dd, J=8.3, 5.7 Hz, 1 H), 7.64 (s, 1 H), 7.77 (m, 
2 H), 7.97 (d, J=6.4 Hz, 2 H), 10.82 (s, 1 H); 13C NMR (75 MHz, DMSO-d6) δ ppm 
168.62, 165.06, 161.79, 145.30, 145.13, 135.49, 133.38, 133.34, 132.87, 130.27, 
129.96, 129.84, 129.42, 129.00, 128.10, 128.08, 125.99, 125.95, 125.80, 125.76, 
123.91, 123.78, 122.16, 118.55, 117.00, 116.96, 107.77, 107.48, 98.57, 98.21. 46(Z), 
1H NMR (300 MHz DMSO-d6)  ppm 6.66 (dd, J=9.2, 2.1 Hz, 1 H), 6.83 (m, 1 H), 
7.73 (m, 3 H), 7.89 (s, 1 H), 8.46 (d, J=7.5 Hz, 1 H), 8.83 (s, 1 H), 10.82 (s, 1 H). * 
More C atoms detected in 13C NMR data than expected. This is due to splitting by F 
and CF3 substitutents in the compound. HPLC determination showed > 95% purity 
(Appendix 1). 
(E)-6-Chloro-3-(3-(trifluoromethyl)benzylidene)indolin-2-one (47), Yield 
51%, mp 204-207 ℃; 1H NMR (300 MHz DMSO-d6)  ppm 6.87 (d, J=7.9 Hz, 2 H), 
7.29 (d, J=7.9 Hz, 1 H), 7.76 (m, 3 H), 7.97 (d, J=7.2 Hz, 2 H), 10.81 (s, 1 H); 13C 
NMR (75 MHz, DMSO-d6) δ ppm 168.26, 144.60, 135.39, 134.66, 132.94, 130.02, 
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129.84, 129.42, 128.06, 126.18, 126.15, 125.94, 125.90, 125.75, 123.46, 122.14, 
121.01, 119.44, 110.33. 47(Z), 1H NMR (300 MHz DMSO-d6)  ppm 6.88 (s, 1 H), 
7.05 (dd, J=8.1, 1.7 Hz, 1 H), 7.72 (m, 3 H), 7.91 (s, 1 H), 8.43 (d, J=7.9 Hz, 1 H), 
8.84 (s, 1 H), 10.81 (s, 1 H). * More C atoms detected in 13C NMR data than expected. 
This is due to splitting by CF3 substitutent in the compound. HPLC determination 
showed > 95% purity (Appendix 1). 
(E)-6-Methoxy-3-(3-(trifluoromethyl)benzylidene)indolin-2-one (48), Yield 
43%, mp 157-160 ℃; MS-APCI: [M+H]+ 320.1 (319.1); 1H NMR (300 MHz DMSO-
d6) δ ppm 3.74 (s, 3 H), 6.40 (dd, J=10.9, 2.6 Hz, 2 H), 7.28 (d, J=8.3 Hz, 1 H), 7.47 
(s, 1 H), 7.74 (ddd, J=15.0, 7.9, 7.6 Hz, 2 H), 7.96 (d, J=7.2 Hz, 2 H), 10.61 (s, 1 H); 
13C NMR (75 MHz, DMSO-d6) δ ppm 169.04, 161.54, 145.14, 135.99, 132.91, 
130.40, 130.16, 129.90, 129.74, 129.44, 129.31, 128.89, 128.72, 125.83, 125.69, 
125.65, 125.59, 123.50, 122.22, 118.61, 113.28, 106.61, 96.75, 55.39. * More C 
atoms detected in 13C NMR data than expected. This is due to splitting by CF3 
substitutent in the compound. HPLC determination showed > 95% purity (Appendix 
1). 
 (E)-3-(3-Methoxybenzylidene)-1-methylindolin-2-one (49), Yield 66%, mp 
139-140 ℃; MS-APCI: [M+H]+ 266.3 (265.1); 1H NMR (300 MHz DMSO-d6)  ppm 
3.19 (s, 3 H), 3.79 (s, 3 H), 6.92 (t, J=7.7 Hz, 1 H), 7.03 (t, J=6.8 Hz, 2 H), 7.28 (m, 3 
H), 7.43 (t, J=7.9 Hz, 1 H), 7.57 (d, J=7.5 Hz, 1 H), 7.67 (s, 1 H); 13C NMR (75 MHz, 
DMSO-d6) δ ppm 167.22, 159.33, 144.13, 136.27, 135.65, 130.23, 129.96, 126.85, 
122.24, 121.72, 121.50, 120.17, 115.70, 114.38, 108.97, 55.23, 26.00. 
 (E)-3-(3-Hydroxy-4-methoxybenzylidene)-1-methylindolin-2-one (50), 
Yield 39%, mp 156-158 ℃; MS-APCI: [M+H]+ 282.4 (281.1); 1H NMR (300 MHz 
DMSO-d6)  ppm 3.19 (s, 3 H), 3.84 (s, 3 H), 6.96 (t, J=7.5 Hz, 1 H), 7.04 (m, 2 H), 
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7.19 (d, J=7.5 Hz, 2 H), 7.31 (t, J=7.7 Hz, 1 H), 7.57 (s, 1 H), 7.76 (d, J=7.5 Hz, 1 H), 
9.40 (s, 1 H); 13C NMR (75 MHz, DMSO-d6) δ ppm 167.63, 149.58, 146.50, 143.77, 
137.11, 129.60, 126.79, 124.34, 122.39, 122.05, 121.59, 120.54, 116.32, 112.06, 
108.73, 55.67, 25.97. 
3-(3-Methoxybenzyl)indolin-2-one (51)27, Yield 84%, mp 65-68 ℃, lit. 89-
90 ℃; MS-APCI: [M+H]+ 254.2 (253.1);  1H NMR (300 MHz CDCl3)  ppm 2.91 (dd, 
J=13.6, 9.0 Hz, 1 H), 3.46 (dd, J=13.8, 4.3 Hz, 1 H), 3.74 (m, 4 H), 6.77 (m, 5 H), 
6.90 (t, J=7.5 Hz, 1 H), 7.16 (t, J=7.9 Hz, 2 H), 7.90 (s, 1 H); 13C NMR (75 MHz, 
DMSO-d6) δ ppm 178.11, 158.91, 142.61, 139.59, 128.97, 127.59, 124.33, 121.55, 
120.93, 114.80, 111.79, 109.13, 54.79, 46.30, 35.20, 30.67. 
3-(4-Methylbenzyl)indolin-2-one (52)28, Yield 70%, mp 146-149 ℃; MS-
APCI: [M+H]+ 238.1 (237.1);   1H NMR (300 MHz CDCl3)  ppm 2.30 (s, 3 H), 2.90 
(dd, J=13.8, 9.2 Hz, 1 H), 3.44 (dd, J=14.0, 4.5 Hz, 1 H), 3.72 (dd, J=9.0, 4.5 Hz, 1 
H), 6.77 (d, J=7.5 Hz, 1 H), 6.87 (dt, J=15.5, 7.7 Hz, 2 H), 7.05 (s, 4 H), 7.15 (t, J=7.5 
Hz, 1 H), 8.56 (s, 1 H); 13C NMR (75 MHz, DMSO-d6) δ ppm 178.11, 142.61, 135.19, 
134.86, 129.15, 128.98, 128.59, 127.54, 124.30, 120.91, 109.10, 46.50, 34.78, 20.59. 
 (Z)-2-(3-Methoxybenzylidene)indolin-3-one (53)29, Yield 20%, mp 161-
162 ℃, lit. 168 ℃; MS-APCI: [M+H]+ 252.3 (251.1); 1H NMR (300 MHz DMSO-d6) 
 ppm 3.82 (s, 3 H), 6.60 (s, 1 H), 6.93 (m, 2 H), 7.13 (d, J=7.9 Hz, 1 H), 7.29 (m, 2 
H), 7.38 (t, J=7.9 Hz, 1 H), 7.54 (m, 2 H), 9.77 (s, 1 H); 13C NMR (75 MHz, DMSO-
d6) δ ppm 186.36, 159.58, 154.23, 136.37, 135.42, 134.56, 129.94, 124.08, 122.23, 
119.98, 119.78, 115.28, 114.12, 112.64, 109.72, 55.17. 
 (Z)-2-(3-Hydroxy-4-methoxybenzylidene)indolin-3-one (54), Yield 17%, 
mp 155 ℃ (decomposition temperature); MS-APCI: [M+H]+ 268.2 (267.1);   1H 
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NMR (300 MHz DMSO-d6)  ppm 3.83 (s, 3 H), 6.54 (s, 1 H), 6.89 (t, J=7.4 Hz, 1 H), 
7.01 (d, J=7.9 Hz, 1 H), 7.16 (m, 3 H), 7.51 (m, 2 H), 9.14 (s, 1 H), 9.62 (s, 1 H); 13C 
NMR (75 MHz, DMSO-d6) δ ppm 185.95, 153.95, 148.52, 146.65, 135.88, 133.25, 
126.96, 123.86, 122.39, 120.28, 119.44, 116.83, 112.66, 112.29, 111.08, 55.69. 
Isoindigo (55)30, Yield 89%, mp 377-378 ℃; 1H NMR (300 MHz DMSO-d6) 
 ppm 6.83 (d, J=7.5 Hz, 2 H), 6.95 (t, J=7.5 Hz, 2 H), 7.33 (t, J=7.7 Hz, 2 H), 9.05 (d, 
J=7.9 Hz, 2 H), 10.87 (s, 2 H); 13C NMR (75 MHz, DMSO-d6) δ ppm 169.00, 144.10, 
133.36, 132.66, 129.32, 121.71, 121.19, 109.57. 
6-Fluoroisoindigo (56), Yield 78%, mp above 380 ℃; 1H NMR (300 MHz 
DMSO-d6)  ppm 6.63 (dd, J=9.0, 2.6 Hz, 1 H), 6.78 (m, 2 H), 6.95 (t, J=7.4 Hz, 1 H), 
7.32 (t, J=7.7 Hz, 1 H), 9.01 (d, J=8.3 Hz, 1 H), 9.14 (dd, J=8.9, 6.2 Hz, 1 H), 10.88 
(s, 1 H), 11.04 (s, 1 H); 13C NMR (75 MHz, DMSO-d6) δ ppm 169.26, 169.04, 166.03, 
162.70, 146.32, 146.15, 144.05, 132.82, 132.77, 132.61, 132.01, 131.97, 131.83, 
131.70, 129.27, 121.60, 121.20, 118.24, 118.20, 109.58, 107.73, 107.44, 97.53, 97.17. 
* More C atoms detected in 13C NMR data than expected. This is due to splitting by F 
substitutent in the compound. HPLC determination showed > 95% purity (Appendix 
1). 
5-Chloroisoindigo (57)31, Yield 90%, mp above 380 ℃; 1H NMR (300 MHz 
DMSO-d6)  ppm 6.85 (d, J=8.3 Hz, 2 H), 6.97 (t, J=7.7 Hz, 1 H), 7.38 (m, 2 H), 9.06 
(d, J=8.3 Hz, 1 H), 9.17 (d, J=1.9 Hz, 1 H), 10.95 (s, 1 H), 11.02 (s, 1 H); 13C NMR 
(75 MHz, DMSO-d6) δ ppm 168.99, 168.67, 144.48, 142.72, 134.77, 133.21, 132.00, 
131.77, 129.70, 128.64, 125.02, 122.94, 121.49, 121.31, 110.78, 109.70. 
6-Chloroisoindigo (58)31, Yield 88%, mp above 380 ℃; 1H NMR (300 MHz 
DMSO-d6)  ppm 6.83 (d, J=8.3 Hz, 2 H), 6.99 (m, 2 H), 7.34 (t, J=7.5 Hz, 1 H), 9.04 
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(dd, J=12.8, 8.3 Hz, 2 H), 10.91 (s, 1 H), 11.03 (s, 1 H); 13C NMR (75 MHz, DMSO-
d6) δ ppm 168.99, 168.97, 145.34, 144.30, 136.43, 133.90, 133.00, 131.86, 130.71, 
129.47, 121.58, 121.29, 120.93, 120.53, 109.68, 109.43. 
6-Trifluoromethylisoindigo (59), Yield 74%, mp above 380 ℃; 1H NMR 
(300 MHz DMSO-d6)  ppm 6.81 (d, J=7.9 Hz, 1 H), 6.95 (t, J=7.7 Hz, 1 H), 7.00 (s, 
1 H), 7.32 (m, 3 H), 9.03 (d, J=8.3 Hz, 1 H), 9.19 (d, J=8.3 Hz, 1 H), 10.92 (s, 1 H), 
11.11 (s, 1 H); 13C NMR (75 MHz, DMSO-d6) δ ppm 168.73, 168.62, 144.81, 144.21, 
136.12, 133.66, 131.80, 131.38, 131.30, 130.96, 130.54, 129.93, 129.71, 129.27, 
125.65, 125.03, 122.04, 121.46, 121.38, 118.43, 117.76, 117.71, 109.79, 105.53, 
105.48. * More C atoms detected in 13C NMR data than expected. This is due to 
splitting by CF3 substitutent in the compound. HPLC determination showed > 95% 
purity (Appendix 1). 
6-Trifluoromethyl-5'-fluoroisoindigo (60), Yield 68%, mp above 380 ℃; 1H 
NMR (300 MHz DMSO-d6)  ppm 6.77 (dd, J=8.7, 4.9 Hz, 1 H), 6.99 (s, 1 H), 7.21 
(m, 2 H), 8.90 (dd, J=11.3, 2.6 Hz, 1 H), 9.20 (d, J=8.7 Hz, 1 H), 10.94 (s, 1 H), 11.18 
(s, 1 H); 13C NMR (75 MHz, DMSO-d6) δ ppm 168.64, 168.62, 158.58, 155.49, 
144.50, 141.15, 135.42, 135.39, 132.48, 132.20, 131.78, 131.35, 130.93, 130.06, 
129.19, 125.58, 124.73, 122.11, 121.97, 120.05, 119.73, 118.36, 117.86, 117.81, 
116.66, 116.29, 110.32, 110.21, 105.63, 105.58. * More C atoms detected in 13C 
NMR data than expected. This is due to splitting by CF3 substitutent in the compound. 
HPLC determination showed > 95% purity (Appendix 1). 
6-Trifluoromethyl-5'-chloroisoindigo (61), Yield 75%, mp above 380 ℃; 1H 
NMR (300 MHz DMSO-d6)  ppm 6.78 (d, J=8.7 Hz, 1 H), 6.98 (s, 1 H), 7.25 (d, 
J=8.3 Hz, 1 H), 7.34 (dd, J=8.3, 1.9 Hz, 1 H), 9.10 (d, J=1.9 Hz, 1 H), 9.17 (d, J=8.3 
Hz, 1 H), 11.03 (s, 1 H), 11.15 (s, 1 H); 13C NMR (75 MHz, DMSO-d6) δ ppm 168.53, 
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168.33, 144.52, 143.36, 134.68, 132.66, 132.19, 131.77, 131.35, 130.92, 130.06, 
129.15, 125.53, 125.17, 124.68, 122.56, 121.92, 117.81, 117.75, 110.94, 105.59, 
105.54. * More C atoms detected in 13C NMR data than expected. This is due to 
splitting by CF3 substitutent in the compound. HPLC determination showed > 95% 
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Appendix 3: X-ray crystal data for 21 and 37 
X-ray crystal data for 21 
Table 1.  Crystal data and structure refinement for 7025. 
Identification code  7025 
Empirical formula  C17 H15 N O 
Formula weight  249.30 
Temperature  223(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/n 
Unit cell dimensions a = 12.440(2) Å = 90°.　  
 b = 4.9770(10) Å = 　
105.446(4)°. 
 c = 22.227(4) Å  = 90°.　  
Volume 1326.5(4) Å3 
Z 4 
Density (calculated) 1.248 Mg/m3 
Absorption coefficient 0.077 mm-1 
F(000) 528 
Crystal size 0.40 x 0.14 x 0.10 mm3 
Theta range for data collection 1.71 to 25.00°. 
Index ranges -14<=h<=14, -5<=k<=5, -26<=l<=26 
Reflections collected 9773 
Independent reflections 2318 [R(int) = 0.0532] 
Completeness to theta = 25.00° 100.0 %  
Absorption correction Sadabs, (Sheldrick 2001) 
Max. and min. transmission 0.9923 and 0.9697 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2318 / 38 / 224 
Goodness-of-fit on F2 1.113 
Final R indices [I>2sigma(I)] R1 = 0.0890, wR2 = 0.1794 
R indices (all data) R1 = 0.1222, wR2 = 0.1954 





X-ray crystal data for 37 
Table 1.  Crystal data and structure refinement for 8390. 
Identification code  8390 
Empirical formula  C19 H13 N O 
Formula weight  271.30 
Temperature  295(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/c 
Unit cell dimensions a = 13.8226(10) Å = 90°.　  
 b = 3.9414(3) Å = 　
101.261(2)°. 
 c = 24.9076(16) Å  = 90°.　  
Volume 1330.85(16) Å3 
Z 4 
Density (calculated) 1.354 Mg/m3 
Absorption coefficient 0.084 mm-1 
F(000) 568 
Crystal size 0.64 x 0.06 x 0.04 mm3 
Theta range for data collection 1.50 to 27.49°. 
Index ranges -16<=h<=17, -5<=k<=5, -29<=l<=32 
Reflections collected 8770 
Independent reflections 3045 [R(int) = 0.0307] 
Completeness to theta = 27.49° 99.8 %  
Absorption correction Sadabs, (Sheldrick 2001) 
Max. and min. transmission 0.9967 and 0.9483 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3045 / 0 / 194 
Goodness-of-fit on F2 1.033 
Final R indices [I>2sigma(I)] R1 = 0.0495, wR2 = 0.1190 
R indices (all data) R1 = 0.0683, wR2 = 0.1284 





Appendix 4:  Physicochemical descriptors of compounds 1-61 
Key: MW = molecular weight; HA = number of hydrogen (H) bond acceptors; HD = number of hydrogen (H) bond donors; Log P = Log 
Partition Coefficient (oil/water); VDWvol = van der Waals volume; MR = molar refractivity; HOMO = energy of highest occupied molecular 
orbital; LUMO = energy of lowest occupied molecular orbital; DM = dipole moment; Rotbond = number of rotatable bonds; VDWH = total 
hydrophobic VDW surface area; TPSA = topological polar surface area; AtomPol = sum of atom polarizabilities; vdwHA =  VDW surface area 
of H bond acceptor; vdwHB = VDW surface areas of H bond donors; H2OSA = water accessible surface area; Delatcarbonyl = chemical shift of 










Compound MW HA HD LogP VDWvol MR HOMO LUMO DM 
1 221.259 1.0 1.0 3.24 224.0 6.79 -8.69 -0.7 2.73 
2 251.285 2.0 1.0 3.19 247.4 7.44 -8.59 -0.6 3.4 
3 251.285 2.0 1.0 3.23 249.1 7.44 -8.66 -0.7 3.37 
4 251.285 2.0 1.0 3.2 247.3 7.44 -8.67 -0.67 3.05 
5 281.311 3.0 1.0 3.19 275.0 8.08 -8.55 -0.59 3.93 
6 281.311 3.0 1.0 3.19 273.3 8.08 -8.56 -0.64 4.19 
7 281.311 3.0 1.0 3.15 275.4 8.08 -8.48 -0.43 4.07 
8 281.311 3.0 1.0 3.26 272.6 8.08 -8.68 -0.7 2.86 
9 311.337 4.0 1.0 2.68 300.5 8.72 -8.75 -0.78 2.33 
10 313.356 1.0 1.0 4.89 309.4 9.45 -8.75 -0.77 3.38 
11 237.258 2.0 2.0 2.93 228.9 6.93 -8.56 -0.72 1.71 
12 237.258 2.0 2.0 2.97 228.4 6.93 -8.68 -0.71 3.39 
13 253.257 3.0 3.0 2.66 234.9 7.06 -8.57 -0.7 4.25 
14 253.257 3.0 3.0 2.73 234.0 7.06 -8.72 -0.74 2.75 
15 267.284 3.0 2.0 2.92 255.8 7.57 -8.55 -0.65 3.88 
16 267.284 3.0 2.0 2.92 257.1 7.57 -8.7 -0.74 2.22 
17 267.284 3.0 2.0 2.92 255.0 7.57 -8.58 -0.59 3.27 
18 235.286 1.0 1.0 3.54 240.6 7.24 -8.68 -0.73 2.61 
19 235.286 1.0 1.0 3.57 241.3 7.23 -8.68 -0.68 2.81 
20 235.286 1.0 1.0 3.54 240.5 7.23 -8.68 -0.67 2.92 
21 249.313 1.0 1.0 4.01 257.4 7.71 -8.68 -0.68 2.95 
22 239.249 1.0 1.0 3.39 226.8 6.85 -8.73 -0.86 3.69 
23 239.249 1.0 1.0 3.43 225.5 6.84 -8.78 -0.86 2.47 
24 239.249 1.0 1.0 3.39 227.8 6.84 -8.79 -0.82 2.09 
25 257.239 1.0 1.0 3.58 227.5 6.87 -8.82 -0.98 2.9 
26 255.704 1.0 1.0 3.87 238.3 7.28 -8.74 -0.82 2.44 
27 255.704 1.0 1.0 3.83 237.9 7.28 -8.76 -0.78 2.24 
28 290.149 1.0 1.0 4.46 252.9 7.74 -8.77 -0.95 2.67 
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29 273.694 1.0 1.0 4.02 240.3 7.34 -8.81 -0.91 2.35 
30 289.256 1.0 1.0 4.17 247.6 7.35 -8.81 -0.98 4.75 
31 289.256 1.0 1.0 4.21 250.6 7.34 -8.87 -1.05 4.03 
32 289.256 1.0 1.0 4.17 248.8 7.34 -8.89 -0.95 2.71 
33 246.269 2.0 1.0 2.9 241.1 7.38 -8.88 -0.94 2.95 
34 222.247 2.0 1.0 1.97 217.6 6.62 -8.72 -0.87 3.98 
35 222.247 2.0 1.0 2.01 216.5 6.62 -8.83 -0.88 2.21 
36 260.296 1.0 2.0 3.61 252.9 7.83 -8.47 -0.63 3.52 
37 271.319 1.0 1.0 4.46 271.3 8.39 -8.7 -0.72 2.76 
38 271.319 1.0 1.0 4.5 271.0 8.38 -8.69 -0.75 2.83 
39 269.275 2.0 1.0 3.42 250.8 7.5 -8.86 -0.89 2.96 
40 285.73 2.0 1.0 3.86 263.3 7.93 -8.64 -0.84 2.44 
41 285.73 2.0 1.0 3.86 262.3 7.93 -8.76 -0.86 3.08 
42 281.311 3.0 1.0 3.23 273.3 8.08 -8.6 -0.66 4.45 
43 285.274 3.0 2.0 3.11 255.6 7.64 -8.83 -0.91 3.47 
44 301.729 3.0 2.0 3.55 269.1 8.07 -8.74 -0.87 3.23 
45 297.31 4.0 2.0 2.92 279.1 8.21 -8.61 -0.69 3.68 
46 307.246 1.0 1.0 4.4 252.3 7.35 -9.06 -1.12 2.7 
47 323.701 1.0 1.0 4.84 263.3 7.83 -8.95 -1.08 2.9 
48 319.282 2.0 1.0 4.2 275.6 8.0 -8.81 -0.93 4.22 
49 265.312 2.0 0.0 3.43 266.6 7.89 -8.75 -0.67 3.38 
50 281.311 3.0 1.0 3.12 272.4 8.03 -8.73 -0.69 3.46 
51 253.301 2.0 1.0 2.7 253.5 7.49 -8.77 -0.02 3.38 
52 237.302 1.0 1.0 3.01 245.6 7.28 -8.78 -0.03 2.77 
53 251.285 2.0 1.0 3.55 248.4 7.44 -8.66 -0.84 3.88 
54 267.284 3.0 2.0 3.24 255.1 7.57 -8.63 -0.84 3.9 
55 262.268 2.0 2.0 2.1 241.6 7.42 -8.71 -1.56 0.11 
56 280.258 2.0 2.0 2.29 243.0 7.48 -8.83 -1.71 1.93 
57 296.713 2.0 2.0 2.73 256.6 7.91 -8.73 -1.66 1.05 
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58 296.713 2.0 2.0 2.73 255.0 7.91 -8.75 -1.68 1.13 
59 330.265 2.0 2.0 3.07 267.9 7.98 -9.0 -1.92 3.95 
60 348.255 2.0 2.0 3.26 270.9 7.98 -9.08 -2.05 2.89 
61 364.71 2.0 2.0 3.7 283.1 8.46 -8.93 -2.02 3.28 
 
Continued: 
Compound PSA Rotbond VDWH TPSA AtomPol vdwHA vdwHD H2OSA Delatcar
bonyl 
1 36.68 1.0 213.8 29.1 35.64 13.57 5.68 440.13 168.61 
2 47.0 2.0 246.04 38.33 39.53 16.07 5.68 479.8 168.63 
3 47.36 2.0 246.04 38.33 39.53 16.07 5.68 474.61 168.63 
4 48.19 2.0 246.04 38.33 39.53 16.07 5.68 475.48 168.95 
5 58.54 3.0 278.27 47.56 43.43 18.57 5.68 515.71 169.05 
6 58.48 3.0 278.27 47.56 43.43 18.57 5.68 521.82 168.69 
7 56.92 3.0 278.27 47.56 43.43 18.57 5.68 513.55 168.73 
8 59.06 3.0 278.27 47.56 43.43 18.57 5.68 517.34 168.59 
9 66.0 4.0 310.51 56.79 47.32 21.08 5.68 553.59 167.34 
10 47.45 3.0 299.3 38.33 49.67 13.57 5.68 550.89 168.54 
11 56.52 1.0 223.83 49.33 36.44 13.57 5.68 447.36 168.88 
12 59.5 1.0 223.83 49.33 36.44 13.57 5.68 444.48 168.77 
13 82.56 1.0 233.86 69.56 37.24 13.57 5.68 455.07 168.95 
14 83.27 1.0 233.86 69.56 37.24 13.57 5.68 455.79 168.88 
15 70.5 2.0 256.07 58.56 40.33 16.07 5.68 488.85 169.21 
16 69.92 2.0 256.07 58.56 40.33 16.07 5.68 487.06 168.99 
17 70.21 2.0 256.07 58.56 40.33 16.07 5.68 485.36 167.68 
18 36.17 1.0 231.03 29.1 38.73 13.57 5.68 453.48 168.42 
19 36.08 1.0 231.03 29.1 38.73 13.57 5.68 463.21 168.75 
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20 36.23 1.0 231.03 29.1 38.73 13.57 5.68 459.28 168.74 
21 36.64 2.0 248.26 29.1 41.82 13.57 5.68 486.54 168.83 
22 36.21 1.0 218.21 29.1 35.53 13.57 5.68 440.87 168.15 
23 36.41 1.0 218.21 29.1 35.53 13.57 5.68 438.23 168.45 
24 36.44 1.0 218.21 29.1 35.53 13.57 5.68 438.09 168.61 
25 36.3 1.0 222.62 29.1 35.42 13.57 5.68 444.63 168.08 
26 36.27 1.0 231.38 29.1 37.15 13.57 5.68 459.2 168.31 
27 36.39 1.0 231.38 29.1 37.15 13.57 5.68 457.08 168.45 
28 36.44 1.0 248.96 29.1 38.66 13.57 5.68 474.38 167.93 
29 36.39 1.0 235.79 29.1 37.04 13.57 5.68 453.7 168.08 
30 36.52 1.0 244.26 29.1 38.4 13.57 5.68 460.01 167.93 
31 36.85 1.0 244.26 29.1 38.4 13.57 5.68 477.66 168.37 
32 36.48 1.0 244.26 29.1 38.4 13.57 5.68 480.64 168.37 
33 63.27 1.0 237.53 52.89 37.83 31.31 5.68 471.14 168.22 
34 50.27 1.0 211.94 41.99 34.31 19.25 5.68 428.5 169.29 
35 50.52 1.0 211.94 41.99 34.31 19.25 5.68 427.73 168.1 
36 52.14 1.0 235.96 44.89 40.92 13.57 11.37 474.96 169.68 
37 36.9 1.0 251.26 29.1 44.01 13.57 5.68 494.56 168.35 
38 36.77 1.0 251.26 29.1 44.01 13.57 5.68 499.31 168.72 
39 48.06 2.0 250.45 38.33 39.42 16.07 5.68 488.58 168.92 
40 48.04 2.0 263.62 38.33 41.05 16.07 5.68 510.03 168.31 
41 48.33 2.0 263.62 38.33 41.05 16.07 5.68 506.94 168.6 
42 59.46 3.0 278.27 47.56 43.43 18.57 5.68 527.35 169.29 
43 69.05 2.0 260.48 58.56 40.22 16.07 5.68 495.3 169.32 
44 69.17 2.0 273.65 58.56 41.85 16.07 5.68 514.37 169.02 
45 81.07 3.0 288.3 67.79 44.23 18.57 5.68 532.03 169.72 
46 36.79 1.0 248.67 29.1 38.29 13.57 5.68 490.53 168.62 
47 36.62 1.0 261.84 29.1 39.91 13.57 5.68 504.12 168.26 
48 48.66 2.0 276.5 38.33 42.3 16.07 5.68 528.1 169.04 
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49 33.76 2.0 273.32 29.54 42.63 16.07 0.0 510.27 167.22 
50 54.93 2.0 283.35 49.77 43.43 16.07 0.0 514.89 167.63 
51 48.64 3.0 248.8 38.33 40.87 16.07 5.68 484.42 178.11 
52 37.03 2.0 233.8 29.1 40.06 13.57 5.68 469.41 178.11 
53 46.2 2.0 246.04 38.33 39.53 16.07 5.68 489.17 186.36 
54 66.71 2.0 256.07 58.56 40.33 16.07 5.68 501.21 185.95 
55 64.06 0.0 224.94 58.2 38.63 27.13 11.37 448.12 169.0 
56 64.13 0.0 229.35 58.2 38.52 27.13 11.37 455.08 169.15 
57 64.2 0.0 242.52 58.2 40.15 27.13 11.37 472.99 168.83 
58 63.95 0.0 242.52 58.2 40.15 27.13 11.37 470.59 168.98 
59 64.22 0.0 255.4 58.2 41.4 27.13 11.37 493.84 168.68 
60 63.96 0.0 259.81 58.2 41.29 27.13 11.37 497.62 168.63 















Appendix 5:  Spearman correlation matrix of NQO1 induction activity (pCD) and physicochemical descriptors. 




Correlation pCD MW HA HD LogP VDWvol MR HOMO LUMO DM 
pCD Correlation Coefficient 
1.000 .491** -.017 .305* 
.170 .223 
.225 
-.253* -.468** -.015 
Sig. (2-tailed) 
. .000 .899 .017 
.189 .083 
.082 
.049 .000 .910 
N 
61 61 61 61 
61 61 
61 
61 61 61 
MW 
Correlation Coefficient 
.491** 1.000 .232 .176 
.281* .766** 
.752** 
-.344** -.442** .140 
Sig. (2-tailed) 
.000 . .072 .174 
.028 .000 
.000 
.007 .000 .283 
N 
61 61 61 61 
61 61 
61 
61 61 61 
HA 
Correlation Coefficient 
-.017 .232 1.000 .447** 
-.646** .430** 
.417** 
.373** .234 .311* 
Sig. (2-tailed) 
.899 .072 . .000 
.000 .001 
.001 
.003 .069 .015 
N 
61 61 61 61 
61 61 
61 
61 61 61 
HD 
Correlation Coefficient 
.305* .176 .447** 1.000 
-.473** .024 
.063 
.137 -.188 -.038 
Sig. (2-tailed) 
.017 .174 .000 . 
.000 .853 
.628 
.293 .147 .770 
N 
61 61 61 61 
61 61 
61 
61 61 61 
LogP 
Correlation Coefficient 
.170 .281* -.646** -.473** 
1.000 .182 
.159 
-.235 -.178 .039 
Sig. (2-tailed) 
.189 .028 .000 .000 
. .161 
.222 
.068 .169 .766 
N 
61 61 61 61 
61 61 
61 
61 61 61 
VDWvol 
Correlation Coefficient 
.223 .766** .430** .024 
.182 1.000 
.972** 
.090 .095 .318* 
Sig. (2-tailed) 
.083 .000 .001 .853 
.161 . 
.000 
.489 .464 .013 
N 
61 61 61 61 
61 61 
61 
61 61 61 
MR 
Correlation Coefficient 
.225 .752** .417** .063 
.159 .972** 
1.000 
.111 .061 .245 
Sig. (2-tailed) 
.082 .000 .001 .628 
.222 .000 
. 




61 61 61 61 
61 61 
61 
61 61 61 
HOMO 
Correlation Coefficient 
-.253* -.344** .373** .137 
-.235 .090 
.111 
1.000 .751** .264* 
Sig. (2-tailed) 
.049 .007 .003 .293 
.068 .489 
.393 
. .000 .040 
N 
61 61 61 61 
61 61 
61 
61 61 61 
LUMO 
Correlation Coefficient 
-.468** -.442** .234 -.188 
-.178 .095 
.061 
.751** 1.000 .297* 
Sig. (2-tailed) 
.000 .000 .069 .147 
.169 .464 
.643 
.000 . .020 
N 
61 61 61 61 
61 61 
61 
61 61 61 
DM 
Correlation Coefficient 
-.015 .140 .311* -.038 
.039 .318* 
.245 
.264* .297* 1.000 
Sig. (2-tailed) 
.910 .283 .015 .770 
.766 .013 
.058 
.040 .020 . 
N 
61 61 61 61 
61 61 
61 
61 61 61 
PSA 
Correlation Coefficient 
.125 .322* .835** .777** 
-.657** .358** 
.378** 
.206 -.012 .176 
Sig. (2-tailed) 
.337 .011 .000 .000 
.000 .005 
.003 
.111 .927 .175 
N 
61 61 61 61 
61 61 
61 
61 61 61 
Rotbond 
Correlation Coefficient 
-.324* .077 .496** -.306* 
-.039 .494** 
.423** 
.436** .645** .427** 
Sig. (2-tailed) 
.011 .555 .000 .016 
.766 .000 
.001 
.000 .000 .001 
N 
61 61 61 61 
61 61 
61 
61 61 61 
VDWH 
Correlation Coefficient 
.147 .726** .539** -.028 
.161 .947** 
.903** 
.115 .168 .399** 
Sig. (2-tailed) 
.259 .000 .000 .831 
.214 .000 
.000 
.376 .195 .001 
N 
61 61 61 61 
61 61 
61 
61 61 61 
TPSA 
Correlation Coefficient 
.149 .262* .868** .786** 
-.690** .313* 
.339** 
.246 -.002 .177 
Sig. (2-tailed) 
.251 .042 .000 .000 
.000 .014 
.008 
.056 .988 .174 
N 
61 61 61 61 
61 61 
61 
61 61 61 
AtomPol 
Correlation Coefficient 
.107 .586** .440** .018 
.103 
.956** 
.948** .251 .295* .320* 
Sig. (2-tailed) 
.412 .000 .000 .892 
.429 
.000 
.000 .051 .021 .012 
N 
61 61 61 61 
61 
61 





.236 .331** .673** .255* 
-.583** 
.413** 
.456** -.018 -.179 .092 
Sig. (2-tailed) 
.067 .009 .000 .047 
.000 
.001 
.000 .893 .167 .480 
N 
61 61 61 61 
61 
61 
61 61 61 61 
vdwHD 
Correlation Coefficient 
.501** .282* -.044 .576** 
-.193 
.045 
.137 -.171 -.474** -.230 
Sig. (2-tailed) 
.000 .028 .738 .000 
.136 
.732 
.293 .187 .000 .075 
N 
61 61 61 61 
61 
61 
61 61 61 61 
H2OSA 
Correlation Coefficient 
.201 .715** .469** -.060 
.225 
.956** 
.909** .095 .143 .400** 
Sig. (2-tailed) 
.121 .000 .000 .646 
.081 
.000 
.000 .466 .270 .001 
N 
61 61 61 61 
61 
61 
61 61 61 61 
Delatcarbonyl
Correlation Coefficient 
.133 -.108 .344** .448** 
-.369** 
.068 
.059 .347** .223 .242 
Sig. (2-tailed) 
.307 .407 .007 .000 
.003 
.604 
.649 .006 .084 .060 
N 
61 61 61 61 
61 
61 
61 61 61 61 
 
Continued: 
Correlation PSA Rotbond VDWH TPSA AtomPol vdwHA vdwHD H2OSA Delatcarbonyl
pCD Correlation Coefficient .125 -.324* .147 .149 .107 .236 .501** .201 .133 
Sig. (2-tailed) .337 .011 .259 .251 .412 .067 .000 .121 .307 
N 61 61 61 61 61 61 61 61 61 
MW 
Correlation Coefficient .322* .077 .726** .262* .586** .331** .282* .715** -.108 
Sig. (2-tailed) .011 .555 .000 .042 .000 .009 .028 .000 .407 
N 61 61 61 61 61 61 61 61 61 
HA 
Correlation Coefficient .835** .496** .539** .868** .440** .673** -.044 .469** .344** 
Sig. (2-tailed) .000 .000 .000 .000 .000 .000 .738 .000 .007 
N 61 61 61 61 61 61 61 61 61 
HD 
Correlation Coefficient .777** -.306* -.028 .786** .018 .255* .576** -.060 .448** 
Sig. (2-tailed) .000 .016 .831 .000 .892 .047 .000 .646 .000 




Correlation Coefficient -.657** -.039 .161 -.690** .103 -.583** -.193 .225 -.369** 
Sig. (2-tailed) .000 .766 .214 .000 .429 .000 .136 .081 .003 
N 61 61 61 61 61 61 61 61 61 
VDWvol 
Correlation Coefficient .358** .494** .947** .313* .956** .413** .045 .956** .068 
Sig. (2-tailed) .005 .000 .000 .014 .000 .001 .732 .000 .604 
N 61 61 61 61 61 61 61 61 61 
MR 
Correlation Coefficient .378** .423** .903** .339** .948** .456** .137 .909** .059 
Sig. (2-tailed) .003 .001 .000 .008 .000 .000 .293 .000 .649 
N 61 61 61 61 61 61 61 61 61 
HOMO 
Correlation Coefficient .206 .436** .115 .246 .251 -.018 -.171 .095 .347** 
Sig. (2-tailed) .111 .000 .376 .056 .051 .893 .187 .466 .006 
N 61 61 61 61 61 61 61 61 61 
LUMO 
Correlation Coefficient -.012 .645** .168 -.002 .295* -.179 -.474** .143 .223 
Sig. (2-tailed) .927 .000 .195 .988 .021 .167 .000 .270 .084 
N 61 61 61 61 61 61 61 61 61 
DM 
Correlation Coefficient .176 .427** .399** .177 .320* .092 -.230 .400** .242 
Sig. (2-tailed) .175 .001 .001 .174 .012 .480 .075 .001 .060 
N 61 61 61 61 61 61 61 61 61 
PSA 
Correlation Coefficient 1.000 .155 .369** .959** .347** .628** .353** .320* .458** 
Sig. (2-tailed) . .232 .003 .000 .006 .000 .005 .012 .000 
N 61 61 61 61 61 61 61 61 61 
Rotbond 
Correlation Coefficient .155 1.000 .649** .130 .557** .114 -.571** .614** .182 
Sig. (2-tailed) .232 . .000 .319 .000 .382 .000 .000 .160 
N 61 61 61 61 61 61 61 61 61 
VDWH 
Correlation Coefficient .369** .649** 1.000 .344** .895** .375** -.166 .975** .016 
Sig. (2-tailed) .003 .000 . .007 .000 .003 .201 .000 .902 
N 61 61 61 61 61 61 61 61 61 
TPSA 
Correlation Coefficient .959** .130 .344** 1.000 .315* .660** .317* .287* .420** 
Sig. (2-tailed) .000 .319 .007 . .013 .000 .013 .025 .001 
N 61 61 61 61 61 61 61 61 61 
AtomPol Correlation Coefficient .347** .557** .895** .315* 1.000 .382** .009 .911** .151 
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 Sig. (2-tailed) .006 .000 .000 .013 . .002 .946 .000 .245 
N 61 61 61 61 61 61 61 61 61 
vdwHA 
Correlation Coefficient .628** .114 .375** .660** .382** 1.000 .401** .365** .222 
Sig. (2-tailed) .000 .382 .003 .000 .002 . .001 .004 .085 
N 61 61 61 61 61 61 61 61 61 
vdwHD 
Correlation Coefficient .353** -.571** -.166 .317* .009 .401** 1.000 -.117 .293* 
Sig. (2-tailed) .005 .000 .201 .013 .946 .001 . .371 .022 
N 61 61 61 61 61 61 61 61 61 
H2OSA 
Correlation Coefficient .320* .614** .975** .287* .911** .365** -.117 1.000 .077 
Sig. (2-tailed) .012 .000 .000 .025 .000 .004 .371 . .554 
N 61 61 61 61 61 61 61 61 61 
Delatcarbonyl 
Correlation Coefficient .458** .182 .016 .420** .151 .222 .293* .077 1.000 
Sig. (2-tailed) .000 .160 .902 .001 .245 .085 .022 .554 . 
N 61 61 61 61 61 61 61 61 61 
 
*. Correlation is significant at the 0.05 level (2-tailed). 
**. Correlation is significant at the 0.01 level (2-tailed). 
